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Abstract
Within the adipocyte, skeletal myocyte and cardiac myocyte the 
sugar transporter GLUT4 exists in numerous distinct subcellular 
membrane compartments, and a complex series of trafficking steps are 
known to regulate its distribution. When insulin binds to its receptor at the 
cell surface, the ensuing cascade of protein-protein and protein-lipid 
interactions leads to the translocation of a GLUT4-containing vesicle 
(GSV) to the plasmalemma (PM), where it docks, binds and fuses in a 
SNARE-dependent manner. In this way GLUT4 is delivered to its 
intended site of action, and glucose can enter the cell. The precise steps 
which regulate intracellular GLUT4 trafficking and those which govern 
GSV-PM fusion are hitherto unknown. GSV-PM fusion is known to 
disrupted in insulin resistant states such as Type-2 Diabetes, which is a 
growing global healthcare concern.
Such SNARE-mediated fusion events are best understood in 
neurons, where membrane fusion occurs in a calcium-dependent 
manner. The calcium-sensing species is an isoform of the 15-member 
Synaptotagmin (SYT) family, which binds the SNARE complex and the 
target and vesicle membranes. As a result, otherwise opposing 
thermodynamic forces between adjacent lipid bilayers are overcome and 
fusion can occur. In this thesis experiments designed to investigate the 
role of SYTs in insulin action in the 3T3-L1 adipocyte are described.
Using RTPCR, the expression SYT isoforms in 3T3-L1 cells was 
demonstrated. SYT7 (calcium-dependent) and SYT11 (calcium- 
independent) were shown to be the predominant isoforms, and SYT 11 
expression was seen to be upregulated as cells acquire insulin sensitivity 
during differentiation. Following their generation, novel affinity-purified 
SYT7- and SYT 11 - specific antisera were used to investigate the 
subcellular localisation of each SYT protein, and both were found to 
occupy intracellular membrane compartments in common with GLUT4. 
siRNA-mediated knockdown of SYT7 potentiates glucose uptake, and 
SYT 11 knockdown leads to abrogated insulin-stimulated glucose uptake 
and reduced intracellular GLUT4. Finally, SYT7 can be seen to bind the 
Syntaxin4 / SNAP23 / VAMP2 SNARE complex in vitro.
Together these data point to an important role for SYT7 and 
SYT 11 in the 3T3-L1 adipocyte, which may represent control of GSV-PM 
fusion, the regulation of intracellular GLUT4 trafficking or both.
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Chapter 1: Introduction
1.1. Diabetes Mellitus: a Brief History
Throughout history mankind has acknowledged the challenges 
presented by Diabetes Mellitus. A papyrus written by the ancient Egyptian 
physician Hesy-Ra was the first to document the disease c1500 BO, 
citing pulyuria as a predominant symptom. Early in the 2"^  ^century AD the 
Greek Arateus coined the term “diabetes" or siphon to describe “the 
melting down of flesh and limbs into urine”. Not until the Middle Ages 
when the urine was tasted in an attempt to reach a diagnosis was 
“mellitus" used to describe the sweet or honey-like taste of urine from 
affected individuals. In the early 19^ century the development of 
biochemical assays for sugars formally confirmed the presence of 
glycosuria, when it was first also observed that dietary restriction could be 
used to suppress the loss of sugar in urine. Around this time Lancereaux 
described diabete maigre (1) and diabete gras (obese), and is 
acknowledged as the first to attempt to classify the two commonly 
observed clinical diabetic syndromes on the basis of aetiology (2).
By the late 19^  ^century work by Minkowski and von Mering 
became noteworthy for demonstrating that a dog could be rendered 
diabetic by surgically removing its pancreas (3). By this time the 
explosion in medical research meant that numerous clinicians and 
scientists worldwide were attempting to determine the precise nature of
the pancreatic factor responsible for controlling blood and urine sugar. 
Separate experiments by Zuelzer in Berlin in 1906, Scott in Chicago in 
1912, Paulescu in Romania 1916 and Kleiner in New York in 1919 all 
resulted in the lowering of blood or urine sugar content by administering a 
crude pancreatic extract, but all shared significant side effects and 
misinterpretation of results.
In summer 1921 the young surgeon Frederick Banting (working in 
Toronto with Charles Best under the supervision of JJR Macleod) used 
pancreatic duct ligation to first isolate the Islets of Langerhans, and then 
successfully used a crude islet extract to treat a (surgically) diabetic dog. 
The extract first termed “Isletin” came to be known as Insulin. Soon 
afterwards in January 1922 Leonard Thomson became the first human 
diabetic subject to be successfully treated with injections of insulin. Rapid 
advances (initially led by Collip) in insulin production and its 
commercialization followed, and numerous patients were given this 
successful treatment for their hitherto invariably fatal disease. The 1923 
Nobel Prize for Medicine and Physiology was awarded to Banting and 
Macleod (who in turn shared the prize with Best and Collip) for the 
discovery of Insulin.
The revolution in diabetic treatment that followed the discovery and 
widespread use of insulin, appropriately heralded as a major scientific 
and therapeutic breakthrough at the time, consequently was proven to be 
a double edged sword. Diabetes was transformed from a rapidly fatal
illness (due to uncontrolled ketoacidosis) to a chronic disease, the result 
of which individuals developed retinitis leading to blindness, proteinuria 
and azotaemia, and premature vascular death. It was to be many years 
before the connection between maintaining tight glycaemic control and 
the prevention of these complications of diabetes would be met with 
widespread acceptance (1 ;4)
Soon after its discovery Falta and Himsworth observed that thin 
individuals who required insulin for the prevention of ketoacidosis were 
sensitive to its glucose lowering effects, whereas obese patients were 
often insensitive or resistant to insulin. The use of techniques devised in 
the 1970s to precisely quantify the extent of insulin resistance also 
revealed the role of p-cell failure in the pathogenesis of what is now 
known as Type-2 Diabetes Mellitus. In contrast, the “insulitis" observed by 
Opie in thin, insulin deficient individuals was not associated with p-cell 
loss or acknowledged to be of autoimmune in origin until this was 
proposed by Gepts in 1965 and Doniach and Gianfrance in 1979 
respectively. Diabetes due to such autoimmune p-cell loss is now known 
as Type-1 Diabetes Mellitus.
Since the early days the understanding of clinical diabetes and its 
consequences has flourished. The development of effective analogue 
insulins, oral hypoglycaemic agents and modifications of cardiovascular 
risk have provided physicians with an efficient armoury with which to treat 
diabetes and prevent the complications that are the result of many years
of this now chronic disease. Detailed epidemiological studies have 
provided insight into factors which seemingly promote the pathogenesis 
of the disease, and also give an indication of the contribution made by 
heredity to both major types of diabetes. Advances in such major 
scientific disciplines as Genetics, Molecular Biology and Cell Biology 
have allowed scientists to gain tremendous insight into the molecular 
pathogenic mechanisms involved in diabetes and its complications. 
Ongoing fruitful collaborations between clinicians and scientists promise 
to deliver novel effective treatments destined to reduce both morbidity 
and mortality associated with the disease.
In recent years reporting of the alarming rise in the incidence of 
type-2 diabetes in developed countries has dominated the 
epidemiological literature. In fact the incidence of diabetes in developing 
countries Is anticipated to increase by more than 150%. Current WHO 
predictions for escalating Diabetes incidence foresee a global doubling of 
diabetes prevalence in the 30 years from the year 2000, with an 
estimated 366 million affected individuals by the year 2030 (5). In spite of 
the detailed descriptions of many aspects of normal physiology and 
biochemistry the precise mechanisms underlying many fundamental 
cellular processes, not least the precise steps which regulate insulin 
action in adipose and skeletal muscle cells (which is known to be 
deranged in T2DM) remain to be elucidated. Without a clear 
understanding of what is normal, there can be little hope for the 
development of therapeutics which may facilitate an effective cure. Thus,
type-2 diabetes is set to become one of the most challenging global 
healthcare issues of our time.
1.2. Diabetes Mellitus
The most recent internationally agreed definition of Diabetes 
Mellitus is
“a metabolic disorder of multiple aetiology characterised by chronic 
hyperglycaemia with disturbances of carbohydrate, fat and protein 
metabolism resulting from defects in insulin secretion, insulin action or 
both" (5)
Strict diagnostic criteria based upon the presence of osmotic 
symptoms alongside elevated blood glucose values (either fasting or 
random), or elevated blood glucose following an oral glucose load in the 
absence of any significant intercurrent illness require to be met before the 
diagnosis can be made. The different types of diabetes are classified 
according to their aetiology. The most commonly encountered forms are 
Types 1 and 2 Diabetes and Gestational Diabetes. Other specific types 
exist but these are uncommon and rarely encountered in clinical practice 
(see TABLE 1.1 below).
6
Type-1 Diabetes Autoimmune p-cell destruction 
Idiopathic
Type-2 Diabetes insulin Resistance Insulin Secretory Defect
Gestationai Diabetes Pregnancy
Genetic Defect of p-cell Function Maturity Onset Diabetes of the Young (MODY)
Mitochondrial Diabetes
Genetic Defect of insulin Action Type-A Insulin Resistance Leprechaunism 
Rabson-Medenhall Syndrome 
Lipoatrophic Diabetes
Diseases of the Exocrine 
Pancreas
Pancreatitis 
Trauma / Surgery 
Neoplasia 
Cystic Fibrosis / Haemachromatosis
Endocrinopathies Cushing’s Syndrome 
Acromegaly 
Phaeochromocytoma 
Thyrotoxicosis
Drug or Chemical induced Glucocorticoids
Pentamidine
Thiazides
P-blockers
Infections Congenital Rubella 
Congenital CMV
Uncommon immune Forms Anti-Insulin Receptor Antibodies 
Stiff Man Syndrome
Other Genetic Syndromes 
Associated with Diabetes
Down’s Syndrome 
Klinefelter’s Syndrome 
Turner’s Syndrome 
Lawrence-Moon-Biedl Syndrome 
Myotonic Dystrophy 
Prader-Willi Syndrome 
DIDMOAD
Table 1.1: Classification of Diabetes Mellitus (adapted from (5))
1.2.1. Type-1 Diabetes Mellitus
Type-1 Diabetes (T1DM) is characterised by autoimmune cell- 
mediated destruction of the p-cells in the Islets of Langerhans of the 
pancreas leading to insulin deficiency. The immune stimulus is a 
combination of both genetic factors and environmental stimuli. Family 
studies reveal that siblings of an affected individual have a 6% chance of 
becoming affected, and monozygotic twins have a 36% lifetime risk of 
developing T1DM. The genomic region with the strongest diabetes 
association lies within the HLA (Human Leukocyte Antigen) locus within 
the MHC (Major Histocompatability Complex) located on the short arm of 
chromosome 6, however the existence of numerous other type-1 diabetes 
association loci throughout the genome within different study populations 
(alongside various environmental factors known to influence T1 DM 
susceptibility) to point to a complex and multifactorial disease aetiology.
Exposure to environmental factors such as viruses (Coxsackie, 
Mumps, Cytomegalovirus, Epstein-Barr virus and rubella), toxins 
(nitrosamines, cows milk protein) and other early life events (foetal blood 
group incompatibility, environmental temperature and “stressful” 
experience) have been shown to be associated with increased T1DM 
occurrence (6). In 80% of affected individuals, circulating antibodies to p- 
cell antigens can be detected at the time of diagnosis, and these can be 
used as disease markers in siblings at risk.
Disease onset is predominantly in childhood or early adulthood 
(although individuals can be affected at any age). Affected individuals are 
no longer capable of producing insulin sufficient to maintain adequate 
glucose homeostasis and so usually present with symptoms of 
hyperglycaemia such as thirst, polyuria and blurred vision. Weight loss is 
common, and represents the general catabolic state induced by insulin 
deficiency.
Individuals with T1 DM are at particular risk of diabetic 
ketoacidosis, a life-threatening metabolic dysregulation which occurs as a 
result of insulin deficiency and insulin counter-regulatory hormone excess 
(glucagon, catecholamines, cortisol and growth hormone) and elevation 
of proinflammatory cytokines (tumour necrosis factora, interleukin-6, 
interleukin-1 p and interleukin-8), free fatty acids, and plasminogen 
activator inhibitor-1 (reviewed in (7)). Uncorrected hyperglycaemia and 
ketone body formation lead to a profound osmotic diuresis and metabolic 
acidosis. Untreated this is manifest clinically as circulatory collapse, 
Kussmaul respiration and eventual coma and death. In spite of advances 
in care diabetic ketoacidosis is associated with 5% mortality. Patients with 
T1 DM therefore have an absolute requirement for lifelong treatment with 
exogenous insulin, usually delivered via multiple daily subcutaneous 
bolus injections.
1.2.2. Type-2 Diabetes Mellitus
Type-2 Diabetes (T2DM) accounts for 85% of all diabetes 
encountered in a Caucasian population, and is characterised by a 
combination of resistance to the actions of insulin accompanied by 
impaired secretion of insulin from the pancreatic p-cell. There is absence 
of insulin- or p-cell autoantibodies, or any other known cause of diabetes 
(as detailed in table 1 above). Many cellular mechanisms have been 
identified that may be responsible for both the cardinal features of insulin 
resistance and defective insulin secretion. In any given individual with 
T2DM it is likely that more than one such defect is present, reflecting the 
heterogeneous nature of the disease. Often T2DM is associated with 
abnormalities of blood pressure and lipid metabolism and this triad is 
termed the Metabolic Syndrome (8).
Susceptibility to T2DM has a stronger genetic contribution 
compared with T1DM, and is proposed to account for 40-80% disease 
susceptibility. Dizygotic twins have a 17-37% chance of developing the 
disease (9; 10), whilst studies in monozygotic twins reveal 60-90% 
concordance (11-13). Candidate genes include those which transduce 
the insulin derived signal in target tissues, and genes concerned with 
insulin generation, secretion and p-cell survival. That no single genetic 
locus has been identified to be responsible for T2DM predisposition
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reflects the likely contribution made by many of these mechanisms in any 
affected individual or pedigree.
Environmental factors are known to significantly contribute to 
T2DM susceptibility. There is a strong association between low birth 
weight and development of T2DM in later life, suggesting that foetal 
malnutrition plays an important role. Furthermore, the modernisation of 
society has been associated with reduced physical activity and increased 
calorie intake, which has led to an explosion of obesity. Both phenomena 
are evidence for the “Thrifty Gene” hypothesis, which suggests that under 
conditions of undernutrition (either in development or under 
environmental stress e.g. at times of famine) such thrifty genes operate to 
maximise energy economy, and capitalise at times of plenty to store for 
times of future need (14). This would provide a clear evolutionary survival 
benefit. Flowever, under conditions of chronic net overnutrition the result 
of such a genotype would be excess adiposity, insulin resistance and the 
development of T2DM. The increase in T2DIVI prevalence observed to 
occur alongside industrialisation in developing countries, in addition to the 
dramatic prevalence amongst individuals from certain ethnic groups when 
a “Westernised” lifestyle is adopted provide further support for the Thrifty 
Gene hypothesis.
The majority of individuals diagnosed with T2DM are obese. Most 
are over 40 years of age with the peak incidence seen in the 7“  ^decade, 
although the incidence in young adults and children is increasing. The
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diagnosis is often coincidental with another unrelated presentation (1/3'"'^ ), 
or is made following presentation with a complication of diabetes. 
Ketoacidosis is seldom seen but can occur in individuals with T2DM.
The most important risk factor for the development of T2DM is 
obesity, as evidenced by the many epidemiological observations between 
diabetes prevalence and average population weight (15). A rise in obesity 
in any given population is followed closely by increasing T2DM 
prevalence. For any given individual the risk of diabetes is associated 
with body fat distribution (central or visceral obesity being more important 
than peripheral or subcutaneous) (16). Evidence is emerging that 
deposition of fat outwith adipose tissue, so-called ectopic fat (e.g. 
intramyocellular lipid, hepatic steatosis, pancreatic p-cells) can be linked 
to insulin resistance and diabetes (17). The rate of increase in weight (18) 
has also been shown to be an important contributor to diabetes risk (19). 
That only 50% of those individuals with BMI > 40kg/m^ develop diabetes 
and observations that a significant number of patients with T2DM are not 
(and have never been) overweight, merely confirms the complex 
multifactorial aetiology of diabetes.
Insulin resistance is an early feature of T2DM, and in any 
individual with this form of diabetes probably exists for around a decade 
prior to the loss of normal tight metabolic control. At the same time, the 
development of insulin secretory defects in the pancreatic p-cell leads to 
an inability to compensate for resistance to insulin. Together, this
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becomes apparent with the development over time of impaired glucose 
tolerance, fasting hyperglycaemia and ultimately the diagnostic criteria for 
T2DM are met (5).
The treatment of T2DM can be broadly divided into two categories; 
treatments aimed at achieving glycaemic control and treatments to 
reduce cardiovascular risk. The former begins with advice regarding 
weight reduction, diet and physical activity, to oral hypoglycaemic agents 
to enhance insulin secretion from the p-cell (Sulphonyl-ureas), improve 
insulin sensitivity and suppress gluconeogenesis (Metformin) when more 
simple measures fail. In advanced disease insulin is used to control 
hyperglycaemia, and the large doses required reflect the insulin 
resistance present. Control of dyslipidaemia with Statins and tight blood 
pressure control with agents which modulate the Renin-Angiotensin 
System (with or without traditional antihypertensives) has been shown not 
only to reduce cardiovascular risk but also to slow the progression of 
particular diabetic complications (20). Newer antidiabetic agents such as 
the PPARy-agonists have multiple effects which include improvement in 
insulin sensitivity, lipid profile and blood pressure, which makes these 
drugs a particularly attractive therapeautic candidate. Agents currently in 
development such as the incretin-mimetics and DDP-IV inhibitors improve 
pancreatic function, enhance insulin sensitivity and have shown beneficial 
weight loss, and are likely to become valuable clinical tools.
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1.2.3. Obesity
The clinical condition of excess body weight as a consequence of 
excess adipose tissue accumulation is termed obesity. The internationally 
used measurement of obesity, the Body Mass Index (BMI) as defined by 
the weight in kilograms divided by height in metres squared was originally 
described in the early 19**^  century by the Belgian statistician Adolphe 
Quetelet (1796- 1874). The accepted classification of obesity status 
based on measurement of BMI is shown in TABLE 1.2 below.
Classification BMI
Underweight <18.5
Normal weight 18.5- 25
Overweight >25
Obese >30
Table 1.2: Obesity Status Defined By BMI
Despite being independent of age or sex, caution must be 
exercised in interpretation of any given BMI. it does not take into account 
the contribution to body weight made by other body tissues (e.g. skeletal 
muscle), or the effects of differing body proportions. Furthermore, 
population studies have demonstrated body fat composition varies with
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ethnicity within similar BMI ranges (18). Despite these drawbacks, the 
ease of calculation of the BMI has led to its universal acceptance.
Increasing weight is associated with increased morbidity due to 
osteoarthritis, gout, breathlessness and sleep apnoea, and subfertility. 
More importantly increasing weight is associated with increased mortality 
principally due to T2DM and Coronary Heart Disease (CHD), (and also 
cancer;(21). The global prevalence of obesity is rising at an alarming rate: 
the 2000 WHO Technical Report on Obesity (Reprinted 2004) (22) 
described in great detail the rise of obesity prevalence amongst children 
and adults in developed and developing countries alike. Many strategies 
exist in order to effect weight loss and to prevent excess weight gain, 
however none have demonstrated sustained benefit over time, or 
improved healthcare endpoints (reviewed in (23)).
1.2.4. Complications of Diabetes
Diabetes has long been known to cause specific complications 
which lead to significant morbidity. As early as the 10^ *^  century ad. in his 
Arabic medical encyclopaedia Avicenna described gangrene and 
impotence in diabetic patients. Englishman John Rollo was the first to 
describe symptoms of diabetic peripheral neuropathy, German von 
Jaeger documented the first detailed description of diabetic retinopathy, 
and Kimmelsteil and Wilson (of renal syndromic fame) whilst working in 
the USA made the connection between diabetes and glomerular disease.
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In the years soon after the discovery and widespread use of insulin in the 
treatment of diabetes it soon became apparent that an excess of 
premature cardiovascular mortality was occurring in affected individuals. 
It was not until Lundbaek's paper of 1954 that “Diabetic Angiopathy” was 
accepted, in spite of ancient observations some 3000 years earlier (24). 
Diabetic complications are listed in Table 1.3 below.
Macrovascular Microvascular
Ischaemic Heart Disease Nephropathy
Cerebrovascular Disease Retinopathy
Peripheral Vascular Disease Neuropathy
Table 1.3: The Macrovascular and Microvascular Complications of
Diabetes.
Excess cardiovascular mortality is still seen in all age groups with 
both T1DM and T2DM, and macrovascular disease remains the main 
cause of death in both T1 DM and T2DM (25). The risk of macrovascular 
complication i.e. myocardial infarction, cerebrovascular disease or 
peripheral vascular disease is increased up to fivefold in an individual 
with T2DM (26). Arterial disease is commonly diffuse at presentation. 
Despite thrombolytic therapy and both percutaneous and surgical
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revascularisation, the rates of re-stenosis are higher in diabetic patients 
versus non-diabetic controls (26).
Diabetes remains the commonest cause of end-stage renal failure 
worldwide, and is the underlying cause responsible for more than half of 
all kidney transplants and the initiation of renal dialysis. Furthermore, 
graft survival is reduced, and morbidity and mortality whilst on dialysis is 
increased amongst diabetic individuals compared with non-diabetic 
controls (27). Diabetic retinopathy is the leading cause of blindness in 
developed countries (28). Specific treatments with panretinal 
photocoagulation and surgical vitrectomy can prevent blindness, but there 
are currently no agents which specifically prevent retinopathy (29). 
Lifetime risk of neuropathy is around 50%, and the presence of 
neuropathy is associated with significant morbidity (and mortality due to 
autonomic neuropathy and sudden cardiac death)(30).
The clear relationship between glycaemic control and the 
incidence of diabetic complications is well established (4). The damaging 
cellular processes initiated by hyperglycaemia within the vascular 
endothelium and leading to the vascular complications described above 
are modulated by genetic susceptibility and factors such as hypertension 
and hyperlipidaemia. Clear benefit is gained in terms of reducing 
complication incidence and severity by both reducing blood pressure (1) 
and by lipid lowering treatment with a statin (31) in diabetic individuals. 
Treatment with an agent that modulates the Renin-Angiotensin system
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(such as an ACE-inhibitor (32) or an Angiotensin II Receptor antagonist 
(33)) provides additional preservation of renal function independent of 
blood pressure reduction.
It is now recognised that increased polyol pathway flux, increased 
advanced glycation endproduct (AGE) formation, activation of protein 
kinase-G (PKC) isoforms and increased hexosamine pathway flux are all 
responsible for endothelial damage, and are the consequence of 
increased intracellular reactive oxygen species (ROS) production due to 
hyperglycaemia (34;35). Whilst there are no current therapeutic agents in 
widespread use designed to specifically address these defects, this area 
of fruitful research has identified multiple novel targets which may prove 
to be effective in preventing diabetic complications: Transketolase 
activators (36), PARP inhibitors (37) and catalytic antioxidants (38) 
demonstrate promising preliminary efficacy.
1.2.5. Insulin Secretion
Despite the presence of elevated circulating levels, the secretion of 
insulin is impaired in T2DM since the level of hyperinsulinaemia observed 
is far lower than would be seen in a non-diabetic individual with a similar 
degree of hyperglycaemia (39). Insulin is synthesised in the p-cell of the 
Islets of Langerhans. Initially translated as preproinsulin this precursor is 
post-translationally modified in a stepwise manner by cleavage to 
proinsulin, and insulin and C-peptide which are stored in intracellular
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vesicles. In response to increasing blood glucose (thus increased glucose 
entry into the p-cell and its subsequent metabolism to generate ATP) 
these vesicles then translocate to the cell surface where the fuse with the 
plasma membrane (PM) releasing insulin into the extracellular space 
(40). Insulin release in response to glucose has a characteristic biphasic 
pattern. The first rapid phase is believed to be due to the rapid 
mobilisation and ATP-independent release of secretory vesicles from the 
so-called ready-releasable pool. The second, more sustained phase of 
insulin secretion is dependent upon ATP, required to mobilise these 
granules from the storage pool to the readily-releasable pool (41).
The release of insulin is largely determined by the activity of the 
glucose sensor glucokinase. This enzyme phosphorylates glucose 
immediately upon its entry into the p-cell, which in turn affects cellular 
energy balance (in terms of available ATP). ATP-sensitive potassium 
channels ( K a t p ) subsequently close, which leads to the depolarisation of 
the cell. Depolarisation leads to opening of voltage-gated calcium 
channels, which increases intracellular calcium concentrations and 
initiates insulin vesicle translocation and exocytosis.
The stimulation of insulin secretion can be modulated by a variety 
of metabolic (amino-acids), hormonal (glucagon and the incretins) and 
neural stimuli in both a positive and negative manner. These factors 
mediate their effects via a range of intracellular secondary messengers
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which either alter the p-cells resting potential, influence Ca^^-channel 
sensitivity or modify vesicle mobilisation and fusion.
Maturity Onset Diabetes of the Young (MODY) is characterised by 
autosomally inherited non-insulin dependent diabetes at an early age 
(42). The particular gene defects observed are associated with p-cell 
dysfunction and defective insulin secretion. Mutations in glucokinase and 
the K a t p  channel subunit Kir6.2 have been elucidated in pedigrees with 
rare monogenic diabetes syndromes (e.g. M0DY2). Other mutations 
affecting transcription factors (HNF1a, FINF4a, HNF1p, IPF-1 and 
NeuroDI) which in turn influence the expression of genes implicated in 
the regulation of insulin secretion are now understood to be responsible 
for other MODY phenotypes (43).
The UKPDS study revealed that around 50% of the insulin- 
secreting capacity of the p-cell is lost at the time of diagnosis of T2DM, 
and that this continues to decline with time in spite of intense glycaemic 
management. Backwards extrapolation of the rate of decline suggests 
that, contemporaneous with the onset of insulin resistance, p-cell failure 
is an early event in the pathogenesis of T2DM and begins around ten 
years before diagnosis is made.
Insulin secretion is an exceedingly complex multi-step 
phenomenon, and it is not surprising that defects can be demonstrated at 
multiple levels of the secretory pathway in T2DM. Whilst some genetic
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defects that produce a clear clinical phenotype are well characterised 
(MODY) it is likely that impaired insulin secretion is the manifestation of 
combinations of multiple inherited factors (as evidenced by the subtle 
abnormalities in p-cell function seen in relatives of individuals with 
T2DM). Other suggested mechanisms are glucotoxicity, amyloid 
deposition and ectopic lipid deposits, and it is likely more than one will 
contribute in any given individual (44).
1.2.6. The Metabolic Syndrome
The term Metabolic Syndrome X coined by Reaven in his 1988 
Banting Lecture described individuals with impaired glucose tolerance (or 
diabetes) with one or more cardiovascular risk components 
(hypertension, hyperlipidaemia, microalbuminuria) who were at increased 
risk of cardiovascular disease compared with risk attributable to any 
individual component. With the addition of obesity to the definition, the 
Metabolic Syndrome became the widely favoured descriptive term (45). 
Since its conception the Metabolic Syndrome has been the matter of 
much discussion, with subtly differing diagnostic criteria used by 
disparate panels of experts (WHO (5); ATPIII: (46); IDF: (47); reviewed in 
(48)). Recently the clinical value in making the diagnosis has been 
questioned, with opponents supporting the idea that, if present 
cardiovascular risk factors should be addressed aggressively and 
independently (49). Proponents still value its use, with recent evidence to 
support elevated global cardiovascular risk in an individual “labelled" with
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the Metabolic Syndrome greater than the risk attributable by each 
independent factor (50).
Given that cardiovascular risk factors are often present for many 
years prior to clinically evident loss of glycaemic control there may be 
some value in the use of the term in such individuals who are also 
overweight; strategies to reduce weight and increase physical activity, 
and thus improve insulin sensitivity may be adopted earlier by primary 
care physicians who manage the vast majority of such patients.
22
1.3. Cellular Actions of Insulin
Insulin is a pluripotent peptide hormone produced and released 
from the (3- cells of the pancreatic islets of Langerhans. Insulin is 
essential for life; untreated diabetic ketoacidosis is fatal (51 ;52); insulin 
gene knockout mice exhibit growth retardation and die within 48 hours of 
birth from ketoacidosis (53). The most prominent, best studied and 
arguably most important actions of insulin are the stimulation of glucose 
uptake into skeletal muscle, the stimulation of glucose uptake into 
adipose cells (and the suppression of lipolysis), and suppression of 
hepatic gluconeogenesis. By virtue of these actions, insulin exerts control 
over carbohydrate metabolism and whole body glucose homeostasis.
Insulin is also known to modulate protein and lipid metabolism, 
suppress inflammation, maintain a healthy vascular endothelium and 
influence cell growth, differentiation and survival (further detailed 
discussion of which is outwith the scope of this thesis).
In order to stimulate post-prandial glucose uptake in a sensitive 
(54) cell insulin must stimulate the translocation of the facilitative sugar 
transporter GLUT4 (see section 1.6.7) from an intracellular location to the 
plasma membrane. Only once insulin binds its receptor can it exert 
influence over this, or any other of its varied metabolic effects within any 
individual cell.
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1.3.1. Glucose Transporter Proteins (GLUTs)
In order to be utilised as a cellular energy substrate circulating 
glucose must first cross the lipid bilayer of the target cell. To facilitate this 
glucose requires a specific transport protein, since its intrinsic 
hydrophilicity prohibits traversing the hydrophobic PM. There are two 
such families of glucose transporters; the Na^-dependent glucose 
transporters (55) and the facilitative glucose transporters (GLUTs). The 
SGLT family harness the electrochemical energy generated by 
transmembrane sodium exchange to move glucose against its 
concentration gradient into the cell, and are responsible for glucose entry 
into enterocytes (SGLT 1-2) or proximal renal tubular epithelial cells 
(SGLT-3). The GLUTs allow glucose to enter the cell by moving down its 
concentration gradient (reviewed in (55)).
There are 13 known GLUTs, each with different substrate 
specificity, tissue distribution and kinetic properties. They share the same 
basic structure of twelve transmembrane domains, possess sugar 
transporter signatures required for the transporter function and can be 
divided into three classes based upon sequence similarity. Most tissues 
express a combination of GLUT molecules at the cell surface to ensure a 
continued energy substrate supply at physiological blood glucose 
concentrations (55;56).
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1.3.2. GLUT4
The specialised insulin-responsive facilitative sugar transporter 
GLUT4 (57) is expressed in those tissues demonstrated to exhibit insulin- 
mediated glucose accumulation i.e. skeletal muscle, adipose and cardiac 
muscle. Subsequent study confirmed the low level expression of GLUT4 
in specific brain regions (58;59) where it may function in a glucose- 
sensing capacity alongside other GLUTs, and regulate memory (60). In 
response to insulin stimulation of the surface-bound Insulin Receptor (IR), 
a cascade of protein-protein and protein-lipid interactions (described in 
detail below) result in the movement of GLUT4-containing vesicles 
(GSVs) from their intracellular location to the plasmalemma where the 
vesicles tether, dock and then fuse. In this way GLUT4 is delivered to its 
intended site of action, and glucose can enter the cell by passing down its 
concentration gradient.
GLUT4 translocation and subsequent glucose uptake also occurs 
following other stimuli such as muscle contraction, hypoxia and 
hypertonicity of the extracellular fluid (61-64). Whilst certain steps are 
shared between these mechanisms each should be considered distinct. 
The major focus of this study shall be on insulin-stimulated GLUT4 
translocation.
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1.3.2.1. GLUT4 knockout Mouse Models
The study of mice genetically engineered with relative, tissue- 
specific or global knockout of GLUT4 protein has provided confirmation of 
the key metabolic role played by this glucose transporter. Mice with global 
GLUT4 knockout show impaired insulin-stimulated glucose uptake, 
slightly impaired insulin sensitivity and only mild hyperinsulinaemia (65). 
There is no upregulation in any other glucose transporter in skeletal 
muscle or adipose, but GLUT2 expression is enhanced in the liver, which 
thus may provide enhanced glucose disposal. In contrast, mice 
heterozygous for GLUT4 knockout are severely insulin resistant, 
hyperglycaemic and hyperinsulinaemic (66) (which may be due to the 
developmental stage at which relative GLUT4 deficiency Is established).
Muscle-specific GLUT4 knockout mice show substantially reduced 
global insulin-stimulated glucose uptake (67). Uptake is reduced in 
adipose tissue, insulin-mediated suppression of hepatic gluconeogenesis 
is impaired, and these mice develop hyperglycaemia and a diabetic 
phenotype. Interestingly, when diabetes is prevented with the use of an 
agent which reduces intestinal glucose uptake and renal tubular glucose 
reabsorbtion, adipose and hepatic responses normalise, indicating that 
glucotoxicity is responsible for impaired action of insulin in these tissues.
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Adipose-specific GLUT4 knockout mice have normal growth and 
development (68). From around 13 weeks they develop 
hyperinsulinaemia, and glucose intolerance soon follows. Only a 
proportion develop frank diabetes (10%). As expected they have 
markedly reduced insulin-stimulated glucose uptake in adipose tissue, but 
also in muscle (in vivo, despite normal GLUT4 expression: ex-vivo 
muscle insulin sensitivity is normal) and liver. Circulating Free Fatty Acids 
(FFAs), TNFa, leptin, resistin and adiponectin are all within normal limits.
Thus, absent adipocyte GLUT4 promotes global insulin resistance; 
does increased adipocyte GLUT4 promote insulin sensitivity? This theory 
was tested when GLUT4 was overexpressed in the adipose tissue of 
GLUT4 muscle knockout mice (69). In this model the adipose-specific 
overexpression of GLUT4 rescued the diabetic phenotype previously 
described. Indeed, insulin sensitivity (as determined by hyperinsulinaemic 
euglycaemic clamp study) was improved when compared with wild-type 
levels. Given that GLUT4 expression and insulin sensitivity is increased 
with physical exercise (70), and reduced in the adipocytes of individuals 
with T2DM, (and their non-diabetic but insulin resistant first degree 
relatives) these studies support the idea that increasing GLUT4 delivery 
to the adipocyte plasma membrane in insulin resistant individuals may 
improve whole body insulin sensitivity (and therefore reverse insulin 
resistance), and thus represents a realistic therapeutic goal.
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1.3.3. Insulin Signalling
1.3.3.1. Insulin Receptor
The insulin receptor (IR) is a plasma membrane-bound 
heterotetrameric glycoprotein composed of two a - and two p- subunits 
(linked by disulphide bonds) which are the product of a single gene (71 ). 
The IR is expressed in most mammalian cells studied, albeit at levels 
which vary by orders of magnitude (72), and is thought to exist as a 
homodimer at the plasma membrane of the classical insulin-sensitive 
tissues: skeletal muscle, adipose and liver. The IR shares homology with 
the Insulin-like Growth Factor Receptors (IGF-1 R and IGF-2 R) and the 
orphan receptor IR-R (Insulin receptor related protein), between which 
heterodimerisation is thought to occur. Together they form the IR / IGFR 
family of receptor tyrosine kinases, which bind insulin and the insulin-like 
peptides with differing affinities (reviewed in Nakae, 2001). Like the IR, 
signalling via the IGF receptors also has influence upon growth and 
metabolism. In spite of such overlap the IR remains the only unique 
element of insulin signalling upstream to its glucose uptake effects.
Individuals with mutation (including functional knockout) of the 
insulin receptor gene exhibit a phenotype which varies from mild insulin 
resistance to leprochaunism (73). In contrast, transgenic mice engineered 
to be heterozygous for deletions of the IR die in the early neonatal period
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with hyperglycaemia and ketoacidosis {74;75). This demonstrates 
different regulation of fetal growth and development, and control of 
neonatal glucose metabolism between mice and man which is almost 
certainly the consequence of species differences in the function of IR / 
IGFR family signalling.
The key signalling role played by the IR is further confirmed by 
animal metabolic studies in which tissue-specific knockout of the IR has 
been achieved. Mice lacking the IR in liver (LIRKO) fail to suppress 
hepatic gluconeogenesis in response to insulin infusion, and 
subsequently become hyperglycaemic and hyperinsulinaemic with a 
phenotype resembling T2DM (76). Mice which lack IR expression in 
adipose tissue show decreased fat mass, normoglycaemia, normal 
circulating insulin concentrations, and have only slightly impaired insulin 
sensitivity (77). Despite the fact that most insulin-stimulated glucose 
disposal is achieved by skeletal muscle, mice genetically engineered to 
have skeletal muscle-specific IR knockout (MIRKO) show only mild 
hyperglycaemia and hyperinsulinaemia. Insulin-induced glucose uptake 
into skeletal muscle is reduced, however glucose uptake in adipose 
tissue is greatly increased in MIRKO mice. These mice become obese 
(with a visceral distribution) and exhibit dyslipidaemia reminiscent of 
T2DM (78). This apparent compensation of impaired skeletal muscle 
insulin action in adipose tissue reflects the complex interplay of insulin- 
mediated energy disposal and storage in different depots.
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Upon insulin binding to the a - subunits a conformational change in 
the receptor activates kinase domains within the [3- subunits. These 
activated kinase domains then auto-phosphorylate the receptor itself.
This in turn results in activation of the ability of the receptor to bind and 
phosphorylate downstream effector proteins. Thus cascades of protein- 
protein interactions (principally further phosphorylation events) and 
protein-lipid interactions lead to the many downstream effects of insulin 
(reviewed in (79) and described below).
1.3.3.2. Insulin Receptor Substrate Family
The Insulin Receptor Substrate (1RS) molecules are central to the 
activation of insulin signalling. All 4 family members share the same basic 
structure of an amino terminal Pleckstrin Homology (PH) domain (80;81) 
followed by a Phospho-tyrosine Binding domain (PTB). The carboxy- 
terminal domain is composed of numerous serine and tyrosine residues.
IRS-1 (82) and IRS-2 (83) are recruited to the activated IR via the 
PTB domain and then rapidly phosphorylated (by the IR) on multiple sites 
within the carboxy-terminal domain (recently reviewed in (84)). This 
serves to provide binding sites which recruit further downstream effector 
molecules such as PI3K (see below), thus propagating the insulin-derived 
signal.
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Transgenic mice engineered with global IRS-1 knockout are 
growth retarded and insulin resistant (85). IRS-1 knockout mice do not 
develop diabetes but can be shown to develop compensatory (3-cell 
hyperplasia and hyperinsulinaemia. Further studies demonstrated that 
lack of IRS-1 was compensated by IRS-2 in the liver of these animals 
(86) but not in skeletal muscle or adipose tissue. This suggests a degree 
of functional redundancy between IRS-1 and IRS-2 in the liver, and 
implies a predominant role for IRS-1 in skeletal muscle and adipocytes. 
These findings are largely supported by studies of IRS-1 expression 
levels and phosphorylation status in obese humans and individuals with 
T2DM (reviewed in (87)).
IRS-2 knockout mice (88) are growth retarded and insulin 
resistant, developing diabetes in the first 10 weeks of life. There is failure 
of the compensatory (3-cell hyperplasia and hyperinsulinaemia seen in 
IRS-1 knockout mice, alongside marked hepatic insulin resistance 
resulting in the diabetic phenotype which closely resembles T2DM. 
Together these data imply that the functions of IRS-2 predominate in the 
liver and (3-cell.
IRS-3 (89) and IRS-4 (90) molecules are described in rodents. 
Whilst knockout studies reveal some influence on adipogenesis and 
glucose homeostasis (91), their precise role in conventional insulin 
signalling remains to be thoroughly determined and is not thought to be 
significant (92).
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1.3.3.3. PI3Kand PI(3,4,5)P3
Class 1A Phopshoinositide 3-kinase (PI3K) is the first major 
effector molecule downstream of the IR in most insulin signalling 
pathways. This ubiquitous lipid kinase has been linked with anti-apoptotic, 
mitogenic and anabolic functions (93). The p85 regulatory subunit of this 
heterodimeric protein complex is recruited to the phosphotyrosine 
residues (generated by IR kinase activity) of the 1RS molecules via its 
SH2 domains. This serves to both activate PI3K kinase activity (located in 
the p110 subunit) and bring the enzyme into close proximity with its 
catalytic target: phosphatidyl inositol 4,5- bisphosphate (PI(4,5)P2).
The conversion of Pl(4,5)p2 to PI(3,4,5)P3is central to the 
downstream effects of PI3K. Inhibition of PI3K activity with the 
pharmacological agent Wortmannin prevents insulin-stimulated GLUT4 
translocation (94-96), a result mirrored in studies where cells are 
transfected with dominant negative p85 subunit lacking the pi 10 binding 
motif (97) or the N-SH2 domain of p85 in isolation (98). Conversely, 
GLUT4 translocation is induced when cells are transfected with 
constitutively active p110 (99), and wortmannin’s inhibitory effect on 
insulin stimulated glucose uptake is abolished in the presence of 
synthetic PI(3,4,5)P3 esters (100). These reports affirm the key role 
played by Pl(3,4,5)p3, and it is this phospholipid species, when generated
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at the plasma membrane which recruits the next step in the insulin 
signalling cascade.
Endogenous negative regulation of PI(3,4,5)P3exists in the form of 
type-11 SH2-Domain containing inositol 5-phosphatase (SHIP2) and 
Phosphatase and Tensin Homolog Deleted on Chromosome 10 (PTEN). 
These phosphoinositide phosphatases convert Pl(3,4,5)p3 to Pl(3,4)p2 
and Pl(4,5) P2 respectively owing to their 5’ and 3’ phosphatase activity 
(101).
Overexpression of wild-type PTEN in 3T3-L1 adipocytes reduces 
insulin-stimulated glucose uptake (102;103), whereas no effect is seen 
when the phosphatase-dead mutant form of PTEN is overexpressed 
(104). siRNA-mediated depletion of PTEN leads to enhanced basal and 
insulin-stimulated glucose uptake in 3T3-L1 cells (105). The same 
method used to deplete SHIP2 failed to influence insulin action in these 
cells (105), whereas the earlier study of transgenic SHIP2 knockout mice 
demonstrated improved insulin sensitivity, glucose tolerance and 
increased GLUT4 translocation in heterozygotes. Such data support the 
key role played by these enzymes in the modulating of 
polyphosphoinositide species at the plasma membrane.
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1.3.3.4. PDK1 /A K T/P KC
The 3-Phosphoinositide-Dependent Protein Kinase-1 (PDK1) and 
Protein Kinase B (or AKT) are recruited to the plasma membrane by 
virtue of their Pleckstrin Homology (PH) domains (106) which bind 
specifically to PI(3,4,5)Ps. AKT requires phosphorylation at two specific 
residues for its activation; S473 and T308 (107). PDK1 was shown to be 
the upstream kinase for phosphorylation at residue T308 following its 
initial purification from rabbit skeletal muscle (108). The elusive S473 
upstream kinase was eventually identified as the rictor-mTOR protein 
complex (109). Originally identified as the mammalian target of 
Rapamycin, mTOR is known to be central to a unique cellular signalling 
pathway that integrates nutrient, energy status and growth factor signals 
and so its intimate relationship with insulin signalling to glucose uptake is 
logical. Dysregulated mTOR pathway signalling is becoming increasingly 
apparent in human diseases such as diabetes and cancer (reviewed in 
(110).
The role of activated AKT as a downstream effector of insulin was 
initially suggested by use of a dominant negative construct in L6 
myotubes and 3T3-L1 adipocytes, where it was shown to induce glucose 
uptake without activation of PI3K (111-114). Subsequent studies of 
microinjection and growth factor response in 3T3-L1 cells and ex-wVo rat 
adipocytes (115), transgenic mice knockout models (116;117) and siRNA
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mediated gene knockout in 3T3-L1 adipocytes (118) established that 
AKT2 (or PKB(3) was the isoform which was most active in the insulin 
signalling cascade.
The third group of candidate effector molecules downstream of 
PI(3,4,5)P3 are the Atypical Protein Kinase C (119) isoforms (119). The 
role of aPKC isoforms appears to be tissue-specific: PKC^ is the active 
isoform in muscle and PKC^ in adipose tissue and liver. Hepatic aPKC is 
a major determinant of hepatic lipid content and influences whole body 
insulin sensitivity (120). siRNA depletion of PKC in 3T3-L1 and L6 cells in 
culture abrogates insulin-stimulated glucose uptake (121). The roles of 
the aPKC isoforms in insulin action and insulin resistance are discussed 
in (119;122).
1.3.3.5. AS 160
In spite of much research the precise molecules downstream of 
AKT2 leading to GSV translocation and glucose uptake remain elusive 
(107). One such target has been identified by immunoprécipitation (using 
an antibody specific for the phospho-motif generated by AKT within its 
putative substrates) and mass-spectrometry in 3T3-L1 cells (123). AKT 
Substrate of 160kPa (AS 160) is a putative Rab GAP, and its 
phosphorylation at 5 distinct sites in response to insulin stimulation is 
required for maximal GLUT4 translocation (124) (only when the Rab GAP 
domain is intact ). AS 160 has also been implicated in both insulin-
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stimulated and contraction-stimulated glucose uptake in skeletal muscle 
(125).
Rab proteins are the largest branch of the Ras superfamily of small 
GTP-binding proteins, and have been shown to play an important role in 
the regulation of vesicle traffic (126;127). They function as molecular 
switches, existing as GDP-bound inactive and GTP-bound active forms, 
and are believed to be key regulators of vesicle transport specificity (128). 
Furthermore, Rab proteins are known to integrate with many signalling 
pathways in diverse tissues, and individual isoforms are known to 
interact with effectors such as PI3K, AKT and PKC (129). Rab proteins 
have previously been implicated in GLUT4 translocation (127): rab4 
(130); rab5 (131); ra b ll (54), and more recently 3 Rab species (Rab 10, 
Rab 11 and Rab 14) were shown to be present on GLUT4 vesicles (132). 
In spite of this, none are known to interact with AS160, and the cognate 
AS 160 Rab remains unknown.
Targeted disruption of AS 160 using RNAi methods results in 
redistribution of GLUT4 from intracellular locations to the plasma 
membrane, and is associated with a corresponding increase in insulin- 
stimulated glucose uptake (40;132). The subsequent re-expression of 
AS160 restores GLUT4 translocation (and insulin-stimulated glucose 
uptake) to wild-type levels; this is not seen when a mutant with absent 
Rab-GAP activity is expressed (40). Furthermore, AS 160 has been 
shown to associate with the Insulin Regulated Amino-Peptidase (IRAP)
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when present on GSVs, and is released upon insulin stimulation (132). 
These data point to a role for AS 160 (and its downstream effector(s)) in 
the basal intracellular restriction of GLUT4.
AS160 has recently been shown to interact with members of the 
14-3-3 family of proteins in an insulin and AKT-dependent manner (133). 
14-3-3 proteins are a highly conserved seven-member family (in 
mammals) which interact with phospho-residues in a variety of different 
proteins (>200 identified to date) in a multitude of cellular processes in all 
tissues studied (134). In spite of apparent specificity, the observed 
interaction of AS 160 with all 7 of the 14-3-3 isoforms described, together 
with the promiscuity observed in subsequent downstream 14-3-3 
interactions, implies that AS 160 /14-3-3 interaction is unlikely to reflect 
the major role for AS 160 in insulin action. Whether AS160s interaction 
with 14-3-3 has influence over its GAP activity will not be determined until 
the elusive cognate AS 160 Rab is identified.
1.3.3.6. PIKfyve
Another downstream target of AKT identified by an identical 
immunoprécipitation / mass-spectrometry technique is Phosphatidyl- 
inositol 3-phosphate 5-kinase (PIKFyve; (135). This mammalian 
homologue of the yeast Fablp protein (shown to regulate late endosome 
to lysosome trafficking (136) was originally identified in adipose tissue 
and was shown to be present in skeletal muscle (137;138). PIKFyve is
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composed of a Pi3P-binding FYVE domain, a DEP (dishevelled, Egl-10 
and Pleckstrin-Homology) domain of uncertain function alongside the 
PI3P 5-kinase domain.
PIKFyve was initially shown to exist predominantly in the cytosol, 
with a portion in the LDM fraction (discrete from GLUT4) and the PM. 
Some PM PIKFyve was found in detergent-resistant PM microdomains 
(lipid rafts; see 1.4.4 below). Subcellular distribution of PIKFyve was 
shown to be altered by insulin (139). Further elegant studies (135) 
demonstrated insulin and PI3K-dependent PIKFyve (S318) 
phosphorylation, revealed colocalisation of PIKFyve with a highly mobile 
subpopulation of GLUT4-containing vesicles which travelled from the PM 
region to the perinuclear region, and demonstrated increased GLUT4 
delivery to the PM in cells transfected with S318A PIKFyve mutant. 
Together these data point to a role for PIKFyve in the regulation of 
GLUT4 subcellular distribution, which may be altered by insulin.
PIKFyve is one of two enzymes that have been proposed to be 
capable of generating PI(3,5)P2 and PI(5)P. These lipid species (found at 
low level in mammalian cell membranes) are part of a 7-member family of 
phosphoinositides, which are believed to be key regulators of various 
signal transduction mechanisms (reviewed in (140;141). The role of other 
phosphoinositide species in the regulation of insulin action is described in 
section 1.4.2.3 above. That PI(3,5)P2 and PI(5)P are found in 3T3-L1
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adipocytes at significant levels suggests that they too may also play a 
role in regulating insulin action.
1.3.3.7. The Alternative CAP / Cbl / TC10 Signalling Pathway
The activated insulin receptor recruits additional downstream 
effector proteins implicated in a second signalling pathway leading 
ultimately to glucose uptake. Originally identified as a PH domain-, and 
SH2 domain-containing gene using the yeast 2-hybrid screening 
technique in Burkitt’s Lymphoma cells and implicated in signalling 
downstream of the B-lymphocyte antigen receptor (142), Adaptor Protein 
Containing a Pleckstrin homology and SH2-domain (APS) is an adaptor 
protein expressed in skeletal muscle, adipose and cardiac muscle which 
is recruited to the phosphorylated IR via SH2 domains (143;144). APS is 
itself tyrosine phosphorylated by the IR (143;144), which then allows 
recruitment of c-Cbl (Cbl), with which it forms a complex.
Cbl is a cellular homologue of a murine retroviral oncogene (145) 
which is implicated in a variety of cell signalling cascades (EGF, PDGF, 
integrins, cytokines etc.; reviewed in (146)). Cbl Associated Protein (CAP) 
is also recruited to the IR / APS / Cbl complex. By virtue of its binding to 
the lipid raft domain protein Flotillin (147), CAP recruits activated Cbl to 
cortical F-actin in PM lipid raft microdomains. This microdomain targeting 
is required for insulin-stimulated GLUT4 translocation (148).
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Insulin is known to stimulate tyrosine phosphorlyation of Cbl, which 
in turn allows Cbl to bind Crk (another cellular oncogene (149); (150).
This interaction has been shown to be dependent upon APS (151). 
Recruitment of Crk also brings the guanine-nucleotide exchange factor 
C3G to the PM on account of their constitutive association (152). C3G 
catalyses exchange of GTP for GDP in a number of small G proteins, 
including TC10 of the Rho-family (153; 154).
Rho-family GTPases are well known to regulate cellular actin 
dynamics (reviewed in (155)), and this property of TCI 0 is recognised in 
3T3-L1 cells (156). Activation of TCI 0 within caveolae leads to 
recruitment of other molecules (discussed in (157)) which interact with the 
cytoskeleton, and the exocyst complex, both of which have been 
implicated in insulin-stimulated GLUT4 translocation. Reviewed by (158).
40
00mIiCO
■ O5
(DTD8(/}(0OO)c
10c.g>
CO
" 3CO_c
CD
CO0_
irT
COÛ-
IICOCL
CMQ.in
CL
IICMCL
0c2X)
E0
(0E0JO
CL
II
I0Q .0IC
C3
II C^
IQC
30_C
IIÛC
Q .IIeII01
o> OÎu_u.
Evidence exists that challenges the alternative CAP / Cbl / TC10 
pathway described above. APS deficient mice are more insulin sensitive 
than wild-type (159) and c-Cbl knockout and mice have subsequently 
been shown to be more insulin sensitive than wild-type (160), the 
opposite phenotypes expected to that suggested by the alternative 
signalling pathway model. In direct opposition is the demonstration that 
siRNA-mediated depletion of Cbl, CAP and Crk had no effect on insulin- 
stimulated glucose uptake or labelled GLUT4 delivery to the PM in 3T3- 
L1 cells (161). The same authors observed that, at least in ex-vivo 
adipocytes, insulin-stimulated glucose uptake is identical in c-Cbl 
knockout and wild-type mice (compare with (160). Furthermore, there are 
observed differences in the role of TCI 0 in the adipocyte and skeletal 
myocyte (162), and Cbl is not seen to be phosphorylated in vivo in 
response to insulin- stimulation (163).
Together, these data call into question the significance of the 
alternative pathway. Not until each step in this model is rigorously tested 
at the cellular, tissue or whole organism level will this issue be fully 
addressed.
A graphical model summarising the current pathways of insulin 
signalling to GLUT4 translocation is seen in Figure 1.1.
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1.3.4. Subcellular Regulation of GLUT4 Trafficking
The finding that cell surface-labelled GLUT4 was rapidly 
internalised in unstimulated cells provides evidence that even in the basal 
state GLUT4 continually recycles between the PM and an intracellular 
location (164). By means of the complex signalling processes described 
above, insulin stimulation significantly increases exocytosis of GLUT4 
vesicles (165; 166) whilst also reducing the rate of internalisation of 
GLUT4 (167). The resulting net increase in cell surface GLUT4 (10 to 20- 
fold) is responsible for insulin stimulated glucose uptake.
Early experiments demonstrated glucose transporter activity 
cofractionated with markers of the Golgi apparatus (168). Subsequent 
more detailed subcellular analysis demonstrated the presence of GLUT4 
in multiple membrane compartments within adipocytes and skeletal and 
cardiac myocytes (169) including sorting endosomes, recycling 
endosomes, the trans Golgi Network (TGN), and vesicles. The presence 
of GLUT4 within the endosomal compartments is reminiscent of other 
proteins (e.g.. the Transferrin Receptor (TfR)) which cycle between the 
PM and these intracellular locations in perpetuity. In skeletal muscle, 
cardiac muscle and adipose cells stimulation with insulin increases 
general endosomal to PM transport, resulting in delivery of many species 
including the TfR to the PM.
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One important difference between these proteins and GLUT4 is 
that in the presence of insulin stimulation, the initial delivery of GLUT4 
occurs at a much faster rate than that of the TfR (170). This, alongside 
observations that in unstimulated cells a significant quantity of 
intracellular GLUT4 is not located within the endosomal system (171), 
and that endosomal ablation failed to prevent insulin-stimulated GLUT4 
translocation (172) suggests that GLUT4 is retained in a readily 
releasable pool outwith the endosomal system.
The TGN is known to play a role in the post-endosomal sorting and 
recycling of a subset of PM proteins (173). A significant fraction of GLUT4 
is found in the TGN (20%), and an acidic motif at the carboxy-terminal 
has been shown to facilitate the transport of GLUT4 from the endosomes 
to the TGN (174). GLUT4 colocalises with Adaptor Protein 1 (175), a 
heterotetrameric coat protein which plays an important role in the genesis 
of vesicles which transport from the TGN, and the Cation-dependent 
Mannose-6-phosphate Receptor (CD-MPR). These molecules are known 
to traffic from the TGN back to the endosomal system, suggesting GLUT4 
also recycles between these organelles (175).
The majority of intracellular GLUT4 is localised on vesicles (so- 
called GLUT4 Storage Vesicles or GSVs), which are responsible for the 
majority of the insulin-regulatable intracellular pool of GLUT4 (176). 
GLUT4 within these vesicles is discrete from the constitutively recycling 
AP-1 and CD-MPR described above (177; 178). The GSVs contain
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molecules such as I RAP, which is known to traffic with GLUT4, and the v- 
SNARE VAMP2, which participates in the delivery of GLUT4 to the PM 
(see 1.5.2 below).
Thus the current model of intracellular GLUT4 trafficking (as 
proposed by (179)) describes two continuous intracellular recycling 
pathways; the first between the PM and the endosomal system, and the 
second between the TGN and endosomes. Sorting occurring at the 
interface between the first and the second cycle would be the first step in 
the sequestration of GLUT4 into an insulin-responsive compartment. 
Once entered into the second cycle a further sorting step would be 
required to segregate the GLUT4 destined to become packaged into the 
specialised GSV pool, and GLUT4 not redirected in this way would be 
returned to the first cycle. Thus, PM GLUT4 in the basal state is largely 
derived from the first cycle. A schematic diagram of intracellular GLUT4 
trafficking is seen in Figure 1.2 below.
Stimulation with insulin increases general endosomal trafficking, 
including the rates of both cycle 1 and cycle 2, but this would make only a 
minor contribution to the large upregulation of PM GLUT4 seen. Most 
apical GLUT4 in the insulin-stimulated state is due to GSV translocation 
to and subsequent SNARE-mediated fusion with the PM.
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Figure 1.2
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Figure 1.2 Schematic Representation of Intracellular GLUT4
Trafficking. In the basal cell GLUT4 continually cycles 
between the Plasma Membrane (PM), Early Endosome (EE) 
and Recycling Endosomal (RE) compartments (Cycle 1), 
and also between the RE and Trans-Golgi Network (TGN) 
(180). Sequestration from the TGN into the GLUT4 Storage 
Vesicle (GSV) compartment creates the insulin responsive 
GLUT4 pool, which is rapidly mobilised to the Plasma 
Membrane in response to insulin stimulation. Arrows indicate 
direction of trafficking.
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1.4. The SNARE Hypothesis
Regulated Exocytosis, the tightly controlled process whereby 
membrane-limited cellular organelles fuse with the plasma membrane, 
governs a diverse array of cellular functions ((181; 182) and Table 1.4 
below). In all eukaryotic cells regulated exocytosis is controlled by 
SNARE (183) and SNARE-associated proteins (184). This well conserved 
group of membrane-tethered proteins possess conserved coiled-coil 
regions capable of specific interaction with cognate partners. Once 
located adjacent to the plasma membrane, the engagement of the v- 
SNAREs (185) and t-SNAREs (186) in a specific fashion to form a ternary 
complex (termed "docking") between the correct SNARE (and accessory) 
proteins allows the vesicle membrane and plasma membrane to come 
into close proximity, overcoming the energy barrier to membrane fusion 
(Figure 1.3). At this docking stage the involvement of further proteins 
(including Seel-like and Munc18) contributes to the regulation of 
membrane fusion (reviewed in (187).
47
Figure 1.3
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Figure 1.3 Schematic representation of the neuronal SNARE complex.
VAMP {(  > ), present on the vesicle membrane forms a 4- 
helix SNARE complex with Syntaxin ( O )  and SNAP (CD ) 
located on the plasma membrane, bringing together the 
vesicle and plasma membranes, which ultimately fuse. 
Adapted from (188).
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Classification of Regulated Exocytosis
Secretory Non-Secretory
Neurotransmission Protein Translocation
• Receptors
• Channels
• Pumps
Neurosecretory / Endocrine Cells
• Adrenal
• Pituitary
Exocrine Glands
• Pancreas
• Breast
Membrane Donation
• Cellularisation
• Axon / dendron growth
• Phagocytosis
• Membrane repairMacrophages / other immune 
cells
Table 1.4: Classification of Regulated Exocytosis
1.4.1. The Neuronal SNARE Complex
Neurotransmission depends upon SNARE-mediated fusion of 
synaptic vesicles with the presynaptic membrane, and is the best 
characterised example of SNARE-mediated regulated exocytosis. The 
neuronal SNARE complex is composed of the v-SNARE VAMP-2, and 
the t-SNARES Syntaxin~1A and SNAP-25 (184).That SNARE-complex 
formation occurs in vitro, followed by membrane fusion between vesicles
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decorated with these SNARE proteins alone (189) suggests that no other 
species is absolutely required for cellular membrane fusion. The in vitro 
fusion occurs at a much slower rate than that observed in vivo, and many 
other proteins have been shown to interact with the SNARE proteins 
(190) thus influencing the speed of the reaction. Recently, post- 
translational modification of SNARE proteins, and especially 
phosphorylation (reviewed in (191) has been demonstrated to regulate 
SNARE complex formation and function. SNARE proteins and the 
SNARE protein complex are extensively reviewed in (192).
It has long been known that in neurons calcium is required to 
trigger exocytosis of synaptic vesicles (193) and that this calcium 
requirement reflects an important role for calcium ions in the formation of 
the ternary SNARE complex. It is envisaged that the SNAREs ‘zipper-up’ 
in a calcium-dependent manner, driving fusion (181). The calcium- 
sensing proteins involved at this step are known as synaptotagmins 
(SYTs) and function by binding the ternary complex and both the 
vesicular and presynaptic membranes (see 1.5 and Figure 1.6 below). 
Upon the arrival of calcium, a conformational change in the protein 
complex allows fusion of vesicle and target membranes and thus delivery 
of neurotransmitter to the cell surface.
50
1.4.2. SNARES Involved in GLUT4 Translocation
The identity of vesicles containing GLUT4 (194; 195)) moving to the 
plasmalemma of skeletal muscle and adipose cells in response to insulin 
stimulation (196) led to the analogy between this mechanism and that of 
neurotransmission being made. The resulting search for homologues of 
the neuronal SNAREs led to the identification of first VAMP-2 (197; 198) 
and then Syntaxin-4 (195;199) in GLUT4-containing insulin responsive 
membrane compartments. The SNAP-25 homologue SNAP-23 was then 
described in rat adipocytes, was noted to bind Syntaxin-4 in vivo and to 
be capable of participating in an in vitro complex formation with Syntaxin- 
4 and VAMP-2 (200). The requirement for these species in insulin action 
was demonstrated by the reduction of insulin-stimulated GLUT4 
translocation when their in vivo association is disrupted (201-203) or 
when the SNAREs are mutated to abrogate binding. Also, the study of ex- 
vivo human adipocytes taken from subjects with T2DM were shown to be 
docked but not fused with the plasma membrane (204), supporting the 
hypothesis that GSV-plasmalemma fusion is an essential step in both 
cellular and whole body insulin sensitivity.
1.4.3. The Role of Calcium in Insulin-stimulated GLUT4 
Translocation
The role of calcium as the trigger for SNARE-mediated neuronal 
and neuroendocrine vesicle fusion is well established (see below and
51
(192). The role of calcium in insulin signal transduction or GSV-PM fusion 
in insulin sensitive tissues is less clear and has become the matter of 
much debate. The first studies of calcium in murine muscle cell line LG 
myocytes (205), the murine adipocyte cell line 3T3-L1 (206), rat 
adipocytes (207), and rat cardiac myocytes (208) were universal in their 
conclusion that calcium played no apparent role. Around the same time 
results from independent experiments performed on rat adipocytes 
suggested that calcium played a permissive role in insulin action (209- 
211).
Upon further scrutiny, the techniques used in all of these systems 
to detect calcium concentration flux were rather crude; whilst sensitive to 
large changes in calcium concentration within the entire cell they would 
fail to detect small perturbations in local calcium concentrations such that 
would be expected to occur in a tightly-controlled physiological process. 
Along similar lines the ionophores and chelators used to influence 
intracellular calcium concentration would effect large whole-cell changes 
that would likely swamp normal physiology. Calcium is likely to exert its 
influence upon insulin action at one or more specific timepoints in the 
signal transduction pathway that are both temporarily and spatially limited 
within the cell. This is especially more likely in the case of skeletal muscle 
and cardiac muscle where intracellular calcium flux has a central 
regulatory influence over contractility and neuronal stimulation of 
contraction.
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A more recent study in 3T3-L1 adipocytes provided strong 
evidence of a role for calcium in both insulin signal transduction and 
GSV-PM fusion (212). When a rapid calcium chelator was used insulin- 
stimulated AKT phosphorylation was reduced, and GLUT4 was present at 
the cytoplasmic but not the extracellular face of the PM (implying GSVs 
were docked but not fused). The implication is of a requirement for 
calcium at the final stages of GLUT4 translocation e.g. GSV-PM fusion.
Targeted knockout of Voltage-regulated Potassium Channel Kv1,3 
has been shown to produce mice with lower body weight, resistance to 
diet-induced obesity and a significantly higher basal metabolic rate than 
their wild-type littermates (213). Intriguingly, pharmacological inhibition of 
the same channel improved peripheral insulin-sensitivity and apparently 
potentiated GLUT4 translocation in wild-type, obese and diabetic mice 
(214). The same group have recently reported a similar effect by toxin- 
mediated Kvi .3 inhibition in adipocytes and skeletal muscle (215). 
Inhibition of the Kvi .3 channel resulted in a wortmannin-insensitive 
increase in insulin-stimulated GLUT4 translocation. This increased 
GLUT4 translocation and glucose uptake was abolished by dantrolene, 
an agent which blocks the release of stored intracellular calcium. These 
data are in support of a requirement of calcium in insulin action 
downstream of PI3K.
Further evidence of a permissive role for calcium is provided by 
recently published work in which pharmacological modulation of non-
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selective cation channels was used to influence Insulin-stimulated 
glucose uptake in isolated murine muscle fibres and whole muscles from 
both normal and insulin resistant mice (216). The investigators report 
reduction in insulin-stimulated glucose uptake with reduced calcium 
influx, and increased insulin-stimulated glucose uptake with increased 
calcium. Interestingly there was no observed influence of either 
intervention over basal, hypoxia- or contraction-induced glucose uptake, 
and no observed changes in AKT phosphorylation. These data support a 
role for calcium downstream of AKT.
Thus three recent independent studies have produced robust data 
consistent with a requirement for calcium ions in insulin-stimulated 
glucose transport in sensitive cells. This requirement Is downstream of 
PI3K or AKT, and may be at the level of GSV-PM fusion. The calcium can 
be derived from either intracellular stores or from inward flux from the 
extracellular space. Such a requirement for calcium suggests a calcium- 
sensing moiety is also required for insulin action: no such molecule has 
previously been confirmed to fulfil this role in any tissue studied.
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1.5. Synaptotagmins
1.5.1. Overview
Synaptotagmin was initially identified as a 65kDa component of the 
neurotransmitter vesicle (217). Subsequent studies confirmed its ability to 
bind calcium (218) and its role in calcium-stimulated neurotransmitter 
vesicle fusion with the presynaptic axonal membrane. The highest level 
of expression of any SYT isoform is observed within the brain, and most 
of the published data describing SYTs is derived from studies of isoforms 
which participate in neural and neuroendocrine systems. Using high 
throughput expression profiling, transcripts of most SYT isoforms can 
also be detected in a variety of extraneuronal tissues (219) and particular 
family members have been assigned a key role in diverse biological 
processes (e.g.. SYT1 and SYT2 in mast cells (220;221), SYT6 and 
SYT8 in the acrosome reaction (222), SYT7 in fibroblast membrane 
repair (223)). The precise role of most SYT isoforms outwith the neural 
and neuroendocrine systems remains largely unknown.
Each member of the SYT family of proteins shares the same basic 
structure (224); a single amino terminal transmembrane domain followed 
by tandem C2 domains (termed C2A and C2B) connected by a short 
linker region (Figure 1.6a and 1.6b). Constant Sequence 2 (02) domains 
were originally described in Protein Kinase C, where they were shown to 
promote membrane localisation in response to binding of calcium ions
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(225). This property was confirmed in SYTs during the initial work with 
SYT 1, and was shown to be due to increased C2 affinity for 
phospholipids upon calcium binding (218). Subsequent studies have 
revealed variable SYT affinity for calcium, with some SYT isoforms 
unable to bind calcium at all (226;227).
1.5.2. Synaptotagmin Genetics
Genomic studies have revealed the presence of 16 highly 
conserved SYT genes in the higher eukaryotic genomes (228). SYT 
genes are located throughout the autosomes of both human and mouse 
genomes, and gene products are known to be translated from transcripts 
comprising 4-11 exons (229). A similar (although not identical) intron 
position is observed within the coding sequence of family members 
(230;231), indicating a likely common ancestor. The transmembrane 
domain is always encoded by a single discrete exon, and splice variants 
resulting from transmembrane exon-skipping have been described for 
several isoforms (232;233). This suggests there may be an (as yet 
undefined) important physiological role for soluble versions of these 
normally membrane-bound proteins. Chromosomal location and gene 
structure for human and murine SYT1-15 is found in Table 1.5 below.
Splice variants resulting in altered molecular phenotype have been 
described for SYT1 (234;235) ,SYT7 (180;236) and SYT8 (237). 
Alternative transcripts are available in online databases for SYT2, SYT3
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and SYT14 (229), although no corresponding functional data are 
published to date.
Synaptotagmins have been implicated in a variety of neurological 
and psychiatric diseases: SYT1 expression appears to be altered in 
certain brain regions in Alzheimer’s disease (238) and Trisomy 13 (239), 
SYT4 knockout mouse has defects of memory and motor function (240), 
SYT4 and SYT 11 are expressed in the substantia nigra and interact with 
proteins known to play a role in Parkinson’s disease (24T,242). 
Furthermore, SYT1 has been Identified as key antigen in the 
paraneoplastic Lambert-Eaton Myaesthenic Syndrome (usually 
associated with small cell bronchial carcinoma) (243). Interestingly, the 
autoimmune myositis associated with the SYT7 knockout mouse is a 
similar phenotype (223). In spite of these disease associations no 
naturally occurring mutations or gene polymorphisms associated with 
human disease have been reported for any SYT family member.
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Table 1.5
Isoform Human Murine
Chromosomal
Location
Exons Chromosomal
Location
Exons
SYT1 12q21.2 11 10 11
SYT2 1q32.1 9 1 9
SYT3 19q13.33 11 7 10
SYT4 18q12.3 4 18 4
SYT5 19q13.42 9 7 8
SYT6 1p13.2 8 3 6
SYT7 16p12.3 8 19 13
SYT8 11p15.5 6 7 9
SYT9 11p15.4 7 7 6
SYT10 12p11.21 7 15 7
SYT11 1q22 4 3 4
SYT12 11q13.2 11 19 8
SYT13 11p11.2 6 2 6
SYT14 1q32.2 8 1 6
SYT15 11q2.2 7 14 8
Table 1.5 Chromosomal location and gene structure of human and 
murine SYT genes.
58
The transcriptional regulation of the SYT genes is in general poorly 
described in the literature. PDX-1, a transcription factor essential for 
pancreatic development and normal function (244) has been 
demonstrated to play a role in SYT1 expression in insulin-secreting cell 
lines (245). The promoter of SYT 11 is known to possess a polymorphic 
33bp repeat motif (246), increased copy number of which has been 
shown to result in increased expression of a downstream reporter gene. 
Cytosine residues on the coding strand of same gene promoter are 
known to be methylated (247). The same authors have demonstrated 
transcription factor binding to the promoter is reduced when residues are 
methylated, and reporter gene expression is subsequently reduced. The 
finding that the degree of SYT11 promoter méthylation varies between 
tissues suggests this epigenetic phenomenon may play a role in 
regulation of SYT gene expression.
Comparison of the murine SYT protein sequences shows similarity 
between isoforms that can be attributed similar structure and function 
(78% alignment for SYT 1 and SYT2, 61 % alignment for SYT6 and 
SYT10). An alignment of 13% between the protein sequences of SYT9 
and SYT14 is the lowest observed between any family members 
(Alignment of the murine SYT protein sequences is shown in Figure 1.4 
below). The most highly conserved residues correspond to those amino 
acids with a key structural role e.g.. maintenance of the hydrophobic core 
of the C2 domains (248) whereas residues mapped to the surface of each
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C2 domain are conserved only between related isoforms. Thus evolution 
of the SYT family has allowed conservation of domain structure (and by 
implication, function) whilst permitting the interaction of discrete family 
members with alternative effector molecules.
A cladogram of murine SYT protein sequences is shown in Figure 
1.5 below.
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Mus_syt4
Mus_sytll
Mus_sytl3
Mus_sytl5
Mus_sytl2
Mus^sytl4
 ATE 3
---------- MRNIFKRNQEPNVAPATTTATMPLAPVAPADNSTE 3 5 MFPE 4
 MKMGHALN 8
------------- MSGVWGAGGP RCQAALAVLASLCRA 2 5
------------- MSFRKEDGVSS LCQKALHIITELCFA 2 6
-AGRRRAFSRARLPGAVRGCGGAMPGARDALCHQALQLLAELCAR 4 4 
----------------- MSGDYEDD LCRRALILVSDLCAR 23
-------------------------------------------------MAPITTSRVEFDEIPT 16-------------------------------------------------MAEITNIRPSPDVSPV 16
-------------------------------------------------MVLSVPVIALGATLGT 16-------------------------------   MAEQLAFLIGGIIGG 15
------------------------------------------ MAVDVTEYHLSVIKSPPGWEVG 22
MAIEGGERTCGVHELICIRKVSPEAVGFLSAVGVPIVLMLLLFLYINKKPCFENVGGFPD 60
Mus_sytl
Mus__syt2
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Mus_sytl KGGKNAINMKDVKDLG-----------------------------------------------------  8 6
Mus_syfc2 KGMKNAMNMKDMK--------------------------------------------------------- 115
Mus_syt5 QAQVHLQEVKELG--------------------------------------------------------- 78
Mus^syte KETVGLGSARNST--------------------------------------------------------- 92
Mus_syt6 PASETLQSPSSRGNMA------------DKLKDPSALGFLEAAVKISHTSPDIPAEVQMSV-- 149
Mus_sy110 SAPTEVFETEEKKEVE------------ENEK--PAPKAIEPAIKX SHTS PDIPAEVQTAL-- 14 8
Mus_syt9 QEPLNYTDTETMEQEN------------SEDFLDPPTPCPDSSMKISHTSPDIPLSTQPGG-- 166
Mus_syt3 PPFAELLEPGGLGGSEPPEPSYLDMDSYPEAAVASWAAGVKPSQTSPELPSEGGTGSGL 2 00
Mus_syt7 NSLETVGTPDSGRGRG-------------------------------- EKKAIKLPAG-------- 76
Mus_syt4 LPNLSLHLDLEKRDLN----------------------------- GNPPKANPKAGSSSD----- 117
Mus_sytll SGRGNLLINAESGLLS----------------------------- HDKDPRGPSPASCMD----- 119
Mus_sytl3 VTAPEVINYADYTLET----------------------------TEESAAPASPQAQSDSR---- 121
Mus_sytl5 HGGDWAVAPQDPCPVP--------------------------------- EHMACTSS---------- 112
Mus_sytl2 KGSLSIEDTFESISELG----------------------------------------------------  111
MU3_Bytl4 DGYSTEASMEDGNCIQR----------- MRRTPPLDELQPPPYQDDSGSPHLSCTPSEIGDA 187
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Mus_syt2
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Mus_sytlO
Mus_syt9
Mus_syt3
Mus_syt7
Mus_syt4
Mus_sytll
Mus_sytl3
Mus_sytl5
Mus_sytl2
Mus_sytl4
Mus_sytl
Mus_syt2
Mus_syt5
Mus_syt8
Mus_syt5
Mus__sytlO
Mus_syt9
Mus_syt3
Mus_syt7
Mus_syt4
Mus_sytll
Mus_sytl3
Mus_sytl5
Mua_sytl2
Mus_aytl4
Mua_sytl
Mus_syt2
Mus_syt5
Mus_syt8
Mus_syt6
Mus_sytlO
Mus_ayt9
Mus_syt3
Mus_ayt7
Mus__syt4
Mus_aytll
Mus_sytl3
Mus ayt: 15
Mus_sytl2
Mus_aytl4
Mus
Mus
Mus
Mus
Mus
Mus
Mus
Mus
Mus
Mus
Mus
Mus
Mus
Mus
Mus
syti
syt2
sytS
syt8
syt6
sytlO
syt9
syt3
syt7
syt4
sytll
sytl3
sytlB
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 KEHIMRHTKLQRQTTEPASSTRHTSPKRHLPRQMHVSSVDY----------GNELPP 196
 KEHLIKHARVQRQTTEPTSSSRHNSPRRHLPRQMNVSSVDPSV------- GTEPIL 197
 QENCAHAVRVQRQVTEPTPSARHNSIR RQLNLSNPDP----------- NIQQL 2 08
LLLPPSGGGLPSAQSHQQVTSLAPTTRYPALPRPLTQQTLTTQADPSTEERPPALPLPLP 2 60
------ GKAVNTAPVPGQTPHDESDRRT E 99
 L 118 Q 120
 L 122
 PLELM 116
KCEISHCSNSPRCSFNKCPSEGSTGHBAESYHN KGYE 2 24
-KTMKDQALKDDDAETGLTDGE---- EKBEPKEEEKLGKLQYSLDYDFQNNQLLVGIIQA 141
-GGQDDDDABTGLTEGEG EGEEEKEPENLGKLQFSLDYDFQANQLTVGVLQA 16 6
 RSYIDKVQPEIEELDRSPSM-PGQQVSDKHQLGRLQYSLDYDFQTGQLLVGILQA 132
------- TTHLVQPDVDCLEPCS---------- GGDQQWGRLLLSLEYDPGSQEIRVGLRQA 13 7
AAAEQPTSIGRIKPELYKQKSVDG--DDAKSEAAKSCGKINFSLRYDYESETLIVRILKA 254 
QRGETRTSIGRIKPELYKQKSVDS- -EGNRKDDVKTCGKLNPALQYDYENELLWKIIKA 255 
QRQEQLTGIGRIKPELYKQRSLDN--DDGRRSNSKACGKLNFILKYDCDLEQLIVKIHKA 266 
GGEEKAKLIGQIKPELYQGTGPGGRRGGGSGEAGAPCGRISPALRYLYGSDHLWRILQA 32 0 
TRSSVSDLVNSLTSEMLMLSPGSEEDEAHEGCSRENLGRIQPSVGYNFQESTLTVKVMICA 15 9 
ENVTPKLPTETEKEANSPESLKS-STSLTSEEKQEKLGTLFLSLEYNFEKKAPWNIKEA 177 
LPIKRDYGEELRSPMTSLTPGESKPTSPSSPEEDVMLGSLTFSVDYNFPKKALWTIQEA 180 
KRQVTEELSIRPQNGWEDVCVMETWNPEKAASWNQAPKLHFRLDYDQKKAELPVTSLEA 182
AKPGDACEMGSINPELYKSPEDTS ETGPPDGCLGRLWFSVEYQQESERLLVGLIKA 168
GRELDLAPYGTLRKSQSADSLNSISSVSNTPGQDFTLGQVEVSMDYDGASHTLHVAVLQG 176 
DDVPSDSTAVLSPEDMSAQGSSSQLPKPPDPEPEAKYGTLDVTPDYDSERQKLLVTVTAV 2 84
AELPALD-MGGTSDPYVKVFLLPDK-KKKPETKVHRKTLNPVFNEQPTFK-VPYSELGGK 198 
AELPALD-MGGTSDPYVKVFLLPDK-KKKYETKVHRICTLNPAFNETPTFK-VPYQELGGK 2 23 
QGLAALD-LGGSSDPYVSVYLLPDK-RRRHETKVHRQTLNPHFGETPAPK-VPYVELGGR 189
GNLKA EGTADPYAWVSVSTQS-GRRHETKVHRGTLSPMPEETCCFL-VPPAELPKA 191
FDLPAKD-FCGSSDPYVKIYLLPDR-KCKLQTRVKRKTLNPTFDENFHFP-VPYEELADR 311 
LDLPAKD-FTGTSDPYVKIYLLPDR-KKKFQTRVHRKTLNPLPDELPQFP-W Y D Q L S N R  312 
VNLPAKD-FSGTSDPYVKIYLLPDR-KTKHQTKVHRKTLNPVFDEVFLPP-VHYNDLEAR 323 
LDLPAKD-SNGPSDPYVKIYLLPDR-KKKFQTKVHRKTLNPIFNETFQFS-VPLAELAQR 377 
QELPAKD-FSGTSDPFVKIYLLPDK-KHKLETKVKRKULNPHWNETFLFEGFPYEKWQR 217 
QGLPAMDEQSMTSDPYIKMTILPEK-KHRVKTRVLRKTLDPVFGETFTPYGIPYPHIQEL 236 
HGLPVMDDQTQGSDPYIKMTILPDK-RHRVKTRVLRKTLDPVFDETFTPYGIPYSQLQDL 23 9
VTSDHEG GCDCYIQGSVAVKTGSVEAQTALKKRQLHTTWEEGLALP-LGEEELPTA 237
QQLQVPS--- ETC STLVKLHLLPDE-RRFLQSKTKHKICNPQFDENFIFQ-VS SKSVTQR 223
KDLLERE-EATFESCFMRVSLLPDE-QIVGISRIQRNAYSIFPDEKFSVP-LDPTALEEK 233 
TDIPTYN-RTGGNSWQVHLVLLPIK-KQRAKTSIQRG-PCPVPTETFKFNHVESEMIGNY 341
TLVMAVYDFDRFSKHDIIGEFKVP--MNTVD------------------------ FGH-VTEE 234
TLVMAIYDPDRFSKHDIIGEVKVP--MNTVD------------------------ LGQ-PIEE 2 59
VLVMAVYDFDRFSRNDAIGEVRVP--MSSVN------------------------ LGR-PVQA 225
TLKVQLWDFKRFSEHEPLGELQLP--LGTVD------------------------ LQH-VLES 22 7
KLHLSVFDFDRFSRHDMIGEVILDNLFEASD------------------------ LSR- ETSI 34 9
ICLHPSIYDFDRFSRHDMIGEVILDNLFEVSD------------------------ LSR-EATV 350
KLHFSVYDFDRFSRHDLIGQVWDHFFDLAD------------------------ FPR-ECIL 361
KLHFSVYDFDRFSRHDLIGQWLDNLLELAE------------------------ QPP -DRPL 415
VLYLQVLDYDRFSRNDPIGEVSIP-'LNKVD------------------------ LTQ-MQTF 2 53
SLHFTVLSPDRPSRDDVIGEVLIP--LSGIE------------------------ LSDGKMLM 273
VLHFLVLS FDRFSRDDVIGE VMVP - - LAG V D ------------------------ PSTGKVQL 276
TLTLTLRTCDRFSRHSVIGELRLG- -LDGAS------------------------ VPL-GAAQ 2 73
VLKFSVYHVNKKRKHQLLGQVLFP- LKNETL------------------------ AGDHHRII 2 61
SLRFSVFGIDEDERNVSTGWELK--LSVLD------------------------ LPLQPFSG 2 70
AVRFRLYGVHRMKKEKIVGEKIFYLTKLNLQGKMSLPVILEPSYNPSGCDSQVSLSEASC 4 01
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Mus_sytl WRDLQSAEKEEQEKLGDICFSLRYVPTAGKLTWILEAKNLKKMDVGGLS--DPYVKIHL 292
Mus__syt2 WRDLQGGEKEEPEKLGDICTSLRYVPTAGKLTVCILEAKNLKKMDVGGLS--DPYVKIHL 317
Mus_syt5 WRELQVAPKEEQEKLGDICFSLRYVPTAGKLTVIVLEAKNLKKMDVGGLS--DPYVKVHL 283
Mus_sytB WYQLGPPGTTEPEQMGELCFSLRYVPSSGSLTVWLEARGLN PGLA--EAYVKIQL 281
Mus_syt6 WKDIQYA-TSESVDLGEIMFSLCYLPTAGRLTLTVIKCRNLKAMDITGYS--DPYVKVSL 406
Mus_sytlO WKDIHCA-TTESIDLGEIMFSLCYLPTAGRMTLTVIKCRNLKAMDITGSS--DPYVKVSL 407
Mus_syt9 WKDIEYV-TNDNVDLGELMFSLCYLPTAGRLTITIIKARNLKAMDITGAS--DPYVKVSL 418
Mus_syt3 WRDILEG-GSEKADLGELNFSLCYLPTAGRLTVTIÏKASNLKAMDLTGFS--DPYVICASL 472
Mus_sy17 WKDLKPC-SDGSGSRGELLLSLCYNPSANS11VNIIKARNLKAMDIGGTS--D PYVKVWL 310
Mus_syt4 TREIIKRNAKKSSGRGELLVSLCYQSTTNTLTVWLKARHLPKSDVSGLS--DPYVKVNL 331
Mus_sytll TRDIIKRNIQKCISRGELQVSLSYQPVAQRMTVWLKARHLPKMDITGLSG-NPYVKVNV 335
Mus_sytl3 WGELKTTAKEPSAGAGBVLLSISYLPAANRLLWLIKAKNLHSNQSKELLGKDVSVKVTL 333
Mus_sytl5 WRDLEAKNLEPPSEFGDIQFCLSYNDYLSRLTVWLRAKGLQLQEDRSWS- - VFVKVSL 319
Mus_sytl2 MLYLQDQ-NKAADAVGEILLSLSYLPTAERLTWWKAKNLIMTNEKSTA- -DPFVKVYL 327
Mus_sytl4 GDSTSSCQSLQHGSVPEILIGLLYNATTGRLSAEVIKGSHFKNLAANRPP--NTYVKLTL 459
Mus_sytl
Mus_syt2
Mus_syt5
Mus_syt8
Mus_sytS
Mus_sytl0
Mus_syt9
Mus_syt3
Mus_syt7
Mus_syt4
Mus_sytll
Mua_sytl3
Mus_sytl5
Mus_sytl2
Mus_sytl4
Mus_sytl
Mus_syt2
Mus_syt5
Mus_sytB
Mu3_syt6
Mus_sytlO
Mus_syt9
Mus_syt3
Mus_syt7
Mu3_syt4
Mus__sytll
Mus_sytl3
Mus_sytl5
Mus_sytl2
Mus_sytl4
MQ-NGKRLKKKKTTIKKNTLNPYYNESPSFEVPFEQIQKVQVWTVLDYDKIGKNDAIGK 3 51 
MQ-NGKRLKKKKTTVKKKTLNPYFNESPSFEIPPEQIQKVQVWTVLDYDKLGKNEAIGK 376 
LQ-GGKKVRKKKTTIKKNTLNPYYNEAPSFEVPCDQVQKVQVELTVLDYDKLGKNEAIGR 34 2 
ML-NQRKWKKSKTSSKKGTTTPYPNEAPVPLVPVSQLQSVDLVLAVWARGLQLRTEPVGIC 340 
LC-DGRRLKKKKTTIKKNTLN PVYNEAIIPDIP PENMDQVSLLISVMDYDRVGHNEIIGV 4 65 
MC-EGRRLKKRKTTTKKNTLNPVYNEAIIFDIPPENVDQVSLCIAVMDYDRVGHNEVIGV 4 66 
MC-DGRRLKKRKTSTKRNTLNPVYNEAIVPDVPPESIDQIHLSIAVMDYDRVGHNEVIGV 4 77 
IS-EGRRLKKRKTSIKKNTLNPTYNEALVPDVAPESVENVGLSIAVVDYDCIGHNEVIGV 531 
MY-KDKRVEKKKTVTKKRNLNPIPNESPAPDIPTEKLRETTIIITVMDKDKLSRNDVIGK 369 
YH-AKKRISKKKTHVKKCTPNAVPNELFVPDIPCESLEEISVEFLVLDSERGSRNEVIGR 390 
YY-GRKRIAKKKTHVKKCTLNPVPNESFIYDIPTDLLPDISIEFLVIDFDRTTKNEWGR 394 
KH-QAQKLKKKQTKRAKHKINPVWNEMIMFBLPDDLLRASSVELEVLGQGEEGPSCELGH 392 
MN - HNKPVKCKRTSAVLGSVWPVYNETFS FKVDTNELDTAS LSLWLQTTEGNKSS PLGR 3 78 
LQ-DGRKMSKKKTAVKRDDPNPVPNEAMIFSVPAIVLQDLSLRVTVAESSSDGRGDNVGH 3 86 
LNSMGQEMSKCKTSTRRGQPNPVYKETFVFQVALPQLSDVTLILSVYNRRSMKRKEMIGW 519
VFVGYNSTG- - AELRHWSDMLANPRRPIAQWHTLQVEEBVDAMLAVKK-------------- 397
IFVGSNATG- -TELRHWSDMLANPRRPIAQWHSLKPEEEVDALLGKNK-------------- 422
VAVGAAVGG--AGLRHWADMLANPRRPIAQWHSLRPPDRARPIPAP---------------- 336
VLLGSRASG--QPLQHWADMLAHARRPIAQWHHLRSPREVDRVLALQPRLPLLRPRS-- 395
CRVGINAEG--LGRDHWNEMLAYPRKPIAHWHSLVEVK KSFKEG TPRL  511
CRTGLDAEG--LGRDHWNEMLAYHRKPITHWHPLLELPGRATSFDSQGSCSSPRPPSTP 523
CQVGNEAER--LGRDHWSEMLSYPRKPIAHWHSLMEKR-------------------------- 513
CRVGPEAADP-HGREHWAEMLANPRKPVEHWHQLVEEKT-LSSPTKGGKGLSEKENSE- 587
IYLSWKSGP- -GEVKHWKDMIARPRQPVAQWHQLKA---------------------------  403
LVLGATAEG- -SGGGHWKEICDFPRRQIAKWHMLCDG-------------------------- 425
LILGAHSVTT-SGAEHWREVCESPRKPIAKWHSLSEY -------------------------- 430
CSLGLHASG--SERSHWEBMLKNPRRQIAMWHQLHL---------------------------  426
VWGPYMYTRGKELEHWGEMLRKPKELVKRWHALCRPTEP------------------------418
VIIGPGVSG- - MGTTHWNQMLATLRRPVSMWHPVRRN--------------------------- 421
ISLGLNSSGE-EELRHWTAMKESKGQQVCRWHALLB---------------------------  554
Figure 1.4 Amino acid sequence alignment of murine SYT 1-15.
Mus_syt1, Mus_syt2 indicate murine SYT 1, murine SYT2 
etc.. * indicates an identical residue, : indicates a conserved 
substitution and . indicates a semi-conserved substitution. 
Sequence alignment performed using Clustalw software 
(249).
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1.5.3. C2 Domains
The structure of the C2A domain of SYT 1 (the first C2 domain 
structure to be determined) is composed of a rigid 8-stranded structure of 
two 4-stranded p-sandwiches with protruding flexible loops which contain 
coordinating residues required for the binding of calcium (250). Upon 
binding calcium in the presence of phospholipid membranes, the tips of 
these coordinating residues are inserted into the lipid bilayer (251;252) 
(Figure 1.6c), which serves to further increase the avidity of calcium 
binding by providing negatively charged phospholipid headgroups to 
assist in the coordination of calcium ions (218).
Differences exist in the properties of distinct C2 domains. SYT 1 
C2A binds 3 calcium ions whereas C2B binds only 2 (253;254). Isolated 
SYT1 C2A interacts with calcium and phospholipid (phosphatidyl-serine 
and phosphatidyl-choline) bilayers as described above, but isolated C2B 
domains of SYT 1 bind only weakly to phospholipids in the presence of 
calcium during in vitro assays (253). Soluble constructs containing mutant 
C2A domains (in which the calcium ligands are mutated) alongside wild- 
type C2B domains exhibited increased lipid binding compared to C2B 
domains alone (255) (256). These data indicate that cooperativity exists 
between the tandem C2 domains of SYT 1, such that the affinity of C2B 
for phospholipid in the presence of calcium is increased by the presence 
of C2A.
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Like the insulin signalling pathways described above, 
neurotransmission and neuroendocrine secretion depend upon the 
regulation of polyphosphoinositide species (258;259). SYT C2B domains 
have been shown to bind in inositol polyphosphates in a calcium 
independent manner via a 30 amino acid motif, whereas C2A binding to 
the same species is dependent on calcium (260). Subsequent studies 
confirmed that C2B bound polyphosphoinositide membranes (with 
variable specificity depending upon the presence of calcium) with only 
minimal contribution of C2A (261 ). Further work has shown that the 
presence of particular phosphoinositide species in a target membrane 
may act as physiological modulators of SYT calcium affinity (262). These 
data suggest a mechanism by which SYT species can integrate signalling 
cascades with depolarisation-induced changes in intracellular calcium 
concentrations to promote vesicle fusion.
In spite of variable calcium and phosphoinositide binding, overall 
C2 domain structure is highly conserved between different isoforms which 
possess differing biochemical properties, and across phyla (228), 
suggesting that loss of metal ion binding ability does not necessarily 
reflect loss of function.
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1.5.4. SYT Interactions
1.5.4.1. SYT Oligomerisation
SYT can form oligomeric complexes (both homo- and hetero­
oligomers) either dependent or independently of calcium. The calcium- 
dependent oligomerisation is mediated by residues in the C2B domain 
(263-265), whereas calcium independent self-binding depends upon 
residues present at the amino terminus, the region between the 
transmembrane domain and C2A, and the spacer region between C2 
domains (266-268).
The function of SYT oligomerisation is unclear. The recruitment of 
additional SYT molecules to an assembled SNARE complex via calcium- 
dependent oligomerisation may drive fusion ; C2B mutations that abolish 
this property have been shown to impair SYT / SNARE complex 
formation in vitro and neurotransmission in vivo (269;270). It has been 
proposed that hetero-oligomerisation of SYTs in vivo resulting in the 
production of long multimeric complexes may function to bring together 
protein complexes present on opposing intracellular membranes, thus 
contributing to the specificity of membrane fusion events (271). Whilst it 
has been demonstrated that SYT isoform ratio can influence calcium 
dependency and formation of certain specialised neuroendocrine 
exocytosis intermediates (SYT1 and SYT4 and the fusion pore (272);
6 8
SYT1 and SYT4 and the choice between “kiss and run” and full fusion 
(273), this hypothesis is yet to be fully tested experimentally.
1.5.4.2. SYT - SNARE Interactions
The t-SNARE Syntaxin was initially identified in a 
coimmunoprecipitation experiment using an antibody against SYT1 (274) 
and as the target of an antibody raised against partially purified neuronal 
proteins (275). Subsequent study has confirmed the essential role for 
members of this protein family in functional (neuronal and extraneuronal) 
SNARE complexes (192). SYT binds with syntaxins in a calcium- 
dependent manner involving residues distinct from those which mediate 
phospholipid binding (276) within the C2A domain (277). The linker 
between the C2 domains also participates (278), reflecting further 
cooperativity between C2 domain function.
SYT also interacts with the other neuronal t-SNARE SNAP25 in a 
calcium-dependent manner. Indeed, calcium promotes SYT interaction 
with assembled Syntaxin / SNAP25 heterodimers, and a complex 
composed of both t-SNARES and Synaptobrevin (VAMP) (278). Elegant 
studies in which vesicle fusion is reconstituted in vitro have confirmed that 
SYT and the SNARE complex comprising t-SNAREs Syntaxin and 
SNAP25 and v-SNARE VAMP represent the minimal protein requirement 
for calcium-dependent membrane fusion (185). Subsequent analysis of 
the SYT-SNARE complex interaction using Fluorescence Resonance
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Energy Transfer techniques suggested that Interaction between the C2B 
and linker domains of SYT and the membrane-proximal area of the 
SNARE complex facilitate their interaction (279). A schematic 
representation of the interaction between SYT and the SNARE complex 
is found in Figure 1.7.
SYT isoforms have been noted to Interact with additional synaptic 
proteins. In support of their role in calcium-dependent neurotransmitter 
release SYTs interact with molecules that are known to influence voltage- 
gated calcium signalling such as neurexins and calmodulin (280). SYTs 
also interact directly with N-type (281) and P and 0-type calcium 
channels (282), an observation that seems logical if SYTs are to rapidly 
detect changes in intracellular calcium concentration.
The role of SYTs in endocytosis is established. Isoforms have 
been shown to directly Interact with components of the endocytosis 
machinery including clathrin, stonin and stoned A and B (283-285). The 
detailed role of SYT in endocytosis is reviewed in (286).
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rFigure 1.7
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Figure 1.7 Schematic representation of SYT (C3) interacting with the 
neuronal SNARE complex. Interaction between the C2 
domains and linker domain of SYT facilitates the formation of 
the SNARE complex composed of VAMP (CD).
Syntaxin (^T)) and SNAP (CD). Insertion of the tandem C2 
domains of SYT into the plasma membrane subsequently 
drives PM-vesicle fusion. Adapted from (188).
I
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1.5.4.3. Other SYT -  Protein interactions
SYT function has also been linked directly to the cytoskeleton, with 
the observation that both C2 domains interact with tubulin in a calcium- 
dependent manner (287). Studies of SYT9 knockdown in a rat leukaemia 
cell line reveal reduced endocytic compartment to PM recycling. This 
observation, along with others which describe coimmunoprecipitation of 
tubulin with SYT9, and SYT9 colocalisation with the microtubulin 
organising centre (MTOC) imply a role for particular SYT isoforms in the 
regulation of intracellular vesicle transport via microtubules (288).
Using the yeast 2-hybrid screen followed by coimmunoprecipitation 
methods it was shown that SYT 11 binds to and is ubiquitinated by the 
ubiquitin ligase Parkin (242). By virtue of this post-translational 
modification Parkin targets misfolded proteins to the proteasome for 
degradation, therefore ubiquitination may represent an additional mode of 
SYT regulation.
1.5.4.4. Phosphorylation
Examination of the amino acid sequences of all SYT isoforms 
reveals multiple potential phosphorylation motifs for a variety of distinct 
protein kinases, thus suggesting that SYT function could be at least in 
part regulated by phosphorylation. That SYTs are phosphoproteins in vivo
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was first evidenced by immunoprécipitation of phosphorylated SYT from 
intact synaptic vesicles (289). SYT1 was shown to be phosphorylated on 
a conserved residue (T132) by casein kinase II (Caskll) (290), a protein 
family implicated in multiple diverse cellular roles. SYT1 was 
subsequently shown to be phosphorylated by PKC, Caskll and 
Calmodulin Kinase II (291) in vitro but not in vivo (PKC and CaMKII 
targeted T i l 2; Caskll targeted T125 and T128). Due to the detection of 
endogenous SYT phosphorylated at T i l 2 the authors suggested SYT 
phosphorylation by PKC and CaMKII could contribute to the regulation of 
vesicle fusion (292).
Further evidence in support of this theory is provided by 
observations that SYT2 coimmunoprecipitates With No Lysine Protein 
Kinase 1 (293). Phosphorylation of SYT2 by WNK1 alters the calcium- 
dependent actions of the C2 domains (293). Furthermore, PKC-mediated 
regulation of SYT6 C2B domain phosphorylation has been implicated in 
controlling the acrosome reaction (294). PKC has also been shown to 
regulate targeting of SYT9 to the endocytic recycling compartment (see 
1.6.2.3 above). Thus it is likely further mechanisms of SYT regulation by 
the action of protein kinases shall be elucidated.
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1.6. Aims of this Thesis
The studies described in this thesis aim to determine whether a 
particular SYT isoform(s) contributes to the regulation of insulin- 
stimulated glucose transport in the 3T3-L1 adipocyte.
Firstly the expression of the SYT genes shall be determined in 
3T3-L1 adipocytes by Reverse Transcription PCR and compared with 
murine skeletal muscle and pooled human adipose cDNA. The relative 
expression of candidate genes shall be determined by Taqman Semi- 
Quantitative Reverse Transcription PCR and compared at various stages 
throughout differentiation. These experiments shall identify the 
predominant isoform expressed in the adipocyte and will guide further 
investigation.
The expression of the candidate SYT protein in 3T3-L1 adipocytes 
shall be confirmed, its subcellular location determined and subcellular 
trafficking in response to insulin demonstrated. sIRNA shall be used to 
achieve targeted deletion of the candidate protein in 3T3-L1 adipocytes, 
and studies made of the resulting phenotype. The in vitro binding of the 
identified candidate with known members of the CSV SNARE complex 
shall be investigated.
In this way the contribution made by a SYT isoform to insulin- 
stimulated glucose uptake in the 3T3-L1 adipocyte shall be determined.
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Chapter 2: Materials & Methods
2.1 Materials
High quality reagents were obtained from the following suppliers for use 
in analysis:
2.1.1 General Reagents
Amersham International Pic, Aylesbury. Buckinghamshire, UK
Horseradish peroxidase (HRP)-conjugated donkey anti-rabbit IgG 
antibody
Horseradish peroxidase (HRP)-conjugated sheep anti-mouse IgG 
antibody
ECL Western Blotting detection reagents 
Anachem Ltd. Luton. Bedfordshire. UK 
30% Acrylamide / bisacrylamide
BioRad Laboratories Ltd, Hemel-Hempstead. Hertfordshire. UK 
N,N,N’,N’“tetramethylethylenediamine (TEMED)
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Boehrinqer Mannheim, Germany
Protease Inhibitor cocktail tablets, complete™ 
Protease Inhibitor cocktail tablets, complete™, Mini
Fisher Ltd. Loughborough, Leicestershire, UK
Ammonium Persulphate (APS)
Ammonium Sulphate 
Calcium Chloride (CaCIa)
Diaminoethanetetra-acetic acid, disodium salt (EDTA)
Disodium hydrogen orthophosphate (NagHPO^)
Ethanol
Glucose
Glycerol
Glycine
N“2“hydroxyethylpiperazine-N-2’"2ethanesulphonic acid (HEPES) 
Hydrochloric acid (HCI)
Isopropanol
Magnesium sulphate (MgS0 4 )
Methanol
Potassium Chloride (KCI)
Potassium dihydrogen orthophosphate (KH2 PO4 )
Sodium dodecyl sulphate (266)
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Sodium chloride (NaCI)
Sodium dihydrogen orthophosphate dehydrate (NaH2 P0 4 ) 
Sodium hydrogen carbonate (NaHCOs)
Sucrose
Trichloroacetic acid 
Glaxo Smith Kline 
Rosiglitazone
Kodak Ltd. Hemel-Hempstead. Hertfordshire, UK
X-Omat S Photographie film
Merck Ltd (BDH). Lutterworth. Leicestershire, UK
Magnesium Chloride (MgCl2 )
Tween 20
New England Biolabs (UK) Ltd. Hitchin. Hertfordshire. UK 
Pre-stained protein marker, broad range (6-175kDa)
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Novo Nordisk. Denmark
Insulin (Porcine)
Morrison’s Grocers
Marvel powdered milk
Schleicher & Schuell, Dassel, Germany
Nitrocellulose membrane
Whatman International Ltd, Maidstone. UK
Whatman No.1 filter paper 
Whatman No.3 filter paper 
Whatman 3mm filter paper
2.1.2 Radioactive Reagents
Amersham International Pic. Aylesbury. Buckinghamshire. UK 
2-deoxy-d-(^H)-glucose
125I-Transferrin
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2.1.3 Kits
Qiaqen
Maxiprep™ DNA purification kit 
Miniprep™ DNA purification kit 
Qiaspin™ DNA purification kit 
RNEasy™ RNA purification kit
2.1.4 Molecular Biology Reagents
Euroqentec. Brussels. Belgium
Taqman oligonucleotide primers 
Taqman oligonucleotide probes 
Taqman realtime PCR buffer 
Taqman Hot Gold Star enzyme
Invitrogen
pAD-CMV-V5-DEST plasmid 
pENTR 1A plasmid 
pENTR D-topo plasmid 
BL-21 E. coli
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■Top 10” E. coli 
“Mach-I” E. coli
Molecular Bio-Products
Certified DNAse- and RNAse-free sterilised PCR tubes 
Promeqa
Restriction endonucleases
Restriction endonuclease buffers
Bovine serum albumin
Thermus Aquaticus (Taq) DNA Polymerase
Mg-Free Taq DNA Polymerase buffer
T4 DNA Ligase
T4 DNA ligase buffer
2.1.5 Tissue Culture Reagents
American Type Culture Collection. Rockville. USA
3T3-L1 fibroblasts 
HeLa cells 
HEK293 cells
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BioRad
Gene-Pulser II Electroporator 
0.2cm Electrode Gap cuvettes 
0.4cm Electrode Gap cuvettes
Dharmacon. USA
Dharmafect transfection reagent 
Lamin A/C siGLO™ control siRNA 
SMARTPOOL™ SiRNA 
Custom siRNA synthesis
Invitrogen
Lipofectamine 2000
Gibco, Paislev, Renfrewshire. UK
Foetal bovine serum (FCS)
Newborn calf serum (NCS)
Dulbecco’s Modified Eagle’s Medium (without sodium pyruvate, with 
4500mg/l glucose) (DMEM)
Dulbecco’s Phosphate Buffered Saline (D-PBS)
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10000U/ml Penicillin, 10000U/ml Streptomycin 
Trypsin/EDTA solution
Costar (Corning)
10cm cell culture plates 
75cm^ cell culture flasks
Falcon
10cm cell culture plates 
20cm cell culture plates 
6 well cell culture plates 
12 well cell culture plates 
24 well cell culture plates 
15ml centrifuge tubes 
50ml centrifuge tubes
Bibbv Sterlin Ltd. Stone, Staffordshire. UK
Sterile pipettes
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2.1.6 Cell Biology Reagents
Avanti Polar Lipids. Alabaster. AL, USA
1-palmitoyl 2-oleoyl phosphatidylcholine (POPC)
1,2-dioleoyl phosphatidylserine (231)
N-(7-nitro-2,1,3-benzoxadiazole-4-yl)-1,2-dipalmitoyl 
phosphatidylethanolamine (NBD-DPPE)
N-(lissamine rhodamine B sulphonyl) 1,2-dipalmitoyl 
phosphatidylethaniolamine (Rhodamine-DPPE)
Siqma-Aldrich. UK
Accudenz'^
Lysozyme
Monoclonal ANTI-FLAG® Ml Antibody from mouse 
Monoclonal ANTI-FLAG® M2 Antibody from mouse 
Monoclonal ANTI-FLAG® M5 Antibody from mouse
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2.1.7 Molecular Biology Buffers
TAE Buffer
2M Tris base, 50mM EDTA in 800ml dHgO, pH to 8.0 with Glacial Acetic 
Acid, make up to 11 with dH20. Dilute 1:50 with dH20 immediately prior to 
use.
2.1.8 Cell Biology Buffers
A200 Buffer
25mM HEPES, 200mM KCI, 10% w/v glycerol, lOmM DTT 
Binding Buffer
150mM NaCI, 50mM Tris pH7.4, 0.5 w/v Tween-20 
Coomassie Brilliant Blue
0.25g Coomassie Brilliant Blue (R250), 90ml 50% Methanol in H2 O, 10ml 
Glacial Acetic Acid
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SDS-PAGE Electrophoresis Buffer
15.1g TRIS, 94g Glycine in 900ml dHgO, 50ml 10% SDS
HES Buffer
20mM HEPES, 250mM Sucrose, 1mM EDTA, pH 7.4 
KRP Buffer
1.28M NaCI, 47mM KCI, 50mM NaH2 P0 4 , 12.5mM MgS0 4 , 12.5mM 
CaCl2 , Dilute 1:10, bring to 37°C, pH 7.4
Phosphate Buffered Saline (PBS)
136mM NaCL, lOmM NaH2 P0 4 , 2.5mM KCI, 1.8mM KH2 PO4 , pH 7.2 
Phosphate Buffered Saline / T fPBS-T)
136mM NaCL, 10mM NaH2 P0 4 , 2.5mM KCI, 1.8mM KH2 PO4 , 0.02% 
Tween-20, pH 7.2
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Protein Transfer Buffer
48mM Tris, 39mM Glycine, 1.3mM SDS, 20% Methanol 
Dilute 125ml in 875ml dHzO and 300ml Methanol
2.1.9 Microbiology Media
2YT
16g Tryptone, lOg Yeast Extract, 5g NaCI, make up to 1 litre with dH2 Ü, 
autoclave and store at 4°C until use
Terrific Broth
12g Tryptone, 24g Yeast Extract, 4ml Glycerol, 2.31 g KH2 PO4 , 12.54g 
K2 HPO4 , make up to 1 litre with dH2 0 , autoclave and store at 4°C until 
use
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2.2 Methods
Molecular Biology Methods
2.2.1 Preparation of Murine Brain mRNA
A wild-type adult Mus~musculus laboratory mouse was euthanised 
by means of decapitation, the brain immediately dissected and removed 
and placed on ice in a sterile polypropylene tube. Once weighed, the 
brain was divided in the midline and each cerebral hemisphere processed 
separately. Following the instruction of the RNEasy (Qiagen) kit protocol, 
brain tissue was minced with a clean scalpel blade and disrupted by 
hand-homogenisation in the presence of lysis buffer (supplied with the 
kit). Cell membranes were disrupted by passing 5 times through a sterile 
18G diameter needle attached to a sterile 5ml syringe. Total RNA was 
isolated by applying cell lysates to RNEasy (Qiagen) columns with strict 
cleanliness in order to minimise risk of nuclease contamination. All 
processing steps were carried out on ice and in a refrigerated centrifuge 
to prevent degradation of nucleic acids.
Once isolated, total brain RNA was quantified spectrophotometrically and 
immediately stored at -80°C.
87
2.2.2 Preparation of Murine Skeietal Muscle mRNA
Once euthanised, whole Mus~musculus hind leg musculature was 
immediately dissected and placed in a sterile polypropylene tube on ice. 
Further dissection on ice was carried out to remove any remaining 
neuronal or connective tissues. Murine skeletal muscle RNA was then 
isolated as for mouse brain RNA using RNEasy (Qiagen) columns, 
quantified spectrophotometrically and immediately stored at -80°C.
2.2.3 Preparation of RNA from 3T3-L1 cells
3T3-L1 cells were cultured and differentiated as described in 
plastic 10cm diameter tissue culture dishes. At the indicated timepoints 
(e.g. confluent fibroblasts, 2 days following differentiation, 4 days 
following differentiation etc.) dishes of cells were removed from the 
incubators and placed on ice. Culture media was removed by aspiration 
and cell lysis buffer (including RNAse inhibitors) applied. Processing 
continued as for mouse brain RNA following the steps highlighted in the 
RNEasy (Qiagen) protocol. Once isolated, 3T3-L1 cell RNA was 
quantified spectrophotometrically and immediately stored at -80°C.
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2.2.4 Human Brain mRNA
Human brain total RNA was a generous gift from Dr Scott 
Mackenzie of the Blood Pressure Laboratory, Division of Cardiovascular 
and Medical Sciences, University of Glasgow, Western Infirmary, 
Glasgow.
2.2.5 Pooled Human Adipose Tissue mRNA
Pooled Human Adipose Tissue RNA (Firstchoice Total RNA, 
catalogue # 7956, Ambion, Austin, TX, USA) was a generous gift from Dr 
Scott Mackenzie of the Blood Pressure Laboratory, Division of 
Cardiovascular and Medical Sciences, University of Glasgow, Western 
Infirmary, Glasgow.
2.2.6 Reverse Transcription of RNA into cDNA
Whole cell RNA samples were prepared as described. Synthesis 
of first-strand complementary DNA was carried out by incubating RNA 
samples with AMV Reverse Transcriptase (Promega) in the presence of 
an oligo d(T) (15) primer (Promega). Samples were kept on ice at all 
times to minimise degradation (unless otherwise stated).
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in accordance with the manufacturer’s instructions O.Sjug oligo d(T) 
primer per pg RNA was added to RNA in a sterile nuclease-free plastic 
tube. Nuclease-free water was added to a total volume of 10 pi per 
reaction. Samples were then heated to 70°C for 5 minutes in a PCR 
machine, placed on ice for 5 minutes and spun briefly in a centrifuge to 
ensure all contents collected at the bottom of the tube.
5pl 5X AMV RT Buffer (Promega), lOmM dNTP (lOmM each 
dATP, dTTP, dCTP and dGTP) mix, 10 units AMV Reverse transcriptase 
(Promega) and nuclease-free water were then added to give a final 
reaction volume of 25pl (final concentration 50mM Tris HCI, 40mM KCI,
8.75mM MgCL, lOmM DTT). Reverse transcription of cDNA was 
performed at 42°C for 1 hour in a PCR machine, after which samples J
were immediately removed and kept on ice. DNA concentration was then i
determined spectrophotometrically and samples immediately stored at -
:
20°C prior to analysis.
2.2.7 Polymerase Chain Reaction
In order to detect expression of each target gene, amplification of a â
ispecific section of the cDNA sequence was performed by Polymerase i
Chain Reaction (PCR). Gene specific oligonucleotide primers (Appendix 
1 ) were synthesised by TAGN, Newcastle. All PCR reagents were kept 
on ice during preparation.
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Into a sterile nuclease-free polypropylene tube were placed in order;
lOx Mg-free Taq DNA Polymerase Reaction Buffer 5pl
25mM MgCb 3pl
lOmM dNTP mix 1]llI
Forward Primer 2.5pl
Reverse Primer 2.5pl
Template cDNA Ipl
dHzO 34|j,l
Taq DNA Polymerase Ipl
TOTAL VOLUME 50pl
Tubes were then spun briefly in a benchtop centrifuge to ensure all 
contents were at the bottom of the tube, then placed in a pre-set PCR 
machine.
The precise cycling conditions for each primer set depended upon the 
melting temperature (Tm) of the primers.
95°C 2 minutes
95°C 15 seconds
55°C 30 seconds X 30
72°C 15 seconds
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72°C 5 minutes
4°C ad infinitum
PCR products were analysed by agarose gel electrophoresis and images 
recorded by digital photography. To ensure amplification of the expected 
gene-specific target sequence PCR products were sub-cloned into pCR
2.1 plasmids and sequenced directly.
2.2.8 Agarose Gel Electrophoresis
PCR products, restriction enzyme digests and plasmid purifications 
were analysed by agarose gel electrophoresis. Percentage of agarose 
depended upon the expected size of DNA fragment (1 % (w/v) for 
fragments >250bp, 2% (w/v) for fragments <250 bp).
Analytical-grade agarose was weighed on a digital balance and 
placed in a sterilised Pyrex conical flask. An appropriate volume of TAE 
buffer was added and the flask placed in a microwave oven and heated 
on “High” until all of the agarose was in suspension. With care, the flask 
was removed and cooled on the benchtop until hand hot with occasional 
agitation. Ethidium Bromide was added to the agarose suspension, which 
was then poured into the gel mould. A comb with an appropriate number 
and size of wells was placed in the still liquid agarose suspension, and 
the gel was left to solidify.
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Once solidified the agarose gel was placed into a gel tank filled 
with TAE buffer, ensuring the agarose was covered, and the comb 
removed. Samples in DNA loading buffer were carefully pipetted into 
individual wells in the agarose alongside a DNA marker of an appropriate 
size and electrophoresed at 65 -  100V until individual DNA bands were 
resolved. DNA bands were visualised under UV light and recorded by 
digital photography. Images were stored as individual photographs and 
scanned into PC documents for presentation.
2.2.9 Taqman Semi-Quantitative Polymerase Chain Reaction
Taqman Realtime PCR was performed according to the 
manufacturer's instruction (Applied Biosystems, Foster City. California, 
USA). Primers and fluorogenic oligonucleotide probes were designed 
using the sequence of the RT-PCR products as template (Appendix 2). 
PCR reactions were performed in the ABI-prism 7700 Sequence detector, 
which contains a Gene-AMP PCR system 9600 (295). A total reaction 
volume of 25pi was used comprising lOmM Tris-HCI buffer pH 8.3, Ipl 
cDNA sample, 50mM KCI, lOmM EDTA, 200pM dATP, dCTP, dGTP and 
dUTP, 5mM MgCE, 300nM each primer, 200nM probe and 0.625 U Hot 
Gold Star Polymerase Enzyme (all Eurogentec, Seraing, Belgium). Each 
PCR amplification was performed in triplicate under the following 
conditions:
50°C 2 minutes
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90°C 10 minutes
95°C 15 seconds
60°C 60 seconds X 40 / 45
72°C 30 seconds
4°C ad infinitum
Data analysis was performed using the Applied Biosystems 
Sequence Detection Software and results downloaded in Microsoft Excel 
format. GLUT4 expression was used as a positive control and samples 
were normalised against (3-Actin mRNA.
Taqman realtime RT-PCR allows quantification of the initial 
amount of target template in comparison with a control (housekeeping) 
gene. In addition to gene-specific PCR primers a dual-labelled gene- 
specific oligonucleotide probe was designed to bind within each target 
amplicon (for both target and control genes), and synthesised with 5’ 
FAM reporter and 3’ TAMRA quencher dyes. Unbound, the transfer of 
FRET energy from reporter to quencher dye results in no probe 
fluorescence. As the reaction proceeds the 5’-3’ exonuclease activity of 
the advancing polymerase enzyme digests labelled probe bound to 
template, and the FAM reporter fluorescence may be detected.
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The strength of the observed signal is directly proportional to the 
amount of PCR product. By detecting fluorescence at the end of each 
amplification cycle it is possible to determine the cycle number at which a 
significant increase in the observed fluorescence is noted (Threshold 
Cycle or Cy). The Cy value is determined when the earliest exponential 
increase in reporter fluorescence above baseline (ARn) is detected (linear 
phase of a logarithmic plot of Cycle number vs. observed fluorescence). 
The higher the initial amount of template, the lower the Cy value.
By comparing the Cy value obtained with a target gene with that 
obtained using the control gene it is possible to calculate the amount of 
initial template relative to the control template (247). The amount of target 
template is given by:
i-AAC t
where AACy = Cy(target) - Cy (control)
For this calculation to be valid it is essential that the efficiencies of 
amplification of both target and control are identical. Efficiency can be 
determined by performing multiple amplifications using serial dilution of 
the same template and examining the gradient of the slope of log 
[template] vs. Cy. The gradient should be as close as possible to 0 (<0.1) 
(User Bulletin #2: ABl PRISM 7700 Sequence Detection System (295)).
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2.2.10 Restriction Endonuclease Digestion
DNA to be digested was placed in a sterile microcentrifuge tube 
containing 1 unit of the appropriate restriction endonuclease in the 
appropriate manufacturer’s buffer (with which it was supplied) with or 
without Bovine Serum Albumin. Digests were carried out at 37 for 3 
hours on a PCR machine. In the case of double restriction digests an 
appropriate buffer (that permits >50% activity of both enzyme) was 
chosen as recommended by the manufacturer. If no such buffer was 
available digests were carried out individually. Following digestion, 
fragments were resolved by 1% Agarose gel (containing ethidium 
bromide) electrophoresis and visualised under UV light. If required for 
downstream cloning applications fragments were cut out of the gel using 
a sterile scalpel blade and purified using the Qiagen Qiaspin DNA 
purification kit.
2.2.11 Cloning Restriction Endonuclease Digestion Products 
into Plasmid Vectors
Both the plasmid vector and the insert were digested with 
compatible restriction endonucleases to ensure efficient cloning and gel 
purified using the Qiagen Qiaspin kit. For each cloning reaction two 
separate mixtures containing a 1:1 and 3:1 v/v insert to vector ratio were 
prepared.
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To a sterile microcentrifuge tube were added \^x\ 10x T4 ligase 
buffer, 1f.ll T4 ligase, 1pl digested vector. Ip! (or 3pi) digested insert and 
the volume was made up to lOpl with dHzO (vector and insert both 
approximately Ijng/pl). Ligations were performed at 16°C in a PCR 
machine overnight. The following morning the entire ligation reaction was 
transformed into competent E. coli.
2.2.12 TA Cloning
TA cloning utilises the innate ability of vaccinia topoisomerase to 
bind to double stranded DNA at specific sites and cleave the 
phosphodiester backbone, resulting in its covalent 3' phosphotyrosyl 
attachment to the cleaved DNA, which is left with an overhanging 
deoxythymidine residue. TA vectors are supplied with topoisomerase 
covalently attached. PGR products produced by Taq polymerase possess 
a 3’ deoxyadenosine residue which targets the deoxythymidine of the 
vector ensuring correct orientation of the insert. The phosphotyrosyl bond 
between the DNA and topoisomerase is cleaved, the enzyme is released 
and the phosphodiester bond between the deoxythymidine of the vector 
and the 3’ residue of the insert completes the cloning reaction.
TA cloning reactions were performed as suggested by the 
manufacturer. Ipl of fresh PCR product (around Ipg) was added to a 
sterile microcentrifuge tube containing 1pl of TOPO vector and 4pl dHaO. 
The reaction was incubated on the benchtop at room temperature for 5
97
minutes, then placed on ice. The entire reaction was then transformed 
into E. coli as described above.
Tissue Culture Methods 
2.2.13 3T3-L1 Fibroblasts
3T3-L1 fibroblasts were cultured at 37°C in incubators generating a 
humidified atmosphere of 10% CO2 in 75cm^ flasks containing DMEM, 
10% (v/v) Newborn calf serum and 1% (v/v) Penicillin and Streptomycin, 
replaced every 48h. At 80% confluency cells were passaged into culture 
plates and dishes of variable size alongside a further 75cm^ carry-on 
flask. Cell culture proceeded until 4 days post-confluency when the 
fibroblasts were differentiated.
2.2.14 Passage of 3T3-L1 Fibroblasts
Cell culture media was aspirated from a 75cm^ flask of 3T3-L1 
fibroblasts and 1m! of trypsin / EDTA solution was added to remove 
residual media from the cells. Once removed by aspiration this was 
replaced by 3ml trypsin / EDTA solution and the flask incubated at 37°C 
in a humidified atmosphere of 10% CO2 for 5 minutes. Gentle agitation 
and trituration allowed the cells to lift from the surface of the flask. This 
cell suspension was then added to an appropriate volume of DMEM 
containing 10% (v/v) Newborn calf serum and 1% (v/v) Penicillin and
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streptomycin and re-seeded onto cell culture plates and a further carry- 
on flask (with gentle agitation to ensure an even distribution of cells in all 
wells filled).
2.2.15 Differentiation of 3T3-L1 Fibrobiasts
3T3-L1 fibroblasts were induced to differentiate into adipocytes by 
the addition of differentiation media containing DMEM, Foetal Calf Serum 
10% (v/v), Penicillin and Streptomycin 1% (v/v), Porcine insulin 1 g/ml, 
Dexamethasone 0.25pM and isobutyl-methylxanthine (IBMX) 0.5mM.
Dexamethasone was stored as a 2.5mM stock solution. A sterile 
500x (55mg/ml) stock solution of IBMX was prepared by dissolving 
0.055g in 1ml 1M KOH and passing the resulting solution through a 0.22- 
micron filter. 1 mg/ml Insulin was prepared in 0.01 M FICI and also filter- 
sterilised by passing through a 0.22-micron filter.
Differentiation Media was prepared by the addition of 0.1ml 2.5mM 
Dexamethasone stock solution to 1.9ml DMEM. 0.2ml of the resulting 
0.125M Dexamethasone solution was added to 5ml DMEM containing 
0.1ml 1 mg/ml Stock Insulin and 0.2ml Stock IBMX, and the resulting 
mixture was passed through a 0.22-micron filter into DMEM containing 
Foetal Calf Serum 10% (v/v), Penicillin and Streptomycin 1% (v/v) to a 
total volume of 100ml.
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3T3-L1 fibroblasts were grown in tissue culture plates until 4 days 
post-confluency. Growth media was removed by aspiration and replaced 
with differentiation media. 48 hours later this was replaced with DMEM, 
Foetal Calf Serum 10% (v/v), Penicillin and Streptomycin 1% (v/v) and 
Insulin at 1pg/ml.
Once differentiated, 3T3-L1 adipocytes were cultured in a 
humidified atmosphere of 10% CO2 . 48 hours following insulin feeding 
and at 48 hour intervals thereafter media was replaced with DMEM, 
Foetal Calf Serum 10% (v/v), Penicillin and Streptomycin 1% (v/v).
2.2.16 HEK 293 Cells
HEK-293 Cells were cultured at 37°C in incubators generating a 
humidified atmosphere of 5% CO2 in 75cm^ flasks containing DMEM, 
10% (v/v) Foetal calf serum, 5% L-Glutamine and 1% (v/v) Penicillin and 
Streptomycin, replaced every 48h. At confluency cells were passaged 
into culture plates and dishes of variable size alongside a further 75cm^ 
carry-on flask. Cells were continually cultured regardless of passage.
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2.2.17 Trypsinisation and Passage of HEK-293 Cells
Cell culture media was aspirated from a 75cm^ flask of HEK- 
293 Cells and 1ml of trypsin / EDTA solution was added to remove 
residual media from the cells. Once removed by aspiration this was 
replaced by 3ml trypsin / EDTA solution and the flask incubated at 
37°C in a humidified atmosphere of 5% CO2 for 5 minutes. Gentle 
agitation allowed the cells to lift from the surface of the flask. This 
cell suspension was then added to an appropriate volume of DMEM 
containing 10% (v/v) Foetal calf serum, 5% (v/v) L-Glutamine and 
1% (v/v) Penicillin and Streptomycin and re-seeded onto cell culture 
plates and a further carry-on flask (with gentle agitation to ensure an 
even distribution of cells in all wells filled).
2.2.18 Freezing and Storage of Cells
Cells were cultured until 80% confluent in a 75cm^ tissue culture flask. 
After removing the media, cells were washed with 1ml trypsin/EDTA 
solution. This was replaced by 3ml trypsin/EDTA solution and the cells 
were then incubated for 5 min at 37°C in an atmosphere of 10% CO2 . 
Gentle shaking allowed cells to lose adherence to the surface of the flask 
and a further 3ml of DMEM with appropriate additives* were added to the 
resulting suspension, triturating to ensure no cells remained adherent.
The suspension was then transferred into a sterile tube and centrifuged at
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2000g for 4 minutes. After removing the supernatant the resulting cell 
pellet was resuspended in 1ml DMEM with appropriate additives* and 
10% (v/v) DMSO. This suspension was then transferred into a 1.8ml 
cryovial and stored at -80°C overnight before being stored in liquid 
nitrogen.
* -10% (v/v) Newborn calf serum in the case of 3T3-L1 fibroblasts
-10% (v/v) Foetal calf serum and 5% L-Glutamine in the case of
HEK293 cells.
2.2.19 Resurrection of Cells Stored in Liquid Nitrogen
A cryovial of cells stored in liquid nitrogen were removed and 
thawed at 37°G in a water bath. The thawed cell suspension was then 
transferred into a 75cm^ flask containing DMEM, Foetal Calf Serum 10% 
(v/v), Penicillin and Streptomycin 1% (v/v) previously equilibrated at 37°C 
in a humidified atmosphere of 10% CO2 . The media was replaced after 24 
hours and cells were cultured as previously described.
2.2.20 Transfection of Cultured Cells Using Lipid-Based 
Transfection Reagents
Cells were transfected using lipid-based transfection reagents 
(Lipofectamine 2000™ and Dharmafect™) as per the manufacturers 
instructions (invitrogen and Dharmacon respectively).
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Briefly, cells were grown in culture as described. On the day prior 
to transfection cells were incubated in appropriate media in the absence 
of antibiotics. Lipofectamine or Dharmafect lipid-nucleic acid complexes 
were prepared at room temperature in an appropriate volume as 
instructed and added to cells. Media was changed after 24 hours and 
cells were used 48 hours following transfection.
2.2.21 Transfection of 3T3-L1 Adipocytes by Electroporation
3T3-L1 cells grown in 150mm^ cell culture dishes were 
differentiated as described above and transfected at day 5 post­
differentiation. One dish per siRNA target was used. Cells were washed 
twice with 10ml Dulbecco's PBS (D-PBS) at room temperature then 
incubated at 37°G with 2ml of Trypsin-EDTA and 3ml of Collagenase (1 
mg/ml in D-PBS). After a 10 minute incubation the dish was shaken 
gently until cells lifted off the surface of the dish. 10ml complete medium 
(DMEM, 10% PCS, 1% Penicillin / Streptomycin) was added to each dish, 
and cells were then transferred into a sterile centrifuge tube (with gentle 
trituration to ensure all cells were removed). Tubes containing cells in 
suspension were washed three times by spinning at 1200rpm for 5 mins 
in Beckman GP centrifuge at room temperature. At the end of each spin 
the pellet was gently resuspended in D-PBS. Following the final spin the 
pellet was resuspended in 0.65ml D-PBS per siRNA target and 
transferred to a sterile electroporation cuvette ready for electroporation.
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siRNA was resuspended in RNAse-free siRNA buffer (Dharmacon) 
to a concentration of 0.1 mM and was kept on ice at all times. Immediately 
prior to electroporation the desired amount of siRNA was added to the 
cell suspension in each cuvette (20 nmoles per target) and mixed by 
gentle agitation. Cells were then electroporated in a Gene Puiser II 
(BioRad) Electroporator (voltage at 0.18 kV and Capacitance at 950 pF) 
for 1-2 seconds.
1ml complete medium was then quickly added to each cuvette, and 
floating debris carefully removed. Cells were gently transferred into a 
centrifuge tube containing complete medium, and then reseeded in clean 
sterile tissue culture dishes (e.g. 1 ml/well in 12-well plates for glucose 
uptake assays, 8ml per 10cm dish for preparing cell lysates).
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Cell Biology Methods
2.2.22 SDS-Polyacrylamide Gel Electrophoresis
SDS / Polyacrylamide Gel Electrophoresis was performed using 
Bio-Rad mini-PROTEAN II apparatus. All reagents were of 
electrophoresis grade. Polyacrylamide concentrations varied in 
accordance with molecular weight of the target protein.
Separating gel was prepared using 30% acrylamide / 
bisacrylamide, 1.5M Tris-HCI (pH 8.8) (to a final concentration of 
375mM), 10% (w/v) SDS (to a final concentration of 0.1%), polymerised 
with 10% (w/v) ammonium persulfate (to a final concentration of 0.1%) 
and TEMED (to a final concentration of 0.019%). Reagents were mixed in 
a sterile polypropylene tube, carefully added to the assembled Bio-Rad 
mini-PROTEAN II gel apparatus ensuring the absence of air bubbles, and 
covered with 0.5- 1ml isopropanol and left to set. The stacking gel was 
then prepared using 30% acrylamide / bisacrylamide, 1M Tris-HCI (pH 
6.8) (to a final concentration of 125mM), 10% (w/v) SDS (to a final 
concentration of 0.1%), polymerised with 10% (w/v) ammonium persulfate 
(to a final concentration of 0.1%) and TEMED (to a final concentration of 
0.05%).
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Protein samples were prepared in 1X SDS-PAGE sample buffer 
(93mM Tris-HCI pH 6.8, 20mM dithiothreitol (added immediately prior to 
use), 1mM sodium EDTA, 10% (w/v) glycerol, 2% (w/v) SDS. 0.002% 
(w/v) bromophenol blue) and loaded into wells in the stacking gel. Broad 
range pre-stained molecular weight markers (Mw 6- 175kDa, New 
England Biolabs) were routinely used. Gels were electrophoresed in 
electrode buffer (25mM Tris, 190mM glycine and 0.1% (w/v) SDS) at a 
constant voltage (typically 80V to ensure optimal definition of protein 
bands).
2.2.23 Coomassie Staining of Protein Gels
During SDS/PAGE a 0.25% coomassie blue stain was prepared 
using 10ml glacial acetic acid, 90ml methanol: H2 O (1:1 v/v) and 0.25g 
Brilliant Blue R, filtered through a Whatman number 1 filter paper. The gel 
was submerged in the stain for 2hours and destained in an acetic acid, 
methanol:H20 solution (prepared as above). Destaining was carried out 
between 3-12 hours. Results were recorded by digital scanning and 
images stored as JPEG files.
2.2.24 Western Blotting
Once separated by SDS/PAGE as described proteins were 
transferred onto a nitrocellulose membrane either using a Bio-Rad mini or 
Bio-Rad trans-blot electrophoretic cell.
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A multi-layered “sandwich” was assembled by placing in order two 
sheets of Whatman 3mm filter paper, nitrocellulose membrane (pore size 
0.45mm), polyacrylamide gel and two further sheets of filter paper 
between two sponge pads. The filter paper and nitrocellulose membrane 
were cut to size and briefly equilibrated in transfer buffer (25mM 
NaH2 P0 4 , pH 6.5) prior to use. Care was taken to carefully eliminate any 
air bubbles found between layers of the sandwich. Transfer was carried 
out in the Bio-Rad mini apparatus at a constant current of 250mA for 3h 
or 40mA overnight in transfer buffer.
In the case of the BioRad trans-blot cell a “sandwich” of filter 
paper, nitrocellulose and polyacrylamide gel was prepared as above 
between the electrodes of the cell. Transfer was carried out at 180mA for 
45 minutes or 50mA overnight.
2.2.25 Staining Western Blots with Ponceau 8
Western blots were prepared as described. Before incubation with 
milk (see below) nitrocellulose membranes were incubated for 10 minutes 
in a 0.2% solution of Ponceau S in order to visualise the resolved 
proteins. This facilitated the subdivision of membranes to allow 
immunolabelling of proteins with different molecular weights from within 
the same sample with distinct antisera. The membrane was then washed 
repeatedly with PBS to remove all traces of the stain.
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2.2.26 Immunodetection of Proteins
Once transferred onto nitrocellulose membrane, non-specific 
binding sites were blocked by incubation for at least 1 hour in 5% (w/v) 
skimmed milk in PBS-T buffer (20mM Tris, 150mM NaCI, 0.02% Tween- 
20, pH 7.4)
With care the membrane was then transferred into an appropriate 
receptacle with primary antibody (at variable dilution as indicated in each 
figure) in 0.5% skimmed milk and PBS-T, and incubated at room 
temperature for at least 2h with constant agitation. Then, following three 
washes in PBS-T buffer the membrane was incubated in a similar manner 
with an appropriate HRP-linked secondary antibody at 1:1000 dilution at 
room temperature for an hour. The membrane was then washed three 
times in PBS-T and once in PBS.
2.2.27 ECL Detection
An equal volume of “Detection Reagent 1” (Amersham) was mixed 
with “detection reagent 2" (Amersham) and used to incubate the washed 
membrane for 60 seconds at room temperature with constant agitation. 
After minimal drying the membrane was then carefully transferred onto 
transparent plastic sheet. The membrane was then used to expose
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Kodak photographie film in a light-tight cassette, and the film developed in 
an X-OMAT processor.
2.2.28 Quantification of Signais
To determine signal strength developed film was digitally scanned 
onto a computer to generate a JPEG image file. Then, using Image-J 
software, band intensity was measured within an area of equal size 
around each signal. A background signal value was subtracted from each 
obtained value. Data were stored and analysed using Microsoft Excel 
Software.
2.2.29 Preparation of Ceii Lysates
Cells were grown in culture as described. 500pl HPFE with 
1 %Thesit were added and the dish incubated at 4°C for 10 minutes, after 
which cells were scraped with a rubber policeman. The resulting solution 
was transferred to a clean, dry microcentrifuge tube and passed 10 times 
through a 20G needle attached to a 2ml syringe. This homogenate was 
spun in a benchtop microcentrifuge at 6000 RPM for 10 minutes at 4 °C. 
4X SDS PAGE buffer were added to the resulting supernatant, and the 
lysates stored at -80°C prior to use.
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2.2.30 The Insulin-Stimulated 2-Deoxyglucose Uptake Assay
3T3-L1 fibroblasts seeded and grown in 12-well tissue culture 
plates were differentiated as described (cells grown in 20 wells of 2 12- 
well plates were used for each experimental condition assayed). On the 
day before performing the assay adipocyte media was replaced with 
serum-free DMEM and cells cultured overnight. The following day tissue 
culture plates were transferred to heated plates at 37 °C, and the cells 
washed three times with KRP (pH 7.4 at 37 °C) to ensure all traces of 
media were removed. 500 p.! KRP were added to each well.
To 4 wells of each experimental condition were added 50 pi KRP 
containing porcine insulin to give each quadruplet a final concentration of 
OnM, InM, lOnM and lOOnM respectively. Cytochalasin-B was added to 
4 wells per condition to a final concentration of 20 pM (296). The cells 
incubated for 20 minutes with occasional gentle agitation.
After 20 minutes 50 pi 2-deoxyglucose solution containing ^H-2- 
deoxyglucose and cold 2-deoxyglucose were added to each well such 
that the final content per well was 0.25 pCi and 50pM cold 2- 
deoxyglucose. After a further 2 minutes the reaction was terminated by 
immersing the entire plate in ice-cold PBS. The plates were allowed to 
air-dry for at least 2 hours, after which 500 pi 1 % Triton were added to 
each well. After a further 2 hours the resulting solution was transferred to
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a clean scintillation tube containing 500 pi scintillation fluid. These tubes 
were placed in an automated scintillation counter and read by liquid 
scintillation spectrophotometry.
2.2.31 Cell Surface Transferrin Receptor Estimation
3T3-L1 cells grown in 6-well tissue culture plates were 
differentiated and transfected with siRNA by electroporation as described 
above. Transferrin Receptor binding studies were performed 
approximately 36 hours following electroporation. For 2 hours prior to 
performing the assay cells were incubated in serum-free media. Cells 
were washed three times in ice-cold KRP containing 1 mg/ml BSA 
(KRP/BSA). To three wells were added 1ml KRP/BSA containing 3nM 
^^^l-conjugated Transferrin, and to the parallel 3 wells on the same plate 
1ml KRP/BSA containing 3nM I-conjugated Transferrin and lOpM cold
(i.e. not radioisotope-labelled) Transferrin. Cells were incubated on ice for 
2 hours after which the media was discarded. Cells were again washed 
three times in ice-cold KRP/BSA to remove all traces of unbound 
transferrin.
The cells were then solubilised with 1ml 1% Triton for Ihour and 
this solution was added to a clean scintillation vial containing 1ml 
scintillation fluid. These tubes were then placed in a y-counter for assay.
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2.2.32 Subcellular Fractionation of 3T3-L1 Adipocytes
Subcellular fractionation of 3T3-L1 adipocytes was performed as 
described (59;297). Briefly, 3T3-L1 cells were seeded in 10cm dishes, 
cultured, and differentiated as described in section 2.2.13- 2.2.15. On day 
9 post-differentiation adipocyte culture media was replaced with serum- 
free media and the cells cultured overnight. For 30 minutes prior to 
commencement of the fractionation protocol cells were incubated with 
serum free media either alone, or with lOOnM insulin.
The cell culture dishes were removed from the incubator and 
placed on ice. Cells were washed 3 times with 5ml ice cold HES buffer 
(with protease inhibitors). 2ml HES were added, cells were scraped using 
a cell scraper and homogenised with 10 up and down strokes of an 
appropriately sized Teflon homogeniser. The resulting cell homogenate 
was then transferred to chilled Oakridge centrifuge tubes and spun at 19 
000 X g for 20 minutes at 4°G in a Beckman J2-21 centrifuge.
The resulting pellet was resuspended in 1ml ice-cold HES and 
carefully layered onto 0.8ml 1.12M sucrose in HES (sucrose cushion) and 
spun at 100 000 x g for 60 minutes at 4°C in a TLS 55 swing-out rotor in 
a Beckman Optima TL benchtop ultracentrifuge. The resulting brown- 
coloured band (found at the interface between the sucrose cushion and 
the HES above) containing the plasma membrane fraction (PM) was
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carefully removed using a 20g needle and 2m! syringe and resuspended 
in a 5-fold excess of HEPES/EDTA, and centrifuged for a further 
eOminutes at 4 °C in a fixed angle rotor in a Beckman Optima TL 
benchtop ultracentrifuge. The resulting pellet was resuspended in SDS 
PAGE buffer and stored at -80 °G prior to use.
The supernatant from the initial spin was transferred to clean 
Oakridge centrifuge tubes and centrifuged at 40 000 x g for 20 minutes in 
a Beckman J2-21 centrifuge at 4°G. The resulting pellet containing High 
Density Microsomes (HDM) was resuspended in SDS PAGE buffer and 
stored at -80 °G prior to use. The supernatant was centrifuged at 180 000 
X g for 60 minutes at 4°G in a TLA 100.4 fixed angle rotor in a Beckman 
Optima TL benchtop ultracentrifuge. The resulting pellet containing the 
Low Density Microsomes (LDM). SDS PAGE buffer was added to this 
and the supernatant containing the soluble proteins (SOL), and both were 
stored at -80°G prior to use.
In  v i t r o  Protein Binding Assays
2.2.33 Pull Down Assays
GST Pull Down assays were performed using GST-tagged 
Syntaxin4, SNAP23 and VAMP2 immobilised on Glutathione Sepharose 
beads, and soluble SYT7 and SYT11 as “bait” either in binding buffer 
containing either ImM calcium or 2mM EGTA. In each 150pl reaction
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were 5pg of each tagged SNARE protein, and soluble SYT7 or SYT11 at 
a 0.5:1, 1:1 or 2.5:1 molar ratio.
Glutathione sepharose beads were washed in 3 x 1ml PBS 
(collecting the beads by centrifugation at 2500 rpm in a Beckman-Coulter 
Allegra X-12R centrifuge each time) before incubation with 5pg GST- 
tagged SNARE protein in binding buffer for 4 hours at 4°C with constant 
rotation. Beads were washed again in 3 x PBS as before. Binding buffer 
with calcium or EGTA was then added, as was soluble SYT7 or SYT11 at 
the SNARE:SYT ratio Indicated above. SYT / SNARE binding was 
permitted for 4 hours at 4°C with constant rotation, after which time the 
beads were again washed in PBS (SDS-PAGE was added to the first 
supernatant i.e. binding buffer with either calcium or EGTA plus soluble 
SYT, which was later assayed by SDS-PAGE/Western blotting for 
unbound protein).
The beads were then resuspended in SDS-PAGE buffer and resolved by 
SDS-PAGE and analysed by analysed by Coomassie staining, or 
transferred to nitrocellulose for immunodetection.
2.2.34 Vesicle co-Floatation Assays
Vesicle co-floatation assays were performed as described in the 
online supporting material to (185). Purified epitope-tagged SNAP23, 
Syntaxin 4 and VAMP2 fusion proteins were prepared following
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expression in E. coli or SF9-celIs. v- and t-SNARE vesicles were 
prepared by rapid dilution and dialysis and subsequent purification by 
floatation in an Accudenz step gradient (as described in (189) and were a 
generous gift from Ms Fiona Brandie. v-SNARE vesicles comprised 82% 
1-palmitoyl 2-oleoyf phosphatidylcholine (POPC), 15% 1,2-dioleoyl 
phosphatidylserine (231), 1.5% N-(7-nitro-2,1,3-benzoxadiazole-4-yl)-1,2- 
dipalmitoyl phosphatidylethanolamine (NBP-DPPE), 1.5% N-(lissamine 
rhodamine B sulphonyl) 1,2-dipalmitoyl phosphatidylethaniolamine 
(Rhodamine-DPPE). t-SNARE (SNAP23/Syntaxin4 complex) vesicles 
comprised 85% POPC, 15% DOPS. Protein-free vesicles comprised 85% 
POPC and 15% DOPS.
40|al t-SNARE, v-SNARE or protein-free vesicles were incubated 
with lOjiM Soluble SYT7 or SYT 11 (lacking the TM-domain) in A200 
buffer to a final volume of 70pl +/- 0.2mM EGTA or +/-1 .OmM CaCE for 1 
hour at 4°C with constant rotation. 70|liI 80% Accudenz +/- 0.2mM EGTA 
or +/-1 .OmM CaCE in A200 buffer were added in a sterile ultracentrifuge 
tube and the solutions mixed gently. This was overlaid with 1ml 30% 
Accudenz +/- 0.2mM EGTA or +/-1 .OmM CaCE in A200 buffer followed 
by 1ml 5% Accudenz +/- 0.2mM EGTA or +/-1 .OmM CaCE in A200 
buffer. The resulting gradient was then spun at 46, 000 rpm in a Beckman 
Optima TL benchtop ultra centrifuge for 4 hours at 4°C. In the case of 
VAMP2 containing v-SNARE vesicles a visible coloured band was seen 
at the interface between the 30% and 5% Accudenz. The base of the 
centrifuge tube was carefully pierced using a sterile 20g needle. Fractions
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were collected in a drop-wise manner, 4X SDS PAGE buffer was added 
and samples stored at -80°C prior to analysis by SDS-PAGE and Western 
Blotting.
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Microbiology Methods
2.2.35 Transformation of Competent £. coli by Heat Shock
Chemically competent E. co//cells (purchased from Invitrogen) 
were thawed on ice for 10 minutes. Ipg plasmid DNA (or the indicated 
volume of cloning reaction) were added, mixed gently and incubated on 
ice for 30 minutes. The mixture was heat-shocked for 45 seconds by 
holding in a water bath at 42°C, then immediately placed on ice. 250|liI 
SOC media at room temperature were added, and the tightly sealed tube 
(secured with tape horizontally on a 200rpm shaking platform within an 
incubator) was incubated at 37°C for 1 hour.
50pl and 150pl from the transformation reaction was spread on a 
separate prewarmed selective agar plate, and both were incubated at 
37°C overnight. The following morning discrete colonies were selected as 
described below.
2.2.36 Preparation of Agarose Plates
2YT media was prepared as described in 2.1.9 above. Immediately 
prior to autoclaving 20g microagar was added. Following autoclaving the 
Agarose / media solution was allowed to cool until hand hot. Using 
aseptic technique the desired antibiotic (for selection purposes) was
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added (Ampicillin to a concentration of 100 pg/mi; Kanamycin to a 
concentration of 50 |ag/ml) and the solution poured into sterile 10cm 
microbiology plates and allowed to cool and solidify. Plates were stored at 
4°C until use.
2.2.37 Selection and Overnight Culture of Transformed E . c o l i
Transformed E. co//were spread on an appropriate antibiotic- 
containing agarose plate and cultured overnight at 37°C as outlined 
above. The following day the resulting discrete clonal colonies were 
picked using a sterile micropipette tip and transferred into a sterile 
universal container containing 2YT media and the same antibiotic. This 
was again incubated overnight at 37°C. The following day plasmid DNA 
from the resulting bacterial suspension was purified using the Qiagen 
Miniprep Kit and analysed immediately or stored at -20°C.
2.2.38 induction of Protein Expression
1ml of an overnight culture of E. coli transformed with a prokaryotic 
expression plasmid transformed with DNA encoding the gene of interest 
was used to inoculate 50ml 2YT media (with appropriate antibiotics) and 
grown overnight at 37°C. The following day the resulting cells were 
pelletted by centrifugation at 2500rpm for 10 minutes in a Beckman- 
Coulter Allegra X-12R centrifuge and resuspended In 1 litre of Terrific 
Broth (with appropriate antibiotics). This was grown at 37°C until the OD
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reached the value previously determined to provide optimal protein 
expression (typically 0D= 0.6- 0.8). IPTG was then added to a final 
concentration of 0.5nM and the culture continued overnight.
2.2.39 Purification of Epitope-Tagged Proteins
Protein expression was induced as described above. Following 
overnight culture cells were pelletted by centrifugation at 4000 rpm for 20 
minutes in a Beckman-Coulter Allegra X-12R centrifuge at 4°C. From this 
point forward all steps were carried out on ice unless otherwise stated. 
The resulting cell pellet was resuspended in 50ml PBS containing protein 
inhibitor tablets. 1 mg/ml Lysozyme was added and the suspension was 
incubated for 30 minutes at 4°C. Cells were broken by sonication for 3 x 
20seconds with 20 second pauses. The broken cells were pelletted by 
centrifugation at 20 OOOrpm for 30 minutes in a Beckman centrifuge and a 
JA-20 rotor.
Meantime, 2mt Sepharose Beads labelled with the appropriate 
affinity tag were washed in 3 x 10ml PBS and 1% v/v Triton, collecting the 
beads by centrifugation at 2500 rpm in a Beckman-Coulter Allegra X-12R 
centrifuge each time. The cleared supernatant (containing the expressed 
protein) was incubated with the beads for 2 hours at 4°C with constant 
rotation after which the beads were again washed in 3 x 10ml PBS and 
1% v/v Triton, collecting the beads by centrifugation at 2500 rpm in a 
Beckman-Coulter Allegra X-12R centrifuge each time.
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Expressed protein was eluted from the beads by repeated (X 4) 
incubation with reduced glutathione (GST beads), reduced pH (Protein G 
Beads) or imidazole (nickel beads) for 5 minutes. The resulting protein 
fractions were then resolved by SDS-PAGE and analysed by Coomassie 
staining, or transferred to nitrocellulose for immunodetection.
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Chapter 3: Synaptotagmin Expression in Murine Brain, Murine
Muscle, Human Brain, Pooied Human Adipose and the 
3T3-L1 Ceii
3.1 introduction
The role of the SNARE complex formed between by VAMP2, 
Syntaxln-4 and SNAP-23 in the fusion of the GSV with the adipocyte and 
skeletal and cardiac myocyte plasma membrane is well established. As 
discussed in the introduction (1.3.8) there are conflicting data regarding 
the requirement for calcium in insulin-stimulated GLUT4 translocation, 
with convincing evidence emerging to suggest a role in the latter stages 
of GSV-Plasma membrane fusion In the 3T3-L1 adipocyte. To date the 
putative calcium sensor required to mediate such a requirement remains 
unknown.
In regulated exocytosis events in other tissues (e.g. 
neurotransmission, endocrine hormone secretion) the requirement for a 
member of the SYT family in governing the final fusion event between 
vesicle and plasmaiemma is now universally accepted. Given that GSV- 
plasmalemma fusion represents a specialised form of regulated 
exocytosis, and the similarities described between all such events it 
remains possible that by facilitating GSV-PM fusion a particular SYT 
isoform may play an important role in mediating insulin stimulated
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glucose uptake. To date there has been no published methodical 
investigation of SYT expression in peripheral insulin sensitive cells.
Reverse transcription PCR is an established method of 
determining the presence of a particular gene transcript in any given cell 
or tissue (i.e. whether or not the gene is expressed) and has previously 
been described for 3T3-L1 adipocytes (298). Taqman Realtime semi- 
quantitative PCR is a validated means of determining the level of 
expression of any given gene of interest (relative to the expression level a 
known constitutive or “housekeeping” gene (299)).
The 3T3-L1 murine fibroblast cell line is a standard tool in the 
study of insulin stimulated glucose uptake. 3T3-L1 cells grown in culture 
can be induced to undergo differentiation (by the addition of insulin, 
dexamethasone and IBMX) into mature insulin-sensitive adipocytes. The 
resulting phenotype produced whilst not indistinguishable, is remarkably 
similar to that of ex-vivo rodent or human adipose cells; 3T3-L1 
adipocytes express GLUT4, which is upregulated to the PM in response 
to insulin, facilitating insulin-stimulated glucose uptake (300;301).
In this chapter the murine synaptotagmin genes expressed in 
skeletal muscle and 3T3-L1 cells, and the human synaptotagmin genes 
expressed adipose tissue shall be determined by Reverse Transcription 
PCR and compared. Using Taqman Semi-quantitative Realtime PCR the 
relative expression (to p-actin) of the expressed synaptotagmin
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complement of 3T3-L1 cells shall be established during differentiation 
from fibroblast to adipocyte. In this way the comparative importance of 
any particular isoform expressed can be inferred, with the expectation 
that upregulation in expression of any candidate gene will coincide with 
acquisition of insulin sensitivity.
3.2 Methods
3.2.1 Synaptotagmin Gene-specific Nucleotide Sequences
The US National Centre for Biotechnology Information (NCBI) 
Genbank Database was interrogated using the search term 
“Synaptotagmin”. All resulting murine and human sequences 
corresponding to part- or full-length synaptotagmin cDNA or mRNA were 
selected. Using Gene-Jockey software running on an Apple Power 
Macintosh 6500 PC species-specific sequences for each individual 
synaptotagmin isoform were compared, and the open reading frame 
identified. Genbank accession numbers for each published SYT 
sequence used are listed in TABLE A1 the Appendix. The human SYT9 
sequence was not published at the time these sequences were identified 
(human SYT9 sequence subsequently published 2004).
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3.2.2 Synaptotagmin Gene-specific Oligonucleotide PCR
Primers
18-mer oligonucleotide PCR primers were designed to amplify a 
200 to 300bp fragment of each synaptotagmin isoform from the full open 
reading frame sequence identified in 3.2.1. Where possible, primers were 
designed to have Tm of around 55°C, identical GC content and to have 
two purine residues at the 3’ end to assist in DNA polymerisation 
initiation. Primer sequences were compared with the published mouse or 
human transcriptome sequence using the NCBI Basic Local Alignment 
Search Tool (302) to ensure species and sequence specificity for each 
isoform. Where splice variants were known (e.g. SYT7) PCR primers 
were designed to amplify a PCR product with each variant that would be 
easily identified by virtue of product size. PCR primer sequences are 
listed in the Appendix.
It should be noted that although these primers were not originally 
designed to be intron-spanning further analysis has revealed that all 
primer pairs are indeed intron-spanning except those for SYT4, SYT9, 
SYT10, SYT12 and SYT14. The location (corresponding exon) of each 
primer is given in table A2 in the Appendix.
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3.2.3 Synaptotagmin Gene-specific Oligonucleotide Taqman
Realtime PCR Primers and Oligonucleotide Probes
21-mer oligonucleotide PCR primers and 18-mer oligonucleotide 
probes were designed to amplify a fragment of around 120 bp for each 
candidate synaptotagmin isoform from the full open reading frame 
sequence identified in 3.2.1. Primers were designed to have Tm of 55°C 
and designed to yield products that span intron-exon boundaries. Primer 
and probe sequences were compared with the published mouse 
transcriptome sequence using the NCBI Basic Local Alignment Search 
Tool (72) (302) to ensure specificity for each isoform. Where splice 
variants were known (e.g. SYT7) PCR primers were designed to amplify 
a PCR product from template sequence common to all variants. PCR 
primer and oligonucleotide probe sequences are listed in the Appendix.
3.2.4 Murine Control cDNA
Most synaptotagmin isoforms are known to be expressed in brain. 
RNA was isolated from the brain of a euthanised wild-type Mus musculus 
lab mouse using the Qiagen RNEasy™ Kit following the manufacturers 
instructions. cDNA was reverse transcribed as described in Chapter 2 
(2.2.1.5). PCR reactions (2.2.1.6) were optimised using brain cDNA 
template, which was then used as a positive control for subsequent test 
reactions. PCR products were TA-cloned and subsequently sequenced to 
ensure specificity of amplification.
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3.2.5 Human Control cDNA
Human brain cDNA was a generous gift from Dr Scott MacKenzie. 
Human Testis cDNA Library was a generous gift from Dr Andrew 
Fielding. PCR reactions (2.2.1.6) were optimised using either Brain or 
Testis cDNA template, which was then used as positive control for 
subsequent test reactions.
3.2.6 3T3-L1 Cell cDNA
3T3-L1 cells were grown in 10cm culture dishes and differentiated 
as described in Chapter 2 (2.2.2.1-3). RNA was isolated at confluent 
fibroblast stage and at 2 day intervals to day 14 post-differentiation using 
the Qiagen RNEasy Kit. cDNA was reverse transcribed as described in 
Chapter 2 (2.2.1.5) and used as template for test PCR reactions.
3.2.7 Murine Muscle cDNA
Insulin-stimulated glucose uptake in skeletal muscle is also known 
to depend upon fusion of GSVs with the plasmalemma. In parallel with 
the adipocyte, the skeletal muscle SNARE complex involved is composed
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of the v-SNARE VAMP-2 and t-SNARES Syntax!n-4 and SNAP-23, and 
thus may employ the same synaptotagmin isoform.
Lower limb skeletal muscle was dissected from a euthanised wild- 
type Mus Musculus lab mouse and placed immediately on ice. RNA was 
then isolated using the Qiagen RNEasy kit. RNA was reverse transcribed 
to cDNA as described in chapter 2 (2.2.1.5) and used for test PCR 
reactions.
3.2.8 Human Adipose Tissue cDNA
Pooled Human Adipose Tissue RNA (Ambion Inc., Austin, TX, 
USA.) was a generous gift from Dr Scott MacKenzie. RNA was reverse 
transcribed into cDNA as described in Chapter 2 (2.2.1.5 and used for 
test PCR reactions).
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3.3 Results
3.3.1 Synaptotagmin Expression in Murine Brain
Figure 3.1a shows products obtained when gene-specific murine 
SYT primers were used in a PCR reaction using murine brain cDNA as 
template. The primer annealing temperature and polymerase buffer 
magnesium concentration was optimised for each individual PCR reaction 
and identical conditions used for all subsequent reactions with that primer 
pair. Polymerase used (Taq polymerase) was non-proof reading.
In figure 3.1 PCR products obtained using primers specific for SYT 
1-14 are of the expected nucleotide length (PCR primer location and 
expected product length is found in TABLE A2 in the Appendix). No 
product is seen for SYT 15.
More than one PCR product can be seen for SYT7. It is expected 
that these products represent the alternatively spiced variants described 
in the Appendix (A1.2.2 and Figure A1). Additional unexpected bands can 
be seen for SYT8 and SYT10. In order to investigate their origin, these 
unidentified PCR products were resolved further in an additional gel 
(Figure 3.1b), then cloned and sequenced as described for the SYT PCR 
products in 3.3.1.2 below.
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At the time of designing RTPCR primers used in these 
experiments consideration was not given to the location of intron-exon 
boundaries. As a result, although most primer pairs are indeed intron- 
spanning some are not (SYT4, SYT9, SYT10, SYT12 and SYT14). For 
those isoforms with intron-spanning PCR primers these data suggest that 
the transcripts of these isoforms are expressed in murine brain tissue. For 
those isoforms without intron-spanning primers it is not possible from 
these data to comment on expression in murine brain.
No product was obtained using SYT15 primers with murine brain 
cDNA. This may be due to lack of expression in brain, or due to a 
problem with the PCR primer pair (e.g. incorrect design, sequence error 
during synthesis, secondary structure). Published expression data 
suggest that SYT15 is not expressed in brain (303) and so these data are 
in support of this observation. However, a positive control would require 
to be shown for these primers to allow this conclusion to be drawn.
Important control PCR reactions using DNAse treatment and non­
reverse transcribed RNA as template were not performed. Further 
discussion of controls both employed and not is found in the discussion of 
this chapter (Section 3.4).
129
Figure 3.1 SYT Expression in Murine Brain
Figure 3.1a SYT Isoform
Kb 1 2 3 4* 5 6 7 8 9* 10* 11 12* 13 14*15
250bp
Figure 3.1a Photograph of PCR products obtained from RTPCR
reactions with gene-specific SYT primers and murine brain 
cDNA template, resolved by agarose gel electrophoresis, 
stained with ethidium bromide and visualised under UV 
light. PCR products are compared with DNA size markers in 
the extreme left lane. PCR product bands can be seen of 
the expected nucleotide length (164). * indicates where 
primers were not intron-spanning.
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Figure 3.1b
SYT8 SYT10
I 1 I 1
Figure 3.1b Photograph of PCR products obtained from RTPCR
reactions with gene-specific SYT primers for SYT8 and 
SYT10, and murine brain cDNA template, resolved by 
agarose gel electrophoresis, stained with ethidium bromide 
and visualised under UV light. PCR products are compared 
with DNA size markers in the extreme left lane (as shown in 
Figure 3.1a above: not labelled in this figure). PCR product 
bands have been identified and labelled. Each product was 
cloned and sequenced as described in 3.3.1.2 below.
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3.3.2 Cloning and Sequencing of Murine SYT RT PCR
Products
Fresh RTPCR products described in 3.3,1.1 above were carefully 
excised from the agarose gel with a clean scalpel blade, purified with the 
Qiaspin™ gel purification kit as instructed by the manufacturers and TA- 
cloned into the pCR-2.1 plasmid, again following the instructions of the 
manufacturer. The resulting plasmids were transformed into competent E. coli 
and grown overnight on selective Agar plates.
Two or three recombinant colonies for each PCR product were 
selected for further overnight growth and plasmid purification. Restriction 
enzyme digestion was performed to confirm the presence of an appropriately 
sized insert (cloned PCR product). One plasmid for each product was 
sequenced.
Figures 3.2a and 3.2b show successfully cloned PCR products of the 
expected size for SYT2 and SYT4- 9 (similar digestion products of the 
appropriate size were obtained for plasmids into which other isoforms were 
successfully cloned).
It can be seen that two SYT5 clones did not contain DNA insert (lanes
5.1 and 5.2 of Figure 3.2a). The strong band of approximately 3Kb most likely 
represents supercoiled (i.e. non-linnearised) plasmid vector DNA, indicating 
that in this case the cloning was not successful. There is one clone of SYT8
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(lane 8.1 in Figure 3.2b) for which there has been an unsuccessful plasmid 
purification. This may be either a failure of the plasmid purification procedure 
or even a spontaneous mutation in an un-transformed E. coli resulting in 
antibiotic resistance and thus growth on selective agar plates.
DNA sequences obtained confirm the sequence identity of each 
expected SYT RTPCR product (including those not shown) and are listed in 
the appendix. The SYT8 and SYT10 products (Figure 3.1b) yielded the 
expected 229 bp SYT8 sequence (81) and the expected 269bp 8YT10 
sequence (101). Sequencing of the remaining bands identified in Figure 3.1b 
(811,10 II, IGin and 10IV) produced sequence that was identical to that of a 
variety of different prokaryotic and eukaryotic plasmid vectors and not 
recognised genomic or transcript sequence.
133
Figure 3.2 Sub-cloning of PCR Products
Figure 3.2a
4Kb
SYT2 SYT4 SYT5
Linnearised
Vector
Cloned Insert
500bp
250bp
2.2 2.3 4.1 4.2 4.3 5.1 5.2 5.3
Figure 3.2b
SYT6 SYT7 SYT8 SYT9
Kb  ^  ^ I \ \ I \
250bp
6.1 6.2 7.1 7.2 8.1 8.2 9.1 9.2
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Figure 3.2
Figure 3.2a and b Photographs of resolved products obtained 
from restriction enzyme (EcoR1) digestion of pCR 2.1 plasmid 
DNA (into which the SYT RTPCR products have been cloned) 
compared to DNA size markers as indicated. Figure 3.2a digested 
plasmid DNA from two clones of SYT2 product (lanes 2.1 and 2.2) 
and three clones each of SYT4 and SYT5 product (lanes 4.1- 4.3 
and 5.1- 5.3 respectively) are shown. Arrows Indicate linnearised 
plasmid DNA of the expected size (3.9Kb) and cloned PCR 
product of the expected size.
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3.3.3 GLUT4 Expression in 3T3-L1 Cells During
Differentiation
Figure 3.3 shows products obtained when gene-specific murine 
GLUT4 primers were used in a PCR reaction using cDNA from murine 
brain, confluent 3T3-L1 fibroblasts, and 3T3-L1 adipocytes at the 
indicated time from differentiation as template (all cells used were derived 
from the same passage). The primer annealing temperature and 
polymerase buffer magnesium concentration was optimised using 
adipocyte cDNA prior to this experiment, and identical conditions were 
used for all subsequent reactions with this primer pair. As can be seen in 
figure 3.3 the PCR product obtained using intron-spanning primers 
specific for GLUT4 is of the expected nucleotide length (164).
These data suggest low level expression of GLUT4 in brain tissue. 
GLUT4 expression is not detected in confluent fibroblasts or immature 
day 2 adipocytes. As cells progress through the differentiation process 
and acquire insulin-sensitivity, high level GLUT 4 expression is detected 
from day 6, and this is maintained at all subsequent timepoints assessed. 
Insulin sensitivity of the cells used was confirmed (at day 12) by 
measurement of insulin-stimulated 2-deoxyglucose uptake (shown in 
Figure 3.4).
These data are in keeping with previously determined GLUT4 
expression data in brain and throughout the 3T3-L1 differentiation
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process. GLUT4 expression is seen to coincide with expected acquisition 
of insulin sensitivity. Alongside insulin-stimulated 2-deoxyglucose uptake 
data they confirm the cells used are typical of 3T3-L1 adipocytes at each 
timepoint, and as such the cDNAs prepared are representative and valid 
templates for use in subsequent experiments to determine SYT 
expression.
An appropriate additional control would be the PCR amplification 
of the cDNA of a housekeeping gene (304) in tandem with that of GLUT4. 
The observation of a uniform product from each timepoint would serve to 
confirm equivalence of template cDNA concentration and thus allow the 
relative expression at each timepoint to be inferred. This control 
experiment was not performed.
There are no additional PCR products observed, and this implies 
there is no contamination of samples with genomic DNA. However, it 
should be noted that DNAse treatment of isolated RNA was not carried 
out, and RNA alone (i.e. prior to the reverse transcription step: non-RT) 
was not used as a negative control. From these data therefore it is not 
possible to completely exclude the possibility of genomic DNA 
contamination.
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Figure 3.3: GLUT4 Expression in 3T3-L1 Ceils
GLUT4
1kbp
750bp
500bp
250bp
Figure 3.3 Photograph of PCR products obtained from RTPCR
reactions with gene-specific GLUT4 primers and murine 
brain cDNA (B), 3T3-L1 confluent fibroblast cDNA (F), 3T3- 
L1 adipocyte cDNA at progressive stages throughout 
differentiation (d2= day 2, d6= day 6 etc.) templates, and no 
template (C), resolved by agarose gel electrophoresis, 
stained with ethidium bromide and visualised under UV 
light. PCR products are compared with DNA size markers in 
the extreme left lane. Single PCR product bands can be 
seen of the expected nucleotide length. The arrow indicates 
a faint band).
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Figure 3.4 Insulin-Stimulated 2-Deoxyglucose Uptake in 3T3-L1 
Adipocytes
1'2  4 m
rt 3 □a o
2  £ 2
[INSULIN]
Figure 3.4 3T3-L1 adipocytes were assayed for insulin-stimulated
deoxyglucose uptake using lOOnM insulin where indicated. 
Data is presented relative to the rate of uptake in basal 
(unstimulated) cells. (N= 3 at each point; error bars indicate 
1 standard deviation from mean values). Data are 
representative of a typical experiment.
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3.3.4 Synaptotagmin Expression in 3T3-L1 cells During
Differentiation
Figures 3.5 and 3.6 show products obtained when gene-specific 
murine SYT primers were used in a PCR reaction using 3T3-L1 cell 
cDNAs as template. Product of the expected size was obtained when 
murine brain cDNA was used as a positive control in each case.
As can be seen in the figures, although the positive control 
reaction yielded the expected product, no PCR product was obtained for 
SYTs 1, 2, 4, and 6 when 3T3-L1 cDNA was screened. These results 
suggest that these isoforms are not expressed in 3T3-L1 cells.
As before no product was obtained using SYT15 primers, 
suggesting this isoform is not expressed In 3T3-L1 cells. However, as 
with murine brain cDNA it would be important to obtain a positive control 
template for this primer pair prior to this conclusion being drawn.
PCR products of the appropriate size can be seen to be amplified 
from 3T3-L1 cell cDNA for SYT 3, 5 and 7 - 1 4 .  In the absence of parallel 
amplification of a housekeeping gene it is not possible to draw any 
conclusion regarding their relative expression at any given timepoint from 
these data.
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On examining Figure 3.6a it is clear that an additional PCR product 
of between 750bp and 1Kb is present following amplifications using 
SYT5. This additional product is seen when both murine brain and 3T3- 
L1 cell cDNA templates are used. The SYT5 primers are intron spanning 
and there were no steps taken to exclude genomic DNA contamination. 
One possibility is that this band represents amplification of the intron(s) 
between the adjacent exons in which the SYT5 primers are located. This 
hypothesis was not tested by sequencing of the additional product.
Closer study of the SYT5 transcript and genomic sequence reveals 
that the forward primer is located in exon 6 and the reverse primer in 
exon 8. The expected product size is 289bp. If genomic contamination 
was present the resulting amplification of the 3’ end of exon 6 (56bp), 
intron 6/7 (613bp), exon 7 (134), intron 7/8 (781) and the 5’ end of exon 8 
(99bp) would result in a PCR product of 1733bp, which is much larger 
than the extra band observed. The additional product may therefore 
represent non-specific off target amplification, however without 
sequencing of this product further hypothesis on its identity is futile.
Similar to the products observed for SYT5, an extra product is also 
seen for SYT14 when 3T3-L1 cDNA template is used. The SYT14 
primers are not intron spanning, and so would not be expected to 
produce products of different lengths if genomic DNA contamination was 
present. Thus, the additional product may represent either non-specific 
off-target amplification or a hitherto undescribed splice variant. Further
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attempts to characterise the additional SYT14 product were not carried 
out.
When the SYT7 primers are used in a PRC reaction with murine 
brain cDNA template three bands of a size corresponding to the expected 
splice variants (SYT7a, SYT7p and SYT7y) can be seen, with SYT7P 
being the most prominent. When 3T3-L1 cDNA is used a band of the 
expected size of the SYT7a product is seen at all timepoints. The SYT7p 
and SYT7y products are not seen. These data suggest that SYT7a is 
expressed in 3T3-L1 cells.
There are three products of 250- 500bp seen for SYT1Q. When 
brain cDNA template is used the predominant product is the smallest 
(~250bp). The predominant product is the larger of the three (~350bp) 
when 3T3-L1 fibroblast and day 2 cDNA is used for PCR amplification. By 
day 10 there are only two bands visible (the larger and the smaller) and 
by day 14 only the smaller band can be seen. The expected product size 
for SYT1Q is 269bp, therefore the smaller band most probably denotes 
the expected product. The SYT10 primers are not intron spanning 
therefore (as for SYT14) the additional bands are unlikely to reflect 
genomic DNA contamination. The results could be explained by non­
specific off-target amplification or by a possible novel splice variant. The 
chance of contamination with non-murine (e.g.. human) DNA remains a 
possibility that was not investigated. No attempt to further characterise 
these bands was made.
142
Figure 3.5: SYT 1, 2, 4, & 6 Expression in 3T3-L1 Cells
Figure 3.5a
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Figure 3.5b
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Figure 3.6: SYT 3, 5 & 7-14 Expression in 3T3-L1 Cells 
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Figure 3.6b
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Figure 3.6c
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Figure 3.6d
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Figure 3.6e
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Figures 3.6a- d
Photographs of PCR products obtained from RTPCR reactions 
using gene-specific SYT primers and cDNA template from murine 
brain (B), confluent 3T3-L1 fibroblast (F), 3T3-L1 adipocyte at 
progressive stages throughout differentiation (d2= day 2, d6= day 
6 etc.) as indicated. PCR products were resolved by agarose gel 
electrophoresis, stained with ethidium bromide and visualised 
under UV light, and can be compared with the indicated DNA size 
markers. Arrows indicate faint bands. Data are representative of 2 
identical experiments for each isoform using cDNA prepared from 
discrete cell populations of different passage.
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3.3.5 GLUT4 and SYT Expression In Murine Skeletal Muscle
Figure 3.7a shows products obtained when gene-specific murine 
GLUT4 primers were used in a PCR reaction using cDNA from 3T3-L1 
adipocytes (at day 10 post-differentiation) and murine skeletal muscle as 
template. As can be seen in the first panel of the figure, the PCR product 
obtained from murine skeletal muscle using intron-spanning primers 
specific for GLUT4 is of the expected nucleotide length and confirms the 
quality of this template for subsequent test reactions.
Figures 3.7b, 3.7c and 3.8 show products obtained from PCR 
reactions using gene-specific murine SYT primers and murine skeletal 
muscle template alongside murine brain cDNA positive control. These 
data indicate that SYT1, 2, 4, 5, 6, 8,9,13 and 14 are not expressed in 
murine skeletal muscle, and suggest that SYT3, 7,10,11 and 12 are 
expressed in murine skeletal muscle.
In Figure 3.7c the gel photograph does not clearly show a band in 
the positive control (Brain template) lane for SYT 10 which was clearly 
visible at the time of performing these experiments.
The SYT15 PCR product band seen in Figure 3.7c is of the correct 
approximate expected size. This band was not further characterised by 
sequencing. In the absence of a positive control or further attempts to
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identify this product it is not possible from these data to comment upon 
the expression of SYT15.
Given that a DNA-se treatment of RNA samples and non-RT 
controls were not performed for these experiments caution must be 
exercised in their interpretation, especially with those PCR products that 
do not span intron/exon boundaries (SYT10 and SYT12). In spite of this, 
the absence of PCR product with SYT4, SYT9 and SYT14 primers 
suggests that there is no genomic DNA contamination in samples derived 
from murine muscle tissue.
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Figure 3.7: GLUT4 and Synaptotagmin Expression in Murine 
Skeletal Muscle 
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Figure 3.7c
250bp
SYT6
r B M r
250bp/i
SYT8 SYT9
B  ^ B IVI ^
SYT10 SYT12
( \B M B M
500bp
250bp
SYT13 SYT14 SYT15
B M
153
Figure 3.7a, 3.7b and 3.7c
Photographs of PCR products obtained from RTPCR 
reactions using gene-specific SYT primers and cDNA 
template from murine brain (B), murine skeletal muscle (M) 
and no template (C) as indicated. PCR products were 
resolved by agarose gel electrophoresis, stained with 
ethidium bromide and visualised under UV light, and can be 
compared with the indicated DNA size markers. Arrows 
indicate faint bands. Data are representative of 2 identical 
experiments for each isoform using cDNA prepared from 
muscles of the opposite leg of the same mouse.
154
Figure 3.8: SYT7 and SYT11 Expression in Murine 
Skeletal Muscle
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Figure 3.8 Photographs of PCR products obtained from RTPCR 
reactions using gene-specific SYT primers and cDNA 
template from murine brain (B) and murine skeletal muscle 
(M) as indicated. PCR products were resolved by agarose 
gel electrophoresis, stained with ethidium bromide and 
visualised under UV light, and can be compared with the 
indicated DNA size markers. Arrows indicate faint bands. 
Data are representative of 2 identical experiments for each 
isoform using cDNA prepared from muscles of the opposite 
leg of the same mouse.
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3.3.6 Synaptotagmin Expression in Pooled Human Adipose
Figure 3.9 shows products obtained when gene-specific intron- 
spanning human SYT7 and SYT11 primers were used in a PCR reaction 
using cDNA from human testis and pooled human adipose tissue as 
template. Cycling conditions and polymerase buffer magnesium content 
were optimised for each primer pair using testis cDNA as template; PCR 
products were of the expected nucleotide length.
These data are suggestive that SYT7 and SYT 11 are expressed in 
human adipose tissue, since a PCR product of the size expected can be 
seen. There are however additional products visible for both isoforms, 
which raises the possibility of genomic (or other) DNA contamination or 
off target amplification. These options were not addressed further 
experimentally. Furthermore, DNAse treatment and non-RT controls were 
not performed, limiting the conclusions that may be drawn from these 
data.
The human adipose tissue cDNA was screened for the presence 
of transcripts of the other SYT isoforms. The results of these experiments 
are in accordance with results observed when 3T3-L1 adipocyte cDNA
was used.
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Figure 3.9: SYT7 and SYT11 Expression in Human Adipose Tissue
SYT7
r r A ^
SYT11
Figure 3.9 Photographs of PCR products obtained from RTPCR
reactions using gene-specific SYT7 and SYT 11 primers and 
cDNA template from human testis (T) and pooled human 
adipose tissue (A) as indicated. PCR products were 
resolved by agarose gel electrophoresis, stained with 
ethidium bromide and visualised under UV light. Arrow 
indicates a faint band. Data are from 1 experiment.
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3.3.7 GLUT4 and SYT Expression in 3T3-L1 Cells as
Determined by Taqman Semi-Quantitative Realtime 
PCR
Prior to assessing relative SYT expression in 3T3-L1 cell cDNA a 
standard curve of AcT vs. template concentration was prepared for all 
Taqman Realtime PCR primer and probe sets and can be seen in Figure 
3.10. Murine Brain cDNA template was used. This demonstrates equal 
efficiency of amplification at all template concentrations for all primer and 
probe sets examined.
Figure 3.11 shows the relative expression (to (3-actin) of the SYT 
isoforms examined in brain. The data for SYT 11 expression are omitted 
from figure 3.11a but included in figure 3,11b (note different scale). 
Threshold cycle (Ct; the point at which product amplification becomes 
log-linear) is indicated for each isoform, and all Cy values (except for 
SYT7) are seen to be <35, indicating expression of the transcript in 
murine brain.
Figure 3.12 shows expression of murine GLUT4 relative to the 
expression of (3-actin in cDNA prepared from 3T3-L1 fibroblasts and 
mature day 8 adipocytes. No expression of GLUT4 can be detected in 
fibroblast cDNA, and a high level of relative expression is observed in
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adipocyte cDNA. It is expected that this is due to upregulation of GLUT4 
expression during the differentiation process. These data confirm that the 
cDNA templates used are representative of 3T3-L1 adipocytes and are 
thus valid for use in experiments to assess SYT expression.
Figure 3.13 shows expression of the indicated murine SYT 
isoforms relative to the expression of p-actin in cDNA prepared from 3T3- 
L1 fibroblasts. SYT11 is the predominant isoform and is expressed at 
approximately 1.6 times the level of SYT7. As indicated by C j values, the 
remaining isoforms are not expressed at a significant level.
Figures 3.14a and 3.14b show the relative expression of the 
indicated SYT isoforms in insulin-sensitive 3T3-L1 adipocytes. The data 
for SYT 11 expression are omitted from figure 3.12a but included in figure 
3.12b (note different scale). These data suggest that SYT11 expression is 
upregulated as 3T3-L1 cells differentiate and acquire insulin-sensitivity. 
SYT 11 is the predominant 3T3-L1 adipocyte isoform. The relative 
expression of SYT7 and SYT11 are further determined in figures 3.15 
and 3.16, where it can be seen that SYT7 expression is maintained, and 
SYT11 expression appears to increase ~18-fold during differentiation.
Expression of SYT11 during differentiation is further characterised in 
figure 3.17 where it can be seen that relative SYT11 expression increases
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steadily during differentiation and is maximal at day 8. Thereafter the 
expression level falls, but remains significantly elevated at day 10 and day 12 
above that of the fibroblast.
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Figure 3.10: Taqman Primer and Probe Standard Curve
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Figure 3.10 Standard curve of AcT at serial template DNA dilutions for 
ail Taqman Realtime PCR primer and probe sets (a 
detailed description of the derivation of values is given in 
section 2.2.9). The parallel line for each set demonstrates 
equivalent PCR efficiency at the range of template 
concentrations indicated. That the lines are (near) 
horizontal indicates each reaction is within the linear 
dynamic range (i.e. the range of template concentrations 
which allow accurate determination relative to the control 
(GAPDH) gene). Data are from a single experiment using 
murine brain cDNA of O.SSpg/pl (determined 
spectrophotometrically).
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Figure 3.11: SYT Expression in Murine Brain Tissue
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Figure 3.11 Relative (to p-actin) expression of murine SYT3 and SYT7- 
SYT13 as determined by Taqman semi-quantitative PCR 
using Murine Brain tissue cDNA template. The upper panel 
shows all except SYT 11. The same data are presented in 
the lower panel including SYT 11. Note different scale (Y- 
axis). (Data presented are from a single experiment ). 
Values indicate the amount of each transcript relative to p- 
actin transcript in the sample analysed (a detailed 
description of the derivation of values is given in section 
2.2.9). Threshold cycle (Ct) is shown for each isoform.
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Figure 3.12: GLUT4 Expression in 3T3-L1 Cells During
Differentiation
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Figure 3.12 Relative (to p-actin) expression of murine GLUT4 as
determined by Taqman semi-quantitative PCR using 3T3-L1 
cDNA template generated at confluent fibroblast (DO) and 
day 8 (D8) post-differentiation. (Data presented are the 
mean of 8 identical experiments; error bars show 1 standard 
deviation). Values indicate the relative amount of GLUT4 
transcript compared to p-actin transcript at each given 
timepoint. Threshold cycle (Cy) is shown.
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Figure 3.13: SYT Expression in Confluent 3T3-L1 Fibroblasts
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Figure 3.13 Relative (to p-actin) expression of murine SYT3 and SYT7- 
SYT13 as determined by Taqman semi-quantitative PCR 
using confluent fibroblast 3T3-L1 cDNA template. (Data 
presented are representative of multiple experiments using 
cDNA derived from discrete cell populations). Threshold 
cycle (C t)  for each isoform is shown.
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Figure 3.14: SYT Expression in 3T3-L1 Adipocytes
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Figure 3.14 Relative (to p-actin) expression of murine SYT3 and SYT7- 
SYT13 as determined by Taqman semi-quantitative PCR 
using 3T3-L1 cDNA template at day 8 (D8) post­
differentiation. The upper panel shows all except SYT 11. 
The same data are presented in the lower panel Including 
SYT11. Note different scale (Y-axis). (Data presented are 
from a single representative of multiple experiments using 
cDNA derived from discrete cell populations). Threshold 
cycle ( C t )  for each isoform is shown.
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Figure 3.15: SYT7 Expression in 3T3-L1 Cells During
Differentiation
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Figure 3.15 Relative (to p-actin) expression of murine SYT7 as
determined by Taqman semi-quantitative PCR using 3T3-L1 
cDNA template at confluent fibroblast (DO) and day 8 (D8) 
post-differentiation. (Data presented are typical of 3 
identical experiments using cDNA derived from discrete cell 
populations). Threshold cycle (Cj) at each timepoint is 
shown.
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Figure 3.16: SYT11 Expression in 3T3-L1 Cells During
Differentiation
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Figure 3.16 Relative (to p-actin) expression of murine SYT 11 as
determined by Taqman semi-quantitative PCR using 3T3-L1 
cDNA template at confluent fibroblast (DO) and day 8 (D8) 
post-differentiation. (Data presented are the sum of 3 
identical experiments using cDNA derived from discrete cell 
populations; error bars show 1 standard deviation). 
Threshold cycle (Cy) at each timepoint is shown.
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Figure 3.17: SYT11 Expression in 3T3-L1 Ceils During
Differentiation: Additional Timepoints
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Figure 3.17 Relative (to p-actin) expression of murine SYT 11 as
determined by Taqman semi-quantitative PCR using 3T3-L1 
cDNA template derived from confluent fibroblast (DO) and 
cells at the days indicated post-differentiation (Data 
presented are the sum of 3 identical experiments using 
cDNA derived from discrete cell populations).
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3.4 Discussion
The initial experimental approach employed in the experiments 
described in this chapter limit the conclusions that can be drawn from the 
data described. In particular, the lack of appropriate controls does not 
allow the precise origin of PCR templates to be accurately determined. 
The RTPCR primers used were not initially designed to be intron- 
spanning. However, the finding that primers for murine GLUT4, human 
SYTs and most of the murine SYTs are indeed intron spanning (table A2) 
allows more certain interpretation of the data generated using them.
Thus, the presence of an appropriately sized PCR product obtained using 
intron spanning SYT3, 5, 7,8,11 and 13 primers, which is identified as 
the target amplicon when sequenced suggests that these isoforms are 
expressed at the mRNA level in the 3T3-L1 adipocyte.
For those isoforms for which primers are not intron spanning 
(SYTs 4,9, 10, 12 and 14) it is not possible from these data to determine 
the origin of the template DNA. Genomic DNA contamination at the RNA 
isolation stage could result in the products obtained in these experiments, 
and this would be indistinguishable from the intended product amplified 
solely from cDNA. This could have been investigated by using both RNA 
prior to reverse transcription as template, and by treating RNA with 
DNAse enzyme as control experiments in which no product would be 
expected. These experiments were not performed. The absence of 
multiple additional PCR product bands in RTPCR reactions is reassuring, 
and suggests no genomic contamination, nevertheless appropriate
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controls would be required to confirm these observations. Thus, from 
these data it is possible to conclude only that the PCR reactions using 
isoform-specific primer pairs for SYTs 4, 9, 10, 12 and 14 produce PCR 
products of the expected size, and no conclusion regarding possible 
expression.
The finding that SYTs 1-14 are expressed in murine brain tissue 
and SYT15 is not confirms published SYT expression profiles. These 
experiments confirm that SYTs are indeed expressed in 3T3-L1 cells, and 
the Taqman data suggest that relative SYT11 expression can change 
during the differentiation process. The developmental upregulation of a 
particular transcript implies a functional role for that gene product in the 
particular developmental stage studied. This has previously been 
observed to be the case with SYT1 in PCI 2 cells, various subpopulations 
of neurons and the retinal neuroepithelium (305-307), SYT1-SYT4 in the 
developing CNS (308) and SYT2 in murine embryo-derived cells (309).
In the absence of parallel experiments to amplify a similar sized 
product from the transcript of a known housekeeping gene using intron- 
spanning primers it is not possible from the RTPCR data to comment 
upon the relative expression level of any isoform at any given timepoint.
It is to be expected that the complement of SYT isoforms 
expressed in muscle and adipocytes is not identical: they are distinct and 
specialised cells. However, their shared embryonic origin is mesodermal.
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and so it is not surprising that there is considerable overlap in the genes 
expressed: SYT3, 5, 7, and 11 are expressed by both skeletal muscle 
and adipocytes. It is possible that the factors regulating skeletal muscle 
and adipocyte GSV fusion differ. Since calcium plays a key role in 
skeletal muscle and cardiac muscle contraction it is possible that an 
alternative (non-calcium-dependent) SYT isoform interacts with the 
assembled GSV-SNARE complex in these tissues, and the differences in 
SYT expression observed between skeletal muscle and adipocytes 
reflects this difference.
Many of the gel images shown in this chapter demonstrate poor 
resolution of DNA bands, which makes accurate assessment of size 
difficult. An alternative strategy would have been to employ 
Polyacrylamide Gel Electrophoresis, which would allow better 
discrimination of PCR products. Furthermore, product identification by 
virtue of a target-specific oligonucleotide probe and Southern blotting 
would have obviated the need for the subcloning and sequencing strategy 
employed in these studies.
The data generated using Taqman Realtime PCR demonstrate 
that the two isoforms expressed in 3T3-L1 cells are SYT7 and SYT 11. 
Transcripts of the other isoforms for which RTPCR products were 
observed are not expressed at a significant level over baseline. These 
differences serve to illustrate the advantage in employing a realtime 
quantitative PCR (qPCR) method over conventional RTPCR.
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Quantitative realtime PCR has a dynamic range of 10  ^whereas 
conventional RTPCR has a dynamic range of 1000 fold. This allows 
qPCR to detect and to discriminate within a much wider range of template 
concentrations. Conventional RTPCR requires a post-amplification 
processing step for product analysis (agarose gel electrophoresis), 
whereas the readout data from qPCR is gathered in tandem with the 
amplification step. This also introduces a further degree of error, given 
that it is not possible to accurately estimate the relative concentration of 
DNA samples loaded onto an agarose gel. Finally, conventional RTPCR 
measures the sum total amount of product produced by all amplification 
steps whereas qPCR measures product after each step. This allows the 
initial exponential phase of target amplicon production to be identified, 
and relative concentration of template can then be calculated (as 
described in section 2.2.9).
The differences observed between the RTPCR data and the qPCR 
data serve to confirm these differences between the two methods. The 
finding of SYT isoforms for which a (228) product was obtained (SYT 3, 8 
and 13) by RTPCR but not found to be expressed at a significant level 
relative to (3-actin by qPCR illustrates that these transcripts are present In 
very low (insignificant) copy number. It is possible that there is no 
translation of these transcripts.
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Taken together these data demonstrate that 3T3-L1 cells express 
SYTs. There is evidence that expression is regulated by differentiation., 
in the insulin-sensitive 3T3-L1 adipocyte SYT11 and SYT7 are the 
isoforms expressed. SYT11 and SYT7 transcripts are also detected in 
murine skeletal muscle and human adipose tissue. The observed 18-foid 
upreguiation of SYT11 as 3T3-L1 cells differentiate and acquire insuiin- 
sensitivity implies a key role for this SYT isoform in the adipocyte, which 
may represent interaction with the STX4 / SNAP23 / VAIViP2 SNARE 
complex and regulation of GSV-PM fusion.
The expression of a particular gene as determined by RTPCR 
(semi-quantitative or not) merely confirms the transcription of the gene of 
interest. The majority of transcribed genes are translated into functional 
proteins but not all. Furthermore, the stability of an individual mRNA 
within any individual cell is governed by a number of disparate factors, 
some endogenous and others exogenous. There is an increasing number 
of regulatory RNA sequences being described in the literature. 
Considering these points caution must be exercised in the interpretation 
of these data: in order to confirm SYT expression the demonstration of 
protein is required.
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Chapter 4: Cellular Localisation of SYT7 and SYT11 in the 3T3-L1
Adipocyte
4.1 Introduction
Within the adipocyte GLUT4 is found in multiple cellular locations. 
In the basal state, GLUT4 is known to rapidly recycle from the PM to the 
endosomal system (186), from where it can enter a slower trafficking 
cycle between the endosomal system, the TGN and the GSV pool (186). 
The stimulation with insulin leads to an increase in the rate of transport 
observed in both cycle 1 and 2 above. Moreover, the intracellular GSV 
store is rapidly mobilised in response to insulin, ultimately leading to 
GSVs docking with the PM. SNARE-mediated GSV-PM fusion then 
delivers GLUT4 to its intended site of action (179).
If either or both candidates SYT7 and SYT 11 identified as the 
predominant isoforms in Chapter 3 do indeed play a role in insulin 
stimulated GLUT4 translocation in the 3T3-L1 adipocyte then a temporal 
and spatial relationship to GLUT4 and the SNARE proteins Syntaxin4 
SNAP23 and VAMP2 must be demonstrated.
To date there have been few published studies which describe the 
subcellular localisation of either SYT7 or SYT 11, and none in adipocytes 
or other insulin-sensitive cells (SYT7 has been described in the lysosome 
and PM of fibroblasts (310); SYT11 has been observed in the PM,
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neuronal synaptic vesicle and within Lewy bodies of the Substantia Nigra 
(242)). At the time of investigation there was no commercially available 
SYT7 antiserum, and there remains no such product available for SYT11.
This chapter will describe the generation and characterisation of 
specific antisera raised against SYT7 and SYT 11. These antisera shall 
then be used to confirm the expression of SYT11 protein, and determine 
the subcellular localisation of SYT7 and SYT 11 protein within the fully 
differentiated 3T3-L1 adipocyte.
4.2 Methods
4.2.1 Identification of Potential Immunogenic SYT7 and 
SYT11 Sequences
The amino acid sequences of murine SYT7 and SYT11 proteins 
were obtained from published sequences found in the US National Centre 
for Biotechnology Information (NCBI) Genbank Database. More than one 
version of each sequence was available; comparison using Vector NTl™ 
software revealed there were no sequence variations.
Careful comparison of the murine SYT7 and SYT11 sequences in 
turn with both the amino acid sequence and the solved structure of SYT3 
(311 ) facilitated identification of amino acid residues that could be 
predicted to be present on exposed areas on the ‘outside’ of the 
molecule. By comparing such potential peptide sequences with the
177
sequences of all the other murine synaptotagmln protein sequences, 
candidate peptides were obtained. The NCBI Basic Local Alignment 
Search Tool (72) (302) was used to analyse potential sequences by 
comparing with all other published murine protein sequences.
In this way, two peptide sequences for SYT7 and SYT11 were 
identified that were both present on exposed areas of the molecule, and 
were specific to each synaptotagmln isoform. Peptide sequences used to 
generate SYT7 and SYT 11 antisera are listed in Table A1.4 in the 
Appendix.
4.2.2 Generation of SYT7 and SYT11 Antisera
The generation of specific antisera raised against the peptide 
sequences identified above was performed commercially by Eurogentec, 
Brussels. Briefly, each peptide was chemically synthesised and the amino 
acid sequence verified by mass spectrometry prior to injection of each 
peptide into an otherwise healthy wild-type rabbit. After three booster 
injections, serum was collected and stored at -80°C. Samples of affinity 
purified antibody were prepared by Eurogentec.
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4.2.3 Characterisation of SYT7 and SYT11 Antisera
In order to determine the specificity of each antiserum generated 
affinity purified antisera were used to probe Western blots of murine brain 
lysates and lysates prepared from HEK293 cells transfected with two 
distinct expression plasmids (pEF-BOS, which uses the human EF-1a 
promoter(312) and pAD-CMV V5 DEST, which uses an adapted CMV 
virus promoter (313)), both containing epitope tagged murine SYT7 or 
SYT 11. The quantity of each antiserum used in future experiments was 
optimised based upon the strength of signal produced using these control 
protein preparations.
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4.3 Results
4.3.1 Characterisation of SYT7 and SYT 11 Antisera
Figure 4.1 shows the specific recognition of SYT7 in cell lysates 
prepared from HEK cells in which SYT7 and SYT11 have been 
expressed from two different plasmid promoters. 4.1a shows the 
immunoreactive bands obtained when the commercially available SySy 
antibody is used, and 4.1b shows immunoreactive bands obtained using 
the affinity purified SYT7 antisera. Both antisera recognise two major 
bands, the largest of which is of ~47.5kDa (predicted molecular weight of 
murine SYT7 is 45.5kDa). No immunoreactive bands are seen in the 
SYT11 lanes indicating that both antisera are specific for SYT7.
Figure 4.2 shows the specific recognition of SYT11 in the same 
cell lysates. 4.2a shows the immunoreactive bands obtained when the 
SYT11 antibody obtained from Prof S Pulst (242) is used, and 4.1b 
shows immunoreactive bands obtained using the affinity purified SYT11 
antisera. Both antisera recognise two major bands, the smaller of which is 
of ~47.5kDa (predicted molecular weight of murine SYT 11 is 48.4kDa).
No immunoreactive bands are seen in the SYT7 lanes indicating that both 
antisera are specific for SYT 11.
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Figure 4.1 Affinity Purified SYT7 Antisera
Figure 4.1a Commercial aSYT7 Antibody (Synaptic Systems) 
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Figure 4.1b Affinity Purified aSYT7 Antisera
1
47.5kDa
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Figure 4.1a and 4.1b
Scanned innages obtained from Western blots using commercially 
available Synaptic Systems (SySy) SYT7 antibody and pooled 
affinity-purified SYT7 antisera. Cell lysates prepared from HEK 
cells 48h following transfection with SYT7 (1 and 2), and SYT11 (3 
and 4) expression plasmids, and non-transfected control (5) were 
resolved by SDS-PAGE (HEK cells were transfected with the 
following plasmids; (1) SYT7 pEF-BOS, (2) SYT7 pAD-GMVV5 
DEST, (3) SYT11 pEF-BOS, (4) SYT11 pAD-CMV V5 DEST). In 
each case transfected cells from 2 wells of a 6-well tissue culture 
plate were used to prepare 500pl whole cell lysates; 20|llI of each 
lysate in 4x SDS-PAGE buffer was loaded per lane. The marker 
corresponds to the molecular weight standard as indicated. SySy 
SYT7 antibody was used at 1:1000, and SYT7 antisera at 1:250 
dilution. Data are from a single experiment.
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Figure 4.2 Affinity Purified SYT11 Antisera
Figure 4.2a Pulst aSYT11 Antibody
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Figure 4.2b Affinity Purified aSYTII Antisera 
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Figure 4.2a and 4.2b
Scanned immunoblot images obtained from Western blots using 
the previously characterised Pulst SYT 11 antibody (242) and 
pooled affinity-purified SYT7 antisera. Cell lysates prepared from 
HEK cells 48h following transfection with SYT7 in pEF-BOS (1) 
and pAD-CMV (2), and with SYT11 in pEF-BOS (3) and pAD-CMV 
(4) expression plasmids, and non-transfected control (5) were 
resolved by SDS-PAGE. 20pl of each lysate in 4x SDS-PAGE 
buffer prepared as described in figure 4.1 was loaded per lane. 
The marker corresponds to the molecular weight standard as 
indicated. Pulst SYT11 antibody was used at 1:1000, and SYT11 
antisera at 1:250 dilution. Data are from a single experiment.
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4.3.2 Subcellular Localisation of SYT7 and SYT11 within the 3T3-L1
Adipocyte
Figure 4.3 shows the distribution of GLUT4 and the t-SNARE 
Syntaxin4 in subcellular membrane fractions prepared from fully 
differentiated mature 3T3-L1 adipocytes in the basal (unstimulated) state, 
and following 30minutes stimulation with insulin. In the basal state GLUT4 
is found predominantly in the LDM fraction, which has previously been 
shown to comprise the endosomal system, the TGN and the GSV pool. 
Following stimulation with insulin there is a redistribution of GLUT4, with a 
reduction in the LDM fraction and a significant increase present at the 
plasma membrane. In these fractions there is a small GLUT4 signal in the 
HDM fraction which increases with insulin. No GLUT4 is detected in the 
soluble protein fraction.
The subcellular distribution of Syntaxin4 is different from that of 
GLUT4. Syntaxin4 is found in the PMs predominantly, with a smaller 
amount in the HDM, and LDM fractions. The distribution of Syntaxin4 
does not change following stimulation with insulin.
These data are in accordance with previous descriptions of GLUT4 
and SNARE protein distribution in 3T3-L1 adipocyte subcellular
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membrane fractions. Thus, these fractions are of sufficient quality for the 
subsequent characterisation of SYT7 and SYT11 distribution.
Figure 4.4 demonstrates the distribution of SYT7 and SYT11 in 
subcellular fractions from 3T3-L1 adipocytes. Both SYT7 and SYT11 are 
found predominantly in the HDM fraction. Insulin has no effect on the 
distribution of either SYT7 or SYT 11. At the exposure indicated neither 
isoform could be detected in other fractions, however with prolonged 
exposure immunoreactive bands were seen for both SYT7 and SYT11 in 
the other membrane fractions. Figure 4.5 examines the same PM and 
LDM fractions as in figure 4.4 above in more detail.
Figure 4.5a confirms the basal and insulin-stimulated distribution of 
GLUT4, and a translocation from the LDM to the PM in response to 
insulin can be clearly seen. I RAP, which has previously been shown to 
traffic alongside GLUT4 shows a similar distribution in both basal and 
insulin-stimulated cells.
Figure 4.5b shows the presence of SYT7 in the LDM and PM 
fractions in both basal and stimulated cells. SYT11 is detected in the LDM 
fraction, but not in the PM. This distribution is not altered by insulin.
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Figure 4.3: Subcellular Fractionation of 3T3-L1 Cells
PM HDM LDM SOL
B B I B I B I
GLUT4
Syntaxin 4
Figure 4.3
Subcellular fractions (plasma membrane (PM), high density 
microsomes (HDM), low density microsomes (LDM) and soluble 
proteins (SOL)) prepared from day 12 post-differentiation 3T3-L1 
adipocytes under basal conditions (B) or following 30 minute 
stimulation with 1Q0nM insulin (I) separated by SDS-PAGE and 
transferred to nitrocellulose. 4x 10cm cell culture dishes per 
condition ((B) or (I)) were subjected to fractionation; membrane 
fractions were resuspended in 150pl SDS-PAGE buffer and 15pl of 
each fraction loaded per well. Immunoblots using GLUT4 antibody 
(1:1000 dilution) or Syntaxin4 antibody (1:1000) are shown. Data 
are representative of 2 identical experiments using discrete 
populations of cells.
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Figure 4.4 SYT7 and SYT11 Distribution in 3T3-L1 Adipocytes
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Figure 4.4
Subcellular fractions (plasma membrane (PM), high density 
microsomes (HDM), low density microsomes (LDM) and soluble 
proteins (SOL) prepared from day 12 post-differentiation 3T3-L1 
adipocytes under basal conditions (B) or following 30 minute 
stimulation with lOOnM insulin (I) separated by SDS-PAGE and 
transferred to nitrocellulose ((-) indicates empty well) alongside 
HEK cell lysates characterised in figures 4.1 and 4.2. 15pl of each 
fraction (prepared as described in figure 4.4) was loaded per well. 
Immunoblots using GLUT4 antibody (1:1000 dilution) or Syntaxin4 
antibody (1:1000) are shown. Data are representative of 2 identical 
experiments using discrete populations of cells.
188
Figure 4.5 3T3-L1 Cell PM and LDM Fractions
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Figure 4.5
Plasma membrane (PM) and low density microsome (LDM) 
fractions prepared from day 12 post-differentiation 3T3-L1 adipocytes 
under basal conditions (B) or following 30 minute stimulation with lOOnM 
insulin (I) separated by SDS-PAGE and transferred to nitrocellulose 
alongside HEK cell lysates characterised in figures 4.1 and 4.2. 25pl of 
the same fractions as described in Figure 4.5 above was loaded per well. 
Immunoblots using GLUT4 antibody (1:1000 dilution) or IRAP antibody 
(1:1000) are shown. Data are representative of 5 identical experiments 
using discrete populations of cells.
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4.4 Discussion
The high degree of sequence homology that exists between 
isoforms of the SYT family (228), the similarities observed between the 
published C2 domain structures (250;311;314); Cheng et al. 2004), and 
evidence for redundancy between isoforms (315) together predict that the 
production of isoform-specific SYT antibodies is likely to be difficult. The 
observed lack of commercially available antibodies to many SYT isoforms 
is in support of these observations, in spite of this, the SYT7 and SYT11 
antisera characterised in this chapter appear to be specific for their 
respective target proteins. However, in order to be certain of full 
specificity, determination of the binding of each antiserum to purified 
protein from each murine SYT isoform would be required.
The antisera characterised in section 4.3.1 were used in an 
attempt to demonstrate the subcellular localisation of SYT7 and SYT 11 in 
3T3-L1 adipocytes by immuno-fluorescent microscopy. Cellular staining 
produced was indistinct from that seen with secondary antibody alone, 
therefore not felt to be specific for either protein at the dilutions used, and 
probably due to non-specific binding as discussed above.
An equal molar concentration of each plasmid to express SYT7 
and SYT 11 was used to transfect identical cell populations. The 
difference in immunoreactivity between adjacent positive control wells for 
both antisera used (seen in figures 4.1 and 4.2) probably reflects a
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combination of two factors: each plasmid possesses a distinct promoter 
which may drive different levels of expression in the same cells, and the 
plasmids are of significantly different size, and thus efficiency of 
transfection will be different for each plasmid (lower efficiency for the 
larger plasmid).
The subcellular distribution data presented in this chapter are 
largely descriptive, and show for the first time the localisation of both 
SYT7 and SYT11 within specific membrane compartments of the 3T3-L1 
adipocyte. The absence of SYT7 or SYT 11 in the soluble fractions 
demonstrates these are indeed membrane-bound proteins in vitro. 
Furthermore, from these data it is possible to conclude that SYT7 is 
predominantly localised within the HDM fraction, which has previously 
been shown to possess ER and lysosomal markers (316). A significantly 
smaller amount of SYT7 is present divided equally between the LDM 
fraction (which is known to contain markers for the TGN), and the PM. 
Insulin stimulation has no effect on the distribution of SYT7 in 3T3-L1 
adipocytes.
SYT 11 shows a similar subcellular distribution to SYT7: the 
majority of the intracellular SYT11 pool is located in the HDM fraction, 
with a small amount in the LDM fraction. Like SYT7, the subcellular 
distribution of SYT 11 is independent of insulin effect.
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The subcellular distribution of endogenous SYT11 has previously 
been described only in human substantia nigra neurons, where it was 
observed to be present in cell bodies and neurites (242). SYT11 was also 
seen to localise in the Lewy bodies in the substantia nigra of two 
individuals known to have Parkinson’s Disease. Epitope-tagged SYT11 
has been exogenously expressed in PC12 cells (242;317). On both 
occasions SYT11 was seen to localise with the Golgi and in immature 
vesicles. This distribution is very similar to the previously described 
subcellular distribution of the SYT family member with the greatest 
similarity to SYT 11, SYT4 (318-321 ). The distribution of SYT 11 described 
here is in agreement with these observations.
The subcellular distribution of SYT7 has previously been studied 
by a combined immunofluorescence microscopy / subcellular 
fractionation approach in the NRK fibroblast and L6 myoblasts (322). In 
these experiments SYT7 was seen to localise to the dense intracellular 
membranes of the mature lysosome and the PM. No SYT7 was detected 
in lower density Golgi fractions, and no colocalisation was seen with 
endosomal markers such as EEA1 or the TfR suggesting that SYT7 was 
not present within these compartments. The data presented here is 
generally in accord with that previously described. The small amount of 
SYT7 observed in the LDM fraction here may be a result of adipocyte 
differentiation, or may simply represent contamination of the LDM fraction 
with HDM proteins.
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The observed distribution SYT7 and SYT 11 is not at first glance in 
support of the hypothesis proposed in Chapter 1, where it was proposed 
that a particular SYT isoform may interact with the Syntaxin4 / SNAP23 / 
VAMP2 SNARE complex and drive GSV-PM fusion. However, the 
presence of a population of SYT7 at the PM remains consistent. From 
these data it is unlikely that SYT11 will prove to play such a role.
GLUT4 trafficking between the endosomal system and the TGN is 
known to be regulated by a number of factors including the t-SNARE 
proteins Syntaxin6 and Syntaxin16 (186;323;324). In addition, molecules 
such as the v-SNARE Vti1a (325) and the synaptogyrin homolog 
Cellugyrin (326) have been implicated. Members of the Golgi-localised y- 
ear containing Arf-binding (GGA) family (327;328) and other species such 
as AP-1 (175) and COPI (304), so called Coat proteins which form 
complexes with clathrin (reviewed in (329)) have also been suggested as 
important molecules in the generation of specialised GLUT4-containing 
membrane compartments.
SYTs have previously been demonstrated to interact with SNAREs 
(as discussed in Chapter 1 section 1.5.6), and the C2B domain of SYT 
has been shown to bind the PM adaptin molecule AP-2, (which shares 
homology with its TGN homologue AP-1 and plays a key role in 
endocytosis) (330). Therefore in experiments designed to assess their 
function, either SYT7 or SYT11 may prove to play a role in a putative
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GLUT4 sorting step at the endosome-TGN interface via interaction with 
molecules such as those listed above.
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Chapter 5 siRNA-Mediated Gene Depletion in the 3T3-L1 
Adipocyte
5.1 Introduction
The discovery of short inhibitory RNA as a further level of natural 
complexity surrounding regulation of eukaryotic gene expression (331) 
and its subsequent exploitation as a method of targeted gene depletion 
has gifted biologists with a means of in vitro genetic manipulation that is 
of immense power and yet provides exquisite specificity and control. This 
methodology has been previously described in the investigation of insulin 
action in 3T3-L1 cells (118;332).
This chapter shall describe the transfection of mature 3T3-L1 
adipocytes with siRNA by electroporation. The use of siRNA 
oligonucleotides directed against key signal transduction molecules in the 
insulin signalling cascade shall confirm data obtained using similar 
methodology in other groups. These techniques shall then be used to 
investigate the phenotype consequent to siRNA-mediated knockdown of 
SYT7 and SYT11 in 3T3-L1 adipocytes with respect to insulin stimulated 
glucose uptake.
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5.2 Methods
5.2.1 Design of siRNA
Lamin A/C siGLO™ control siRNA, Smartpool™ siRNA directed 
against PTEN, AKT and SYT7, and Non-targeting siRNA were obtained 
from Dharmacon, USA. Lamin A/C siGLO™ control siRNA used is an 
siRNA directed against a housekeeping gene covalently attached to a 
fluorescent reporter, thus allowing direct visualisation of transfected cells. 
Smartpool™ siRNA represents a group of 4 separate siRNA 
oligonucleotides directed against each specific target transcript. Non­
targeting siRNA represents a 20-mer duplex siRNA oligonucleotide 
designed to have no activity against (thus no sequence homology with) 
any transcribed murine gene.
The siRNA directed against SYT11 was designed by Dr Prasenjit 
Mitra, Umass Medical School, Worcester, MA, USA. Briefly, the 
secondary tRNA structure was predicted using Vienna Secondary mRNA 
Structure Prediction software (333). Target regions of 15-20 nucleotides 
were selected that were predicted to be present on the “exposed” surface 
of the mRNA. Each proposed siRNA sequence was then compared to the 
entire mouse transcriptome sequence using the NCBI Basic Local 
Alignment Search Tool (72) to ensure specificity for SYT11 (302); (the 
SYT11 siRNA nucleotide sequence is given in section A1.4 in the 
Appendix).
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Scrambled SYT 11 siRNA has identical base pair complement to 
the SYT 11 siRNA sequence but the residues are in a randomised order. 
The sequence was compared with the mouse transcriptome using the 
NCBI Basic Local Alignment Search Tool (72) (302) to ensure there 
would be no unexpected activity against any other transcribed murine 
gene.
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5.3 Results
5.3.1 Efficiency of Transfection by Electroporation
In order to assess the efficiency of transfection by electroporation 
a fluorescently labelled siRNA was transfected into 3T3-L1 adipocytes 
and the observed fluorescence compared to that present in cells 
simultaneously transfected with an unlabelled siRNA species. 
Concentration of siRNA transfected was similar to that used in 
subsequent experiments (4 nmoles/10® cells).
In Figure 5.1 a fluorescent signal can be seen in every cell 
transfected with siRNA. The strength of signal between cells is variable, 
with the reporter signal being stronger in some cells than in others. More 
fluorescence can be seen with cells transfected with 4.5nmoles/10® cells 
compared to 0.5nmoles/10® cells implying a dose-dependent effect. No 
fluorescence is seen with cells transfected with an unlabelled siRNA 
(4.5nmoles/10® cells), confirming the fluorescent signal observed is 
derived from the labelled siRNA used and not due to adipocyte 
autofluorescence.
Image data collected in transmission mode (46) confirms the 
typical adipocyte appearance of electroporated cells, with very few cells 
having a fibroblast appearance. This confirms the success of the 
adipocyte differentiation process, that the electroporation technique used
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achieves transfection of these differentiated adipocytes, and that post­
transfection survival of adipocytes is maintained.
These results suggest a 100% transfection efficiency when 3T3-L1 
adipocytes are electroporated with siRNA.
200
Figure 5.1 Efficiency of Transfection
Figure 5.1a siGLO^ *'^  Lamin A/C siRNA 0.5nmoles/10° cells
Panel 1 Fluorescence
Panel 2 Transmission
Panel 3 Merge
100 pm100 urn
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Figure 5.1 Efficiency of Transfection
Figure 5.1b siGLO '^'  ^Lamin A/C siRNA 4.5nmoles/10® cells
Panel 1 Fluorescence
100 [jrn Panel 2 Transmission
Panel 3 Merge
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Figure 5.1 Efficiency of Transfection
Figure 5.1c Control cells
(Non Targeting siRNA 4.5nmoles/10® cells)I1
Panel 1 Fluorescence
Panel 2 Transmission
Panel 3 Merge
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Figure 5.1a, 5.1b and 5.1c
Confocal microscopy images of 3T3-L1 adipocytes 48hours 
following transfection with the indicated concentration of 
fluorescently labelled siGLO™ Lamin A/C siRNA and unlabelled 
control siRNA (NT). Panel 1 shows image acquired using 
fluorescence microscopy. Panel 2 shows transmission image. 
Panel 3 merges Panels 1 and 2. 100pm size bar shown. Images 
acquired using a Carl Zeiss Pascal Confocal microscope, 488nm 
excitation energy, 510 Ip  detection filter and 63x objective lens. 
Data are from a single experiment.
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5.3.2 Influence of siRNA Mediated Knockdown of PTEN and
AKT2 on Insuiin-Stimulated Deoxyglucose Uptake
Figure 5.2 shows insulin-stimulated 2-deoxyglucose uptake in 3T3- 
L1 adipocytes transfected with siRNA directed against PTEN, AKT2 and 
non-targeting control siRNA. In the basal state, and at all concentrations 
of insulin examined PTEN knockdown potentiated glucose uptake, and 
AKT2 knockdown reduced insulin-stimulated glucose uptake compared to 
cells transfected with a Non-Targeting control siRNA.
The extent of target knockdown was not assessed (either at the 
mRNA level e.g.. by semi-quantitative PCR, or at the protein level e.g.. by 
Western blotting). Nevertheless, these data show potentiation and 
abrogation of insulin action of the same magnitude to that previously 
reported when expression of PTEN and AKT are knocked down using the 
same siRNA sequences (105;118). Therefore, whilst efficient transfection 
cannot be confirmed, successful siRNA-mediated gene knockdown is 
implied.
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Figure 5.2 2-Deoxyglucose Uptake in siRNA Transfected 3T3-L1 
Adipocytes: PTEN and AKT
I
NT
1nmol lOnmol[Insulin]
□  PTEN
lOOnmol
□  AKT
Figure 5.2 3T3-L1 adipocytes were electroporated with non-targeting
(NT), PTEN or AKT siRNA Smartpools™ as described in 
section 123 and assayed for insulin-stimulated 
deoxyglucose uptake at the indicated concentrations of 
insulin as described. Data is presented relative to the basal 
rate in non-transfected cells. (N= 3 at each point; error bars 
indicate 1 standard deviation from mean values; p values 
indicating difference from non-transfected cells at that given 
insulin concentration determined using a two-sample 
Student’s T-test assuming unequal variance; (*) indicates 
p< 0.05;(+) indicates p< 0.005; (f) indicates p< 0.001; ($) 
indicates p< 0.0001; (334) indicates p< 5x10'^. Data are 
representative of two identical experiments with discrete 
populations of cells.
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5.3.3 Influence of siRNA Mediated SYT11 Knockdown
siRNA-mediated knockdown of SYT11 in 3T3-L1 adipocytes has 
no apparent effect on cell size (Figure 5.3). Non Targeting, Scrambled 
and SYT 11 knockdown cells are morphologically similar and have similar 
lipid content when examined by light microscopy. Intracellular lipid 
droplets are clearly visible within all cells. The number of electroporated 
cells per well were not formally counted however the light microscopic 
appearance indicates equal number of cells in each well. This suggests 
that surviving cell density is identical regardless of siRNA species used. 
The cells can be seen to be terminally differentiated there would not be 
expected to be further cell division. Together these data suggest post- 
transfection cell viability is identical for each siRNA studied.
Figure 5.4 reveals the effect of transfecting 3T3-L1 adipocytes with 
siRNA directed against SYT11 on insulin-stimulated glucose uptake. 
SYT11 knockdown has no effect on basal glucose uptake. In cells 
stimulated with insulin SYT11 knockdown results in reduced glucose 
uptake compared to cells transfected with a non-targeting (NT) control 
siRNA. The difference in glucose uptake between SYT11 and NT siRNA 
is significant at 10nM insulin (P<0.05), and approaches significance at 
1nM insulin (p=0.059).
The immunoblots shown in figure 5.5 show a reduction in SYT11 
protein detected in cells transfected with SYT11 siRNA. The reduction in
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SYT 11 protein compared to Non-targeting (NT) and Scrambled (SCR) 
siRNA was quantified and results are shown in figure 5.6. These data 
suggest a 30% knockdown compared to Non-targeting, and a 40% 
knockdown of SYT11 compared to Scrambled siRNA (Figure 5.6a and 
5.6b respectively). These data suggest the SYT11 siRNA oligonucleotide 
has facilitated targeted disruption of the SYT11 transcript, and that there 
has been no such effect produced by NT or SCR siRNA. The size of the 
protein knockdown is disappointingly small. Furthermore, assessment of 
SYT 11 transcript knockdown e.g. by Taqman RTPCR was not performed.
Figure 5.5 also shows that there has been no effect on TfR protein 
level with either NT, SCR or SYT 11 siRNA. The third panel in figure 5.5 
shows the effect of SYT 11 knockdown on GLUT4 protein. There is no 
effect on GLUT4 protein with NT siRNA, and a reduction in GLUT4 
protein in cells transfected with SYT11 siRNA. Surprisingly, there is 
reduced GLUT4 protein in cells transfected with SCR siRNA.
Data were not gathered to formally assess protein concentration in 
cell lysates from cells transfected with the siRNAs described. However, 
the data in figure 5.4 and 5.5 demonstrates there is no effect on the level 
of the Transferrin Receptor or GAPDH proteins relative to that of any 
other siRNA studied. Since both of these proteins can be considered as 
having a “housekeeping” role in 3T3-L1 cells these data serve to (at least 
in part) confirm that any observed effect is indeed due to the influence of 
gene knockdown over components of the insulin signalling mechanism as
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opposed to influence over cell viability or survival. As can be seen in 
Figure 5.7 protein levels of species known to influence GSV-PM fusion 
such as Syntaxin4, and SNAP23 (and I RAP) remain unchanged in cells 
transfected with either NT, SCR or SYT 11 siRNA.
Figure 5.8 shows there is no difference in fold-stimulation of 
insulin-stimulated cell surface transferrin labelling compared to basal cells 
when either SYT 11 or NT siRNA are used. This confirms an intact 
endocytic trafficking system.
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Figure 5.3 Light Microscopy Appearance of Transfected Cells
Figure 5.3a Non-Targeting siRNA
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Figure 5.3 Light Microscopy Appearance of Transfected Cells
Figure 5.3b SYT11 Scrambled siRNA
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Figure 5.3 Light Microscopy Appearance of Transfected Cells
Figure 5.3c SYT11 siRNA
Figure 5.3 Light Microscopy of live 3T3-L1 cells 48 hours following 
transfection with the indicated siRNA by electroporation. 
Images acquired using a Carl Zeiss Axiovert 135 
microscope and 135x objective lens. Data are from a single 
experiment.
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Figure 5.4 Influence of SYT11 Knockdown on Insulin-Stimulated 2-
deoxyglucose Uptake
0)
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1nM [Insulin]
Non-Targetting
10nM
□ SYT 11
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Figure 5.4 3T3-L1 adipocytes were electroporated with Non-Targeting
or SYT 11 siRNA and assayed for insulin-stimulated 
deoxyglucose uptake at the indicated concentrations of 
insulin as described. Data is presented relative to the basal 
rate in cells transfected with Non-Targeting siRNA. (N= 3 at 
each point; error bars indicate 1 standard deviation from 
mean values; (**) indicates p< 0.005; Statistical differences 
were calculated by paired Student’s t-test. Data are the 
mean of three identical experiments using discrete 
populations of cells.
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Figure 5.5 SYT11 siRNA
Non-Targeting SYT11 SCR SYT11
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aSYT11
TfR
GLUT4
Figure 5.5
Scanned images obtained from Western blots using affinity- 
purified SYT11 antisera, transferrin receptor (238) and GLUT4 
antibodies. Cell lysates prepared from 3T3-L1 adipocytes 72 hours 
following electroporation with Non-Targeting, SYT11 scrambled 
(SCR) and SYT 11 siRNA, and the previously characterised 
SYT 11 -transfected HEK cell control (11) were resolved by SDS- 
PAGE. Cells from a 10cm tissue culture plate were used to 
prepare SOOpI whole cell lysate; the volume indicated (in 4x SDS- 
PAGE buffer) in pi was loaded per well. TfR and GLUT4 antibodies 
were used at 1:1000; SYT11 antibody was used at 1:250 dilution. 
Data are representative of three experiments using discrete 
populations of cells.
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Figure 5.6 Quantification of SYT11 Knockdown
Figure 5.6a
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Figure 5.6b
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Figure 5.6a and 5.6b
Quantification of SYT 11 knockdown. A Mercury scanner was used 
to generate a Photoshop digital image of the SYT11 immunoblot in 
5.3 above, and the image analysed using Image J software to 
assess band intensity. Intensity of SYT11 immunoreactive band in 
SYT11 siRNA cells is compared to Non-targeting siRNA in 5.5a, 
and to Scrambled siRNA in 5.5b.
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Figure 5.7 I RAP, Syntaxin4, SNAP23 and GAPDH in SYT11 siRNA-
Transfected 3T3-L1 Adipocytes
Non-Targeting SYT11 SCR SYT11
( \ f \ \
10p[ 20pl 10pl 20pl 10pl 20pl
IRAP
Syntaxin 4
SNAP23
GAPDH
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Figure 5.7
Scanned images obtained from Western blots using IRAP, 
Syntaxin4, SNAP23 and GAPDH antibodies. Cell lysates prepared 
from 3T3-L1 adipocytes 72 hours following electroporation with the 
indicated siRNA were resolved by SDS-PAGE. Cells from a 10cm 
tissue culture plate were used to prepare 500pl whole cell lysate; 
the volume indicated (in 4x SDS-PAGE buffer) in pi was loaded 
per well. IRAP, Syntaxin4 and SNAP23 antibodies were used at 
1:1000; GAPDH antibody was used at 1:2000 dilution. Data are 
representative of three experiments using discrete populations of 
cells.
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Figure 5.8 Cell Surface Transferrin Binding In 3T3-L1 Adipocytes 
Transfected with SYT11 sIRNA
^  1.5
CO 0.5 -
Basal Insulin
Non-TargettIng □  SYT11
Figure 5.8
Fold basal cell surface radiolabelled transferrin binding in 3T3-L1 
adipocytes transfected with Non-Targeting or SYT 11 siRNA and 
stimulated with IpM insulin. Data presented are from an individual 
experiment; error bars show 1 standard deviation from mean 
values; significance of variance was determined using a two- 
sample Student’s T-test assuming unequal variance.
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5.3.4 Influence of sIRNA Mediated SYT7 Knockdown
Figure 5.9 reveals the effect of transfecting 3T3-L1 adipocytes with 
siRNA directed against SYT7 on insulin-stimulated glucose uptake.
These data suggest that in the basal state, and at all insulin 
concentrations examined SYT7 knockdown results in a significant 
increase in glucose uptake compared to cells transfected with a non­
targeting (NT) control siRNA. The difference observed between SYT7 
and Non Targeting siRNA reaches statistical significance at 1nM insulin 
(p<0.05) and at lOOnM insulin (p<0.01).
The extent of SYT7 knockdown at both the mRNA and protein 
level remains to be confirmed. Furthermore (and as for SYT 11 ) the 
influence of SYT7 knockdown on GLUT4 (and other species known to be 
required for its effective delivery to the PM in response to insulin) requires 
to be assessed before any firm conclusion regarding the mechanism 
responsible for the effect seen in figure 5.9 can be drawn.
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Figure 5.9 Influence of SYT7 Knockdown on Insulin-Stimulated 2 
Deoxyglucose Uptake (P=0.009)
*  *
P=0.03)
[Insulin] lOOnM
NT □  SYT7
Figure 5.9
Fold basal 2-deoxy glucose uptake in 3T3-L1 cells transfected with 
Non-Targeting (NT) or SYT7 siRNA and stimulated with insulin at 
the concentration indicated. Data presented are the sum of 3 
identical experiments using discrete cell populations; error bars 
show 1 standard deviation from mean values; (278) indicates 
p<0.05, (**) indicates p<0.01 calculated using paired Student’s t- 
test.
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5.4 Discussion
The efficiency of transfection of differentiated 3T3-L1 adipocytes 
with a fluorescently labelled siRNA by electroporation is shown here to be 
near 100%. For subsequent experiments the transfection efficiency was 
assumed to be identical regardless of siRNA sequence used.
PTEN acts as a negative regulator of insulin signalling by 
converting PM Pl(3,4,5)p3 to PI(3,5)P2, thus reducing signalling via PI3K, 
and AKT plays a central role in the insulin signalling cascade downstream 
of PI3K (as discussed in Section 1.3.7 and 1.3.8 above). Czech and co­
workers have optimised the technique of transfecting differentiated 3T3- 
L1 adipocytes by electroporation, and have used this powerful method to 
examine the role of these and other species in insulin-stimulated glucose 
uptake (Zhou et.al. 2004). In their experiments a 2-4 fold enhancement 
with PTEN, and 60% depletion with AKT2 knockdown was demonstrated 
in insulin-stimulated glucose uptake. These data have been reproduced 
in the current study by employing an identical technique and identical 
siRNA oligonucleotides.
As can be seen in Figure 5.1, in the basal state and at low 
concentrations of insulin > 2-fold increase in uptake is seen with PTEN 
siRNA when compared to a non-targeting control siRNA. This effect 
remains present, but is less pronounced at high (supra-physiological) 
insulin concentration. One can conjecture that the reduction of effect seen
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with high insulin dose is due to saturation of the PM with PI(3,4,5)P3 
generated by PI3K, thus overcoming the effect of PTEN knockdown. In 
the same figure it is possible to see a reduction in insulin-stimulated 
glucose uptake in the basal state and with insulin-stimulation when AKT2 
is targeted with siRNA when compared to control. The central signalling 
role played by this enzyme is supported by the observation that, in its 
absence not even stimulation with supra-physiological insulin doses can 
restore normal cellular glucose uptake.
These experiments were performed twice, and identical results 
were obtained on both occasions. However, neither assays of PTEN or 
AKT (157) nor RTPCR of their transcripts were performed. Thus whilst it 
is not possible to conclude that knockdown of PTEN and AKT were 
responsible for the effect, the data are in support of this.
The preceding results chapters in this thesis have identified the 
SYT11 and SYT7 transcripts as the predominant isoforms in the 3T3-L1 
adipocyte. SYT11 mRNA is upregulated as cells differentiate and acquire 
insulin sensitivity. Upon subcellular fractionation, SYT7 and SYT11 
proteins are present mostly in the high density microsome fraction. Both 
are also present at lower abundance in the low density microsomes, and 
SYT7 is present at low level in the plasma membrane. The distribution of 
neither SYT isoform is altered by insulin stimulation.
223
The immunoblot of lysates from SYT11 knockdown cells (seen in 
figure 5.3) shows only a small apparent reduction in SYT11 protein.
When quantified directly from the immunoblot this amounts to around 
30% knockdown of SYT 11. This is disappointingly small. Possible 
reasons for this are manifold, and include reduced transfection efficiency 
with this oligonucleotide, poor target recognition resulting in reduced 
RISC activation, and a long half life of SYT 11 protein.
The immunoblots examining the extent of SYT11 protein 
knockdown were performed using a whole cell lysate. Given that the 
SYT 11 molecule has a transmembrane domain and is believed to be a 
membrane protein in vivo the preparation of whole cell membranes and 
subsequent immunoblotting may reveal a more profound protein 
knockdown.
On closer inspection of the scanned immunoblot image it is 
possible to observe that the signal from the adjacent SYT 11 control 
protein lane is so strong as to increase the signal in the SYT11 siRNA 
lanes. The result is an overestimation of SYT11 protein signal in these 
lanes, and a corresponding underestimation of siRNA effect. The fact that 
a significant effect on glucose uptake is seen with such a small reduction 
in protein supports a major role for SYT 11 within the adipocyte.
SYT11 siRNA-treated 3T3-L1 adipocytes exhibit abrogated insulin- 
stimulated glucose uptake regardless of insulin concentration used. Basal
224
uptake is unchanged. The reduction in insulin-stimulated glucose uptake 
is marked with 1nM and is significant with 10nM insulin. The effect is less 
marked when lOOnM insulin is used to stimulate the cells. This suggests 
that the effect of SYT11 knockdown can be rescued by maximal 
stimulation with insulin in a similar way to PTEN knockdown as discussed 
above.
GLUT4 protein levels are reduced in SYT11 knockdown cells. 
These data support the suggestion that SYT11 in the adipocyte is at least 
in part concerned with the regulation of GLUT4. SYT11 may be required 
for the sequestration of GLUT4 from the endosomal recycling pathway 
into the slower TGN / endosomal / GSV pathway, and the subsequent 
production of GSVs. In the absence of SYT 11 GLUT4 may be prevented 
from entering this pool, leading to less GLUT4 destined to become the 
GSV compartment and so fewer GSVs are produced within the cell. Such 
mistargetting of GLUT4 may lead its eventual degradation, accounting for 
the reduced levels seen in SYT11 knockdown cells.
A reduction of GLUT4 in the specialised insulin-regulatable 
compartment would reduce the GSV pool available for translocation in 
response to insulin, requiring more insulin for any given effect. The 
GLUT4 content of the endosomal system would be unchanged, therefore 
basal glucose uptake (to which GSV-derived GLUT4 makes only a small 
contribution), would be preserved. I RAP is however unaffected by SYT11 
knockdown, and so the selection step for GLUT4 that leads to its
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sequestration and ultimate degradation within this model would require to 
be specific for GLUT4, and occur prior to the formation of the GSV. Thus, 
in keeping with data from Chapter 3 and Chapter 4 concerning the timing 
of SYT11 expression during differentiation, the role of SYT11 may be in 
the generation of the GSV compartment in differentiating adipocytes.
It is unlikely that within the adipocyte SYT 11 is regulated acutely 
by insulin. Experimental evidence supporting this idea is provided by 
figure 5.5. No reduction in cell surface TfR labelling (which in turn reflects 
general endosomal recycling) is observed in SYT11 knockdown cells. No 
reduction in TfR protein level is observed (Figure 5.3). These data are in 
support of a specialised role for SYT 11 in post-endosomal or TGN sorting 
of GLUT4 since endosomal recycling is unaffected by its removal.
The SCR siRNA was not expected to target any adipocyte 
transcripts, and thus act as a negative control. In all experiments using 
both NT and SCR siRNA there was a small reduction in insulin-stimulated 
glucose uptake seen with SCR compared with NT. This difference was 
not statistically significant (data not shown). The GLUT4 immunoblots in 
figure 5.3 suggest that GLUT4 is reduced in SCR siRNA transfected cells. 
These data suggest that SCR siRNA does indeed have an effect on 
GLUT4 and thus it is not a valid control siRNA. Since the SCR 
oligonucleotide sequence was designed to have no homology to any 
murine transcript the nucleotide sequence of this siRNA may be incorrect.
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Analysis by nnass-spectrometry could be employed to further investigate 
these observations.
sIRNA-mediated knockdown of SYT7 produces a 3T3-L1 
adipocyte with both enhanced basal and insulin-stimulated glucose 
uptake. These data are from experiments performed at the very end of 
the time available for laboratory work, and so there are no data 
concerning the level of SYT7, GLUT4, TfR or SNARE proteins or the 
effect of SYT7 knockdown on cell surface TfR labelling. It is therefore not 
possible to confidently suggest a mechanism for this effect. However, the 
glucose uptake data alone suggest that SYT7 may have a negative effect 
on GSV-PM fusion, and that in its absence GSVs are more likely to fuse 
with the PM. Both the glucose uptake data and the subcellular localisation 
of SYT7 demonstrated in Chapter 4 suggest that SYT7 is also unlikely to 
be acutely regulated by insulin. SYT7 data presented here are 
incomplete, and future experimental investigation of GLUT4 and TfR (and 
its cell surface labelling) are required in SYT7 knockdown cells to clarify 
SYT7s role.
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Chapter 6 Interaction of SYT7 and SYT11 with VAIVIP-2, Syntax!n-4 
and SNAP-23
6.1 introduction
The preceding results chapters in this thesis have identified the 
SYT 11 and SYT7 transcripts as the predominant isoforms in the 3T3-L1 
adipocyte. The mRNA of both is upregulated as cells differentiate and 
acquire insulin sensitivity SYT11 much more than SYT7. Upon subcellular 
fractionation, SYT7 and SYT 11 proteins are present mostly in the high 
density microsome fraction. Both are also present at lower abundance in 
the low density microsomes, and SYT7 is present at low level in the 
plasma membrane. The distribution of neither SYT isoform is altered by 
insulin stimulation.
siRNA-mediated knockdown of SYT11 produces a 3T3-L1 
adipocyte with abrogated insulin-stimulated glucose uptake, reduced 
GLÜT4 protein, and normal cell surface TfR labelling. These data are in 
support of the hypothesis that the function of SYT 11 in the adipocyte is 
concerned with the retention of GLUT4 outwith the endosomal system. 
SYT11 may also participate in the generation of the specialised GSV 
pool. The absence of SYT11 at the PM suggests this function is not in 
promoting GSV-PM fusion. Together these observations suggest that 
SYT 11 would not be expected to participate in the Syntaxin4 / SNAP23 / 
VAMP2 SNARE complex.
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The presence of SYT7 at the PM supports a fusogenic role for this 
isoform. However the increased basal, and potentiated insulin stimulated 
glucose uptake seen with SYT7 knockdown is the opposite of what would 
be expected if this was its role. The phenotype seen with siRNA-mediated 
SYT7 knockdown is in support of PM SYT7 restricting GSV-PM fusion, 
which it may do by regulating the Syntaxin4 / SNAP23 / VAMP2 SNARE 
complex.
In other experimental systems the in vitro interaction of other SYT 
isoforms with their SNARE partners has been clearly demonstrated by 
various experimental approaches including co-immunoprecipitation, pull­
down assay and vesicle fusion assay. The data presented in this thesis 
so far suggests the interaction of the two candidate SYTs with the v- and 
t-SNARE proteins involved in GSV-PM fusion remains worthy of further 
investigation.
This chapter shall explore possible in vitro interaction between 
SYT7 and SYT11 and the SNARE proteins known to be required for 
insulin-stimulated translocation of GSVs in the skeletal muscle cell and 
adipocyte by examining the binding of a sol SYT7 (sol SYT7) or SYT11 
(sol SYT 11 ) molecule (devoid of the TM domain) with previously 
characterised epitope-tagged versions of both v- and t-SNAREs by two 
distinct methods: the “pull-down” assay and “vesicle floatation” assay.
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6.2 Methods
6.2.1 Generation of Epitope-Tagged Sol SYT7 and Soi SYT11
cDNA encoding N-terminal FLAG-tagged full length murine SYT7 
or SYT11 cloned into the pEF-BOS plasmid (a generous gift from M 
Fukuda, Fukuda Initiative Research Unit, The Riken Institute of Physical 
and Chemical Research, Wako, Saitama, Japan) was used as template 
for a PGR-based strategy to generate epitope-tagged SYT7 and SYT 11 
lacking the transmembrane (TM) domain.
Oligonucleotide PGR primers (designed to contain appropriate 
restriction enzyme sites at the extreme 5’ and 3’ ends of the amplified 
products) were used to amplify SYT7 and SYT11 cDNA corresponding to 
residues from the amino terminal to the TM domain, and from the TM 
domain to the translation stop signal. These PGR products were 
subjected to restriction endonuclease digestion followed by gel 
purification, and the resulting DNA fragments ligated into the pET-21 
plasmid, itself previously digested with the same restriction 
endonucleases in order that the sol SYT cDNA fragment was in-frame 
with the G-terminal 6X HIS epitope tag. The resulting plasmid was 
transformed into E. coli, and induced protein was purified as described.
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6.2.2 The Vesicle co-Floatation Assay
Binding of sol SYT7 or sol SYT11 protein with GSV SNARE 
proteins was also assessed using the Vesicle co-Floatation Assay as 
described in 2.2.3.12.2 and (185). Sol SYT7 or sol SYT11 protein was 
incubated in the presence of EGTA or Calcium ions with vesicle vesicles 
(prepared as described by(189) decorated with recombinant v-SNAREs 
(VAMP2) or t-SNAREs (Syntaxin 4 and SNAP 23). The vesicle-protein 
complexes were then resolved by centrifugation in a gradient of 
Accudenz and the resulting fractions analysed by SDS-PAGE and 
immunoblotting.
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6.3 Results
6.3.1 Soluble SYT7 and SYT11
Figure 6.1a and 6.1b show sol SYT7 and sol SYT11 proteins (233) 
expressed and purified from E coll., resolved by SDS-Page and 
visualised after Coomassie staining. Both proteins are seen as the major 
band of a molecular weight slightly below that previously observed (due 
to the absent TM domain).
The same proteins are seen in the immunoblots in figure 6.2. Both 
sol SYT7 and SYT11 are fusion proteins tagged with N-terminal FLAG 
and c-terminal HIS(6) tags. As can be seen in the figure both are 
recognised by the aFLAG and the aHIS antibodies. Additionally, sol 
SYT7 and sol SYT 11 are recognised by the SYT7 and SYT 11 antisera 
respectively.
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Figure 6.1: Sol SYT7 and SYT11 Protein
Figure 6.1a: Sol SYT7
1 2 3
175 tyw :: -
47.5
32.5
Figure 6.1b: Sol SYT11
1 2
175
83 mp
62 .
47.5
32.5 
25 4-
V
%
233
Figure 6.1a and 6.1b
Photographs of purified Sol SYT7 and 8YT11 protein resolved by 
SDS-PAGE and visualised by Coomassie staining. The markers indicated 
correspond to the equivalent molecular weight (89). Lanes 1 to 4 in figure 
6.1a contain lOpg, 6.4pg, 22pg and 6.8pg sol SYT7 protein respectively. 
Lanes 1 to 4 in figure 6.2 contain 7.4pg, 7.8pg, 9.3|ig and 11.6pg sol 
SYT11 respectively. Arrows indicate the expected protein. Data are from 
a single experiment.
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Figure 6.2: Antibody Recognition of Sol SYT7 and SYT11
aHIS aFLAG aSYT7 aSYT11
Figure 6.2
Scanned images obtained from Western blots using commercially 
available aHIS, aFLAG and affinity-purified SYT7 and SYT11 antisera. 
50ng sol SYT7 (7) or sol SYT 11 (11) was resolved by SDS-PAGE, 
transferred to nitrocellulose and probed with the antibody indicated. The 
markers correspond to the molecular weight standards as indicated. aHIS 
and aFLAG antibodies were used at 1:2000, SYT7 and SYT11 antisera at 
1:250 dilution. Data are from a single experiment.
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6.3.2 Interaction of Sol SYT7 and Sol SYT11 with GSV SNARE
Proteins
Sol SYT7 and Sol SYT11 binding to Syntaxin4, SNAP23 and 
VAMP2 were initially assessed by GST-pulldown. In spite of repeated 
attempts using different binding conditions no consistent results could be 
produced (data not shown). Therefore binding was assessed by the 
vesicle co-floatation assay.
Figures 6.4 and 6.5, which show interaction of sol SYT7 and sol 
SYT11 with V - and t-SNARE vesicles should be viewed alongside Figure 
6.6, which shows the SNARE-protein labelled vesicles alone.
The upper two panels of figure 6.4 show interaction of sol SYT7 
with t-SNARE vesicles in the presence of either calcium or EGTA. Sol 
SYT7 can be seen to bind t-SNARE vesicles under both binding 
conditions, but binding is greatly enhanced in the presence of calcium. A 
similar binding pattern can be seen with v-SNARE vesicles in the middle 
two panels. Sol SYT7 can be seen to bind v-SNAREs with EGTA, and 
binding is enhanced in the presence of calcium. The lower two panels of 
figure 6.4 show that sol SYT7 also binds only weakly to protein-free 
vesicles in the presence of calcium, and that in the presence of EGTA no 
binding is observed.
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Figure 6.5 show binding experiments performed with sol SYT11 
and V- and t-SNARE vesicles in the presence of calcium and EGTA. As 
can be seen in the figure no binding is observed under any experimental 
conditions, and soluble SYT 11 is collected from the bottom of the 
gradient.
Figure 6.6 shows the position of Syntaxin4 and VAMP2 in the 
same density-gradient centrifugation fractions. Both proteins can be seen 
to be present in most fractions however both are increased in fractions 
from 2/3""^  through the gradient i.e. the interface of 5% and 30% Nycodenz 
(see Chapter 2 section 2.2.35). These fractions also correspond to 
binding of sol SYT7.
Together these data indicate that sol SYT7 binds both Syntaxin4 / 
SNAP23 t-SNARE complex and VAMP2 when present on vesicles, and 
that binding is enhanced by calcium. Sol SYT 11 does not bind to either 
SNARE protein.
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Figure 6.3 interaction of SYT7 with Syntaxin4, SNAP23 and VAMP2
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Figure 6.3
Scanned immunoblots using SYT7 antisera at 1:250 dilution. Each 
lane represents an equal fraction obtained from density gradients in 
which SYT7 incubated with the indicated v- or t-SNARE vesicles (in the 
presence of calcium or EGTA) have been resolved. Density-gradient 
fractions were resolved by SDS-PAGE (bottom-most fraction on the left, 
top fraction on the right) and transferred to nitrocellulose. Results are 
from an individual experiment.
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Figure 6.4 Interaction of SYT11 with Syntaxln4, SNAP23 and
VAMP2
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Figure 6.4
Scanned immunoblots using SYT11 antisera at 1:250 dilution. 
Each lane represents an equal fraction obtained from density 
gradients in which SYT7 incubated with the indicated v- or t- 
SNARE vesicles (in the presence of calcium or EGTA) have been 
resolved. Density-gradient fractions were resolved by SDS-PAGE 
(bottom-most fraction on the left, top fraction on the right) and 
transferred to nitrocellulose. Results are from an individual 
experiment.
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Figure 6.5 Distribution of Syntaxin4 and VAMP2 vesicles in 
Nycodenz Gradients
Bottom Top
Stx4
Vamp2
Figure 6.5
Scanned immunoblots, each lane representing an equal fraction 
obtained from density gradients in which the indicated v- or t- 
SNARE vesicles (in the presence of calcium or EGTA) have been 
resolved. Density-gradient fractions were resolved by SDS-PAGE 
(bottom-most fraction on the left, top fraction on the right) and 
transferred to nitrocellulose and immunolabelled with the 
Syntaxin4 (Stx4) or VAMP2 (Vamp2) antibody indicated at 1:1000 
dilution. Results are from an individual experiment.
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6.4 Discussion
The prokaryotic expression and purification of SYT7 and SYT11 
proteins which lack the TM domain but possess both N- and C-terminal 
epitope tags has been successfully achieved. As can be seen in figure
6.1 the major species in each fraction corresponds to a protein of the 
expected molecular weight, and subsequent analysis (figure 6.2) clearly 
demonstrates appropriate antibody recognition; HIS and FLAG antibodies 
recognise both proteins, SYT7 and SYT11 antisera are specific for each 
soluble isoform. Thus the identity of the purified expressed proteins is 
confirmed and as such, both are suitable for use in binding assays.
Further analysis of the Coomassie-stained gel photographed in 
figure 6.1 reveals that other bands are visible. In particular, a band of 
approximately double the apparent molecular weight of each isoform is 
present. SYT isoforms have been demonstrated to form SDS-resistant 
oligomers both in the presence and absence of calcium (335), therefore 
this band may represent SYT7 or SYT 11 dimers. The other larger 
proteins are likely to be bacterial contaminants, which have previously 
been noted to occur when SYTs are expressed in a prokaryotic system 
(336). The smaller molecular weight species may also be contaminants, 
but it is possible that these represent fragments of the expressed soluble 
SYT7 and SYT 11 that are the result of dénaturation.
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In figure 6.3 Sol SYT7 is seen to bind the protein-free vesicles in a 
calcium-dependent manner. Based on published data this is likely to be 
mediated by the C2A domain (although the C2B domain was also shown 
to bind lipid vesicles in a calcium-dependent manner using a less- 
stringent vesicle-based assay such as in the current study) (337). Sol 
SYT11 did not bind empty phospholipid vesicles in the presence or 
absence of calcium, which is in agreement with previously published work
(338). Sol SYT7 is seen to bind to v- and t-SNARE vesicles with an 
apparent greater affinity than empty vesicles alone, suggesting that there 
Is direct binding between the vesicle-bound SNARE proteins and sol 
SYT7.
In figure 6.4 no binding is observed to either t- or v-SNARE 
vesicles with sol SYT 11, Indicating this isoform does not bind Syntaxin4 / 
SNAP23, or VAMP2. This would be expected, given the role proposed for 
SYT 11 in the regulation of a post-endosomal or TGN GLUT4 sorting step 
(Chapter 5 Section 5.4). Therefore from these data, together with the data 
presented in Chapter 4 and Chapter 5 it is possible to conclude that 
SYT11 does not contribute to GSV-PM fusion in 3T3-L1 adipocytes.
SYT 11 may interact with an intracellular SNARE complex composed of 
alternative v- and t-SNARE proteins e.g.. Vti1a, Syntaxin 6, Syntaxin 10, 
Syntaxin 16. Such an interaction could be investigated in this way using 
appropriately labelled vesicles.
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As can be seen in figure 6.3 Sol SYT7 binds v-SNARES and t- 
SNAREs in the absence of calcium. The extent of binding is increased 
when calcium is included in the binding buffer. SYT7 has previously been 
implicated in interaction with VAMP2 at the PM of Swiss 3T3 fibroblasts
(339), although no direct evidence of binding was demonstrated. SYT7 
has also been identified in NRK fibroblasts, where SYT7 C2A domain has 
been shown to bind the t-SNAREs Syntaxin4 and SNAP23, and a 
SNARE complex composed of Syntaxin4 / SNAP23 and VAMP7 (340). 
Thus, the data presented here are in agreement to previous observations, 
and imply that SYT7 can influence SNARE-mediated membrane fusion 
facilitated by the Syntaxin4 / SNAP23 / VAMP2 complex. Direct evidence 
of such an interaction could be investigated by means of an in vitro 
liposome fusion assay between separate Syntaxin4 / SNAP23-, and 
Vamp2-labelled liposomes and Sol SYT7 (as described in Tucker, Weber 
& Chapman 2004).
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Chapter 7 Conclusions
In 2006 the global epidemic of T2DM is well underway. Much is 
known about the regulation of insulin action, but there remain many gaps 
in our knowledge. It has been proposed that 1 in 3 of the children born in 
the USA during the first year of this millennium will develop diabetes at 
some stage in their lives (341). Novel therapeutic agents designed to 
correct disordered insulin action in these future diabetic individuals will 
not be developed until the complex mechanisms regulating normal insulin 
action are determined.
Within the skeletal muscle, cardiac muscle or adipose cell GLUT4 
is engaged in a series of sequential trafficking steps between membrane 
compartments, steps which are governed by SNARE-protein interactions. 
Upon insulin binding to its receptor at the cell surface, a cascade of 
protein-protein and protein-I ip id interactions leads ultimately to the 
translocation of a GLUT4-containing specialised vesicle from an 
intracellular location to the plasmalemma, where the vesicle fuses by 
SNARE-mediated regulated exocytosis and glucose can enter the cell by 
flowing down its concentration gradient. The ability to stimulate glucose 
uptake in this way in response to insulin is significantly impaired in 
individuals with diabetes (204). The precise signals that regulate both 
GSV-PM fusion and GLUT4 intracellular trafficking remain elusive (179).
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The work described in this thesis describes the investigation of 
members of the Synaptotagmin family of proteins in the adipocyte, and 
their influence on insulin-stimulated glucose uptake.
Members of the SYT family of type-1 membrane proteins have 
been shown to bind calcium and phospholipids, and exhibit calcium- 
dependent and independent SNARE protein interactions (315). SYT 
isoforms have been implicated in a variety of cellular processes which 
require membrane fusion events however most work investigating SYTs 
has hitherto been confined to neuronal or neuroendocrine cells.
I have demonstrated that SYTs are expressed in 3T3-L1 cells, 
murine skeletal muscle and human adipose tissue. In the 3T3-L1 
fibroblast SYT11 is the predominant isoform, and its expression is 
upregulated during differentiation into a mature, insulin-sensitive 
adipocyte. SYT7, which is also expressed in 3T3-L1 fibroblasts (although 
at lower levels than SYT 11 ) also is seen to be upregulated during 
differentiation.
SYT11 protein is found predominantly in the HDM fraction of the 
adipocyte (which corresponds to the ER and lysosomes) and a smaller 
amount is observed in the LDM fraction (which contains TGN markers). 
The location of SYT 11 is not influenced by insulin stimulation. siRNA- 
mediated knockout of SYT 11 in 3T3-L1 adipocytes results in normal 
basal-, and abrogated insulin-stimulated glucose uptake (which appears
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to be partially overcome with increasing insulin stimulation). GLUT4 levels 
are reduced in GLUT4 knockout cells. SYT11 knockdown does not 
influence general endosomal trafficking. Finally, soluble SYT11 (devoid 
of the TM domain) is unable to bind phospholipid vesicles or the GSV 
SNAREs Syntaxin 4, SNAP23 or VAMP2.
SYT7 protein is also found mostly in the HDM fraction in 3T3-L1 
adipocytes however the LDM and PM fractions also yield a lesser amount 
of SYT7. Like SYT 11, SYT7 protein distribution is not changed following 
stimulation of the adipocyte with insulin. Preliminary studies suggest that 
siRNA-mediated depletion of SYT7 results in increased basal- and 
potentiated insulin-stimulated glucose uptake. The influence of SYT7 
knockout on GLUT4 and endosomal traffic is yet to be determined. Lastly, 
the binding of SYT7 to GSV-SNARE proteins and phospholipid-containing 
vesicles has also been investigated, and it is possible to demonstrate 
calcium-dependent and independent binding of SYT7 to lipid vesicles, 
and to V - and t-SNARE-containing vesicles.
Together these data suggest that the SYT isoforms studied do 
indeed play a role in glucose uptake in the adipocyte. The potential role of 
each is discussed further below.
The study of SYT11 has until now been limited to examination of 
its individual domains, or of its function in neurons where it is thought to 
play a role in the regulation of neurotransmission (272). In neurons
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SYT11 has been identified as a substrate for the E3 ubiquitin ligase 
Parkin (242), and ubiquitination of SYT11 led to its proteasomal 
degradation. It has been shown that ectopic expression of GLUT4 in 3T3- 
L1 fibroblasts results in its lysosomal degradation (342), and mistargetting 
of (GLUT4 by depletion of Syntaxin 16) also reduced intracellular GLUT4 
(324). Moreover, a recent study of insulin action in L6 cells in culture has 
revealed an apparent reduction in association of components of the 
ubiquitination-proteasome pathway components with GLUT4 upon insulin 
stimulation (343). Thus the reduction of GLUT4 protein seen with SYT11 
knockdown suggests a potential link between SYT11 and an intracellular 
degradation pathway.
The SYT-family member with the most homology to SYT 11 is 
SYT4 (228), and that together SYT4 and SYT 11 comprise a unique 
subgroup of SYT isoforms that have lost the ability to bind phospholipid or 
calcium by virtue of point mutations in the C2A and C2B domains 
(338;344;345).That the C2A domains of both SYT4 and SYT 11 have 
otherwise retained their sequence homology with the other SYT family 
members suggests that other intrinsic C2 domain functions (such as 
SNARE-interaction) have been retained.
It has been demonstrated that SYT4 is necessary for the 
maturation of immature Secretory Granules (ISG) in PCI2 cells (346). 
These observations are particularly interesting given the similarities that 
can be drawn between ISG maturation and GSV production in the
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adipocyte. The ISGs of endocrine and neuroendocrine cells (which 
contain the peptide or catecholamine precursors) bud from the TGN and 
undergo a series of processing steps prior to becoming large dense core 
vesicles (LDCV) or Mature Secretory Granules (MSG), which 
subsequently fuse with the PM via a mechanism of regulated exocytosis 
(347).
In their studies Ahras, Otto and Tooze observed that SYT4 was 
present in a high density subcellular fraction that contained markers for 
the Golgi and ISGs. SYT4 was seen to be recruited to the ISG vesicle via 
protein-protein interactions, and this was independent of any intrinsic 
phospholipid binding properties, which is in keeping with the known 
binding properties of this isoform. Furthermore, the C2 domains of SYT4 
were shown to bind the ISG-bound SNARE protein Syntaxin 6 in a 
cooperative, calcium-independent manner. Thus the closest homolog to 
SYT 11 is present in a similar subcellular membrane compartment (albeit 
in a different cell type), interacts with a t-SNARE protein and is implicated 
in the maturation of a specialised vesicle that is fated to undergo 
regulated exocytosis at the plasma membrane.
The similarity with adipocyte GSVs is implicit, and it is tempting to 
speculate that within the adipocyte SYT11 may play a similar role in 
facilitation of GSV maturation. The expression, subcellular localisation, 
siRNA and lipid binding data presented in this thesis are supportive of
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such a function, however further experimental evidence is required before 
such a role can be assigned to SYT 11.
SYT7 has been more intensively studied than SYT 11. It is seen to 
be expressed in most tissues, and in all higher eukaryotic organisms 
examined (236). Of all the C2 domains studied SYT7 C2A and C2B 
appear to bind phospholipids and SNAREs with a greater affinity and 
lower calcium dependency than any others (337:348). Once bound, the 
complexes formed by SYT7 with membranes and proteins disassemble 
slower than other SYTs (344). This is suggestive of a low-calcium 
requirement for the activation of SYT7.
The subcellular localisation of SYT7 has been examined in NRK 
fibroblasts, HEK cells, 3T3 fibroblasts and OHO cells (322;344;349) 
where it was observed to localise predominantly to the lysosomal 
compartment, and in pancreatic (5-cells and PC12 neuroendocrine cells 
where it was seen to colocalise with lysosomes and insulin granules, and 
with LDCVs respectively (350;351). Where SYT7 has been observed to 
be associated with a vesicle, a calcium-dependent functional role has 
been supported (352).
In elegant Total Internal Reflection Fluorescence Microscopy (TIR- 
FM) studies of fibroblasts derived from SYT7-knockout mice, it was 
observed that in cells lacking SYT7 the fusion of lysosomal vesicles with 
the PM was complete, and the fusion pore intermediates commonly seen
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with lysosomal exocytosis were abolished (353). In the same study SYT7 
was shown to have a negative influence on the speed and extent of 
vesicle-PM fusion. The fusion events described remained calcium- 
dependent even when SYT7 was not present.
When considered together these observations are in keeping with 
SYT7s proposed involvement with GSV-PM fusion. The small increase in 
SYT7 expression seen with 3T3-L1 adipocyte differentiation may reflect 
the important role this isoform plays in both the fibroblast and adipocyte. 
A large upregulation may not be required. Secondly, the subcellular 
localisation data for SYT7 is in agreement with that previously described 
above. The increase in basal and insulin-stimulated glucose uptake seen 
when SYT7 is removed with siRNA may reflect the role the SYT7 protein 
plays in controlling the speed and extent of SNARE-mediated GSV-PM 
fusion. The apparent calcium requirement for GSV-PM fusion may prove 
to be mediated by another as yet unidentified species. As previously 
stated, further characterisation of the SYT7 knockout phenotype is 
required before any firm conclusions may be drawn.
The data presented in this thesis can be considered preliminary, 
as more work is required to further define the role of SYT isoforms in 
insulin-stimulated GLUT4 translocation in the 3T3-L1 adipocyte. Future 
experiments in vitro should include assessment of binding of the SYT7 
and SYT11 isoforms to other proteins implicated in GLUT4 trafficking 
(e.g.. Syntaxin 6, Syntaxin 16, Vtila, GGAs and Coat proteins that
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interact with clathrin). The subcellular localisation of both isoforms could 
be investigated by careful immunofluorescence microscopy (although the 
antisera available may limit this line of enquiry). Expression of epitope- 
tagged SYT7 and SYT11 could obviate this problem, however, as has 
been observed with the expression of myc-tagged GLUT4 this may result 
in mistargetting and degradation. The expression of the soluble isoforms 
of SYT7 and SYT11 in 3T3-L1 adipocytes may be expected to act in a 
dominant-negative manner by binding to effector molecules and 
preventing their interaction with endogenous protein. It would be 
expected that these experiments would produce a phenotype similar to 
that observed using antisense approaches.
Finally, despite of its existence, there has been no report of 
disordered carbohydrate metabolism in the SYT7 transgenic knockout 
mouse (223). Glucose homeostasis may not have been examined in 
these animals, or the myositis observed may mask an effect of SYT7 
knockout. Should the in vitro investigations of SYT7 and SYT11 confirm 
an apparent role in insulin-stimulated glucose uptake, the generation of 
an adipose-specific knockout mouse (for either isoform) and its 
subsequent study would be an important step to the understanding of 
their influence on cellular, tissue-specific and whole organism insulin 
action.
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Appendix 1: Oligonucleotide Sequences and PCR Products
A1.1 Published Synaptotagmin cDNA sequences
Table A1
SYT Isoform Murine Sequence Human Sequence
Synaptotagmin 1 NM_009306 NM_005639
Synaptotagmin 2 NM_009307 NM_177402
Synaptotagmin 3 N M „016663 NM_032298
Synaptotagmin 4 NM_009308 NM_020783
Synaptotagmin 5 NM_016908 NM_003180
Synaptotagmin 6 NM_018800 NM_205848
Synaptotagmin 7 NM_018801 NM_004200
Synaptotagmin 8 NM__018802 NM_138567
Synaptotagmin 9 NM_021889 Not Available at time of anaiysis
Synaptotagmin 10 NM_018803 NM_198992
Synaptotagmin 11 NM_018804 NML152280
Synaptotagmin 12 N M J34164 NM_177963
Synaptotagmin 13 NM_030725 NM_020826
Synaptotagmin 14 N M J81546 NM_153262
Synaptotagmin 15 NM_181529 N M J81519
Table A1 Genbank accession numbers for Murine and Human SYT genes
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A1.2 Reverse Transcription PCR Primer Sequences
A1.2.1 Murine Reverse Transcription PCR Primer Sequences
GLUT4 Forward 5’-GGAGCGAGTGACTGGAAC-3’
Reverse 5’-CACGGCCAAGACATTGTT-3’
Syt 1 Forward 5’-TACTCGGAATTAGGTGGC-3’
Reverse 5’-GTCTCTTGCCGTTCTGCA-3’
Syt 2 Forward 5’-CAGGCCAACCAGCTCAGG-3’
Reverse 5’-GGTAGGGGAAGGAGGTAG-3’
Syt 3 Forward 5’-GAGTTGGAGGGGTTGTGG-3’
Reverse 5’-GAGGGAGGTGGAAGAGGA-3’
Syt 4 Forward 5’-TGGGGTGGTGTTGAGTGT-3’
Reverse 5’-AGGTGAGGGAAGTGGTGG-3’
Syt 5 Forward 5’- GGTGATTGTGTTGGAAGG-3’
Reverse 5’- GGGAGGGGGAGGGAGTGG-3’
Syt 6 Forward 5’-GGAGATGGAGTAGGGTAG-3’
Reverse 5’-GTATGATGTGGTTGTGGG-3'
Syt 7 Forward 5’-TGTGGGAGTGGTGTGAGG-3’
Reverse 5’-TGGGGGGAGGTTGTGTGG-3’
Syt 8 Forward 5’-AGTGGAGGGTGGGGGTGT-3’
Reverse 5 -GAGAGGGTGAGTGGGGAG-3
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Syt 9 Forward 5’-AAGCCTGCGGGAAACTGA-3’
Reverse 5’-AAGTCGGCCAAGTCGAAG-3’
Syt 10 Forward 5’-GAGAACGAGCATCGGGAG-3’
Reverse 5’-AAGTCTTCCGGTGCACGC-3’
Syt 11 Forward 5’- GACAAGGGGCATCGAGTG -3’
Reverse 5’-TGTGGGAGGGGGTGGTAT-3’
Syt 12 Forward 5’-TGAGGAGGGGAGGAGTAG-3’
Reverse 5’-GAGGATGTGTTGGTGTGG-3’
Syt 13 Forward 5’-GGAGAGATGGAGGGGAAG-3’
Reverse 5’-GAGGGGAGTGTGAGTGTG-3’
Syt 14 Forward 5’-AGGTGGTGGTAAGGGTGA-3’
Reverse 5’-GGAGTATGAGGGGTAAGG-3’
Syt 15 Forward 5’-TGGGTGGAGTAGGAAGAG-3'
Reverse 5’-GATGATAGGGTGGTGGTG-3’
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A1.2.2 SYT7 RTPCR Primers
In higher eukaryotic cells SYT7 is known to have three alternatively spliced variants 
(236). The genomic structure of the murine SYT7 gene is shown in figure A1 below.
Figure A1
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Figure A1 Schematic diagram representing the genomic structure of the murine SYT7
gene. Transcripts of SYT7a (a), SYT7p (P) and SYTy (y) are shown. It can be 
seen that SYT7a comprises exons 1,2,3 and 7- 13, SYT7p comprises exons 
1,2,3,4 and 7-13 and SYT7y comprises exons 1,2,3 and 5-13 (229).
In order to explore the expression of possible alternative isoforms of SYT7 expressed 
in 3T3-L1 cells RTPCR primers were designed to produce a specific product in the presence of 
each transcript that would be identifiable by virtue of size. The SYT7 forward primer is located 
in exon 2 and the SYT7 reverse primer is located in exon 8. Both of these exons are common 
to ail three of the published SYT7 splice variants. Based upon the schematic diagram above, 
the expected PCR products would be 305, 437 and 647bp when these primers were used to 
amplify SYT7a, SYT7p and SYTy cDNA respectively.
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Table A2
Target Gene Forward Primer 
Location
Reverse Primer 
Location
Product Size (246
GLUT4 Exon 2 Exon 4 310
SYT1 Exon 9 Exon 11 322
SYT2 Exon 4/5 Exon 7 388
SYT3 Exon 5 Exon 7 361
SYT4* Exon 2 Exon 2 368
SYT5 Exon 6 Exon 8 289
SYT6 Exon 3 Exon 5/6 328
SYT7a Exon 2 Exon 7 305
SYT7P Exon 2 Exon 7 437
SYT7y Exon 2 Exon 8 647
SYT8 Exon 7 Exon 9 229
SYT9* Exon 3 Exon 3 342
SYT10* Exon 3 Exon 3 269
SYT11 Exon 2 Exon 3 305
SYT12* Exon 4 Exon 4 369
SYT13 Exon 1 Exon 2 276
SYT14* Exon 4 Exon 4 318
SYT15 Exon 4 Exon 5 333
Table A2: Murine RT PCR primer location and expected product sizes. * indicates non-
intron-spanning primers.
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A1.2.2 Human Reverse Transcription PCR Primer Sequences
Syt 1 Forward 5’-CCTGTCACCACTGTCGCGAC-3’
Reverse 5’-GAGGGCCTGATCTTTCATCG-3’
Syt 2 Forward 5’-TGAGGAGTGGAGAGACGTGC-3’
Reverse 5’-GAGCACGGTGACCACTACCT-3’
Syt 3 Forward 5’-CTGACACCAACGACAGGTGC-3‘
Reverse 5’-CAGCAAAGGGTGGATGGTGG-3’
Syt 4 Forward 5’-GGATGAGCAGTCGATGACCT-3’
Reverse 5’-CTCACCCCGTCCTGAAGACT-3’
Syt 5 Forward 5’-CGACTCCAGTCGCATCAGCC-3’
Reverse 5’-ACCAGCAGCTGGCCACTCTG-3'
Syt 6 Forward 5’-GCAGCGGCAAACTACAGAGC-3’
Reverse 5’-CAGGATACGCACAATCAGGG-3’
Syt 7 Forward 5’-CTGCCATCATCACCGTCAGC-3’
Reverse 5’-TGGTGAGGGAGTTGACGAGG-3’
Syt 8 Forward 5’-GCTGGCACCACAGCTAT ACC-3’
Reverse 5’-GGCTTCCAAAGTCGAACTCC-3’
Syt 10 Forward 5’-ACATCGTCACCGAGCTGTGC-3’
Reverse 5’-CTTCTGCTGGGATGTCAGGG-3’
Syt 11 Forward 5’-GCTGCCAGTGATGGATGACC-3’
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Syt 12
Syt 13
Syt 14
Syt 15
Reverse 5’-GAGCTCCCCTCTGCTGATGC-3’
Forward 5’-TGAGCGTGTGGAAGCTGTGG-3’
Reverse 5’-GTTGGTGAGGGAGGAGATGG-3’
Forward 5’-AGGAGGGAGGGTGTGAGTGG-3’
Reverse 5’-AATGAGGAGGAGGAGGAGGG-3’
Forward 5’-GGGGGGTTTGGAGATGTTGG-3’
Reverse 5’-GTGGTGGGTGGAATTGATGG-3’
Forward 5'-TG AG AG GTG GTG G GTG AG AG-3 '
Reverse 5’-GGTGTGGGTGATGGTGTTGG-3’
258
Table A3
SYT Isoform Forward Primer 
Location
Reverse Primer 
Location
PCR Product Size 
(246)
SYT1 Exon 4 Exon 5/6 318
SYT2 Exon 6 Exon 9 319
SYT3 Exon 3 Exon 4 351
SYT4 Exon 2 Exon 3 322
SYT5 Exon 2 Exon 4/5 330
SYT6 Exon 2 Exon 3 277
SYT7 Exon 2 Exon 2 276
SYT8 Exon 1 Exon 4 313
SYT10 Exon 1 Exon 2 378
SYT11 Exon 2 Exon 3 337
SYT12 Exon 6 Exon 7 306
SYT13 Exon 4 Exon 5 368
SYT14 Exon 3 Exon 5 335
SYT15 Exon 1 Exon 3 360
Table A3: Expected human reverse transcription PCR primer location and expected
product sizes in base pairs (246).
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A1.2.3 Murine Synaptotagmin PCR product sequences
Listed below are the sequences of RT-PCR products obtained from reactions using 
murine brain cDNA template as described in Chapter 3. PCR products were TA-cloned into 
pCR-2.1 plasmids and sequenced by the University of Dundee Sequencing Service. Primer 
sequences are in boid text, PCR product underlined and plasmid sequence is in plain text.
(R) indicates where the reverse sequencing primer was used. All sequences were analysed 
using Vector NTl software are found to be homologous with the published Genbank 
sequence (shown in brackets).
SYT1 (NM_009306 mus syt 1 )
TGGACCATGCTACGGAGCTCGGATCCACTAGTAACGGCCGCCAGTGTGCTGGAATTCG
CCCTTTACTCGGAATTAGGTGGCAAGACACTGGTGATGGCTGTGTATGATTTTGACCGC
TTCTCCAAGCACGACATCATTGGAGAGTTCAAAGTTCCTATGAACACCGTGGATTTTGGC
CACGTCACAGAGGAGTGGCGCGATCTCCAGAGTGCTGAGAAAGAAGAGCAAGAGAAAC
TGGGTGACATCTGCTTCTCCCTCCGCTACGTCCCTACTGCCGGCAAGCTGACTGTTGTC
ATTCTGGAAGCCAAGAACCTGAAGAAGATGGATGTGGGTGGCTTATCTGATCCCTATGT
AAAGATTCACCTGATGCAGAACGGCAAGAGACAAGGGCGAATTCTGCAGATATCCATC
ACACTGGCGGCCGCTCGAGCATGCATCTAGAGGGCCCAATTCGCCCTATAGTGAGTCG
SYT2 (NM_009307 mus syt 2)
ACGGCCCCTTTGGGACGAGCTCGGATCCACTAGTAACGGCCGCCAGTGTGCTGGAATT
CGCCCTTCAGGCCAACCAGCTCACCGTGGGTGTCCTGCAGGCTGCGGAACTCCCAGC
CCTGGACATGGGTGGCACATCAGACCCTTATGTCAAAGTCTTCCTCCTCCCAGACAAGA
AGAAGAAATATGAGACTAAGGTGCATCGGAAGACGCTGAACCCAGCCTTCAATGAGACA
TTCACTTTCAAGGTGCCATACCAGGAGTTAGGAGGCAAGACCCTGGTGATGGCAATCTA
TGACTTTGACCGCTTCTCTAAGCATGACATCATCGGGGAGGTGAAGGTACCCATGAACA
CAGTGGACCTTGGCCAGCCCATCGAGGAATGGAGAGACCTACAAGGCGGAGAGAAGGA
AGAGCCAGAGAAGTTGGGTGACATCTGTACCtCCTTGCGCTACGAAGGGCGAATTCTG
CAGATATCCATCACACTGGCGGCCGCTCGAGCATGCATCTAGAGGG
SYT3 (R) (NM„016663 mus syt3)
GGCCGCCTTGGTTCCGGAGCTCGGATCCACTAGTAACGGCCGCCAGTGTGCTGGAATT
CGCCCTTGAGCCACGTCGAACACCAGGGCCTCGTTGTACGTGGGGTTCAGTGTGTTCT
TCTTAATGGAGGTCTTCCGTTTCTTCAGACGCCGCCCCTCGCTGATCAGAGAGGCCTTC
ACATAGGGGTCTGAGAAACCAGTGAGGTCCATTGCTTTGAGGTTAGAGGCTTTGATGAT
GGTCACGGTGAGGCGCCCAGCCGTGGGGAGGTAGCAGAGAGAGAAGTTGAGCTCTCC
GAGATCTGCCTTTTCCGAGCCACCCTCCAGGATGTCCCTCCAGAGCGGGCGGTCAGGG
GGCTGTTCAGCCAGCTCCAGCAGGTTGTCCAAAACCACCTGGCCAATGAGATCATGCC
GCGAGAAGCGGTCGAAGTCAAGGGCGAATTCTGCAGATATCCATCACACTGGCGGCCG
CTCGAGCATGCATCTAGAGGGCCCAATTCGCCCTATAGTGAGTCGTATTACAATTCACT
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SYT4 {NM_009308 mus syt 4)
AGGGGGAACCTTGAAACCGGAGGCTCGGATCCACTAGTAACGGCCGCCAGTGTGCTGG
AATTCGCCCTTTGGCCTCGTCTTCACTGTCTCTCTCTTTGCGTGGATCTGCTGTCAGAGA
AGATGAGGGAAATGGAAGAAGACTCCTCCATACAAGTTTGTGCACGTGCTTAAAGGAGTT
GATATGTAGGGAGAAAAGGTAAGTAGGAAAAAGAAGTTTGGAGGAGATGAGAAGAGTGA
AGTGAAGGGTAAAGGGGGTGTGGGGAAGGTTTGGGTGGATGTTGAGGTAGAGAAGGGAG
AGGTGAATGGGAAGTTGGGGAAAGGGAAGGGGAAAGGTGGGAGGTGTTGTGATGTGGAA
AATGTGAGGGCAAAGGTCTTTAGGGAGAGAGAAAAGGAGGGGAATTGGGGTGAGAGGTT
GAAGTCCAGCACTTCCGTCACGTAAGGGGGAATTGTGGAGATATGGATGAGAGTGGGGG
GGGGTGGAGGATGGATGTAGAGGGGGGAATTGGGGGTATAGTGAGTGGTATTAGAATTG
SYT5 (NM_016908 mus syt 5)
GGGAATGGTGGATGGGAGGTGGGATGGAGTAGTAAGGGGGGGGAGTGTGGTGGAATTG
GGGGTTGAGGGGGGGGAAGGTGAGCGTCATTGTCTTGGAAGCTAAAAAGGTGAAGAAAA
TGGATGTAGGAGGAGTGTGAGATGGGTATGTGAAGGTGGAGGTGGTGGAGGGAGGTAAA
AAGGTTGGGAAGAAGAAAAGGAGGATTAAGAAGAAGAGGGTGAAGGGGTATTAGAAGGA
GGGGTTGAGGTTTGAGGTGGGGTGTGAGGAGGTGGAGAAAGTGGAGGTGGAGGTGAGT
GTTGTGGATTATGAGAAAGTGGGGAAGAATGAGGGGATGGGGAGAGTGGGGGTGGGGG
ÇAGCAGTCGGTGGGGCTGGCGTGGGGGAGTGGGGTGAGAAGGGGGAATTGTGGAGAT
ATGGATGAGAGTGGGGGCGGGTGGAGGATGGATCTAGAGGGGCGAATTGGGGGTATAGT
SYT6 (NM„018800 mus syt 6)
GCGAGTGGGGGAAGGGAGGCTGGGATGGAGTAGTAACGGGGGGGAGTGTGGTGGAATT
GGGGGTTGGACATCCAGTACGCTACTAGTGAAAGTGTGGAGTTGGGAGAGATGATGTTG
TGGGTGTGGTAGGTGGGGAGAGGAGGGAGGGTGAGGGTGAGAGTGATGAAGTGTGGAAA
TGTGAAAGGAATGGAGATGAGAGGGTAGTGAGATGGGTAGGTGAAAGTATGGGTAGTGTG
TGATGGAGGGAGGGTGAAAAAGAAGAAAAGGAGGATAAAAAAGAAGAGGGTAAAGGGGG
TGTAGAAGGAGGGGATGATGTTTGAGATGGGGGGAGAAAAGATGGAGGAAGTGAGGGTG
GTGATGTGGGTTATGGAGTATGATAGAGTTGGCCACAACGAGATCATAGAAGGGGGAAT
TGTGGAGATATGGATGAGAGTGGGGGGGGGTGGAGGATGGATGTAGAGGGGGGAATTGG
SYT7a (R) (NM_018801 mus syt 7)
AGGGGGATTTGGTTAGGGGAGGTTGGGATGGAGTAGTAAGGGGGGGGAGTGTGGTGGA
ATTGGGGGTTTCGGCCCAGGTTCTCTCGGGTGCAGGCGTGGTGGGGGTGATGGTGGTGA
GAAGGTGGGGAGAGGATGAGGATGTGGGTGGTAAGGGAGTTGAGGAGGTGGGAGAGAG
AGGAAGGGGTGTGGGTTGTGGGGTGAGÀGTGATGGTGTGGGGTGTGGGGGGGGAGTGG
GGGTGTATTGAGAGGGTTGGGTGGTGGAGGGAAGTTGATGGGTTTGTTGTGAGCGGGGG
GAGGGGGGGAGTGTGGGGTGGGGAGGGTGTGGAAGGAATTGTTGTAGGGTTTGGGGAGT
TTGGGCTGACACCAGTGGCACAAAiGGGGGAATTGTGGAGATATGGATGAGAGTGGGGG
GGGGTGGAGGATGGATGTAGAGGGGGGAATTGGGGGTATAGTGAGTGGTATTAGAATTG
SYT8 (R) (NM_018802 mus syt8)
GGGGGGTGGGGGTGGGAGGTGGGATGGAGTAGTAAGGGGGGGGAGTGTGGTGGAATTG
GCGGTTCACAGGCTCAGTCCGGAGGTGGAGAGGAGGGGGGGAGAGAGGGAGGAGGAG
GTGGAGAGTGTGGAGAGATGTAGAGGGGATGGTTGTGAGTTTGGGATGGGAGAAGGTGG
GAGGGGAGTGTGGGGTTGGTGGGAGGTGGGTAGGTGGAGGTGGGTAAGGGGAAGGAGG
AAGAGGAAGGGGTGGTTGAAGTAGGGGGTAGTGGTGGGTTTGTTGGAGGATGTTTTGGT
GTTCTTGGATTTTGTGTGGTTTAAGATAAGGTGGATGTTGAGGTAGGGGTGTGCACGAGT
GAGAAAGTTGAAGAAGGGAGTGGGATAGATGGAGAGGAGGGTGGAGGTGGGTGTGGAG
AAAAGTATGGGTGTGAGGTGGAAGGGGGGGATTGAGACCCCGAGCCTCCAGTAAGGGG
GAATTGTGGAGATATGGATGAGAGTGGGGGGGGGTCGAGGATGGATGTAGAGGGGGGAA
261
SYT9 {NM_021889 mus syt9)
CCGCCCGGGGCTCCCGAGCTCGGATCCACTAGTAAACGGCCGCCAGTGTGCTGGAATT
CGCGGTTAAGCCTGCGGGAAACTGAACTTCATTTTAAAATATGACTGCGACTTGGAACA
GGTGATGGTGAAGATGGAGAAAGGGGTGAATGTGGGTGGGAAGGAGTTGTGTGGGAGTT
GAGATGGTTATGTGAAGATGTAGTTGGTTGGTGAGGGGAAAAGAAAAGAGGAGAGTAAAG
TTGAGAGGAAGAGGGTGAAGGGTGTATTTGATGGGGTGTTTTTATTTGGTGTTGAGTAGA
ATGAGGTTGAAGGTGGGAAGGTTGAGTTGTGTGTGTATGAGTTTGAGAGGTTGTGTGGGG
ATGAGGTGATTGGTGAGGTGGTGGTGGAGGAGTTCTTCGACTTGGCCGACTTAAGGGG
GAATTGTGGAGATATGGATGAGAGTGGGGGGGGGTGGAGGATGGATGTAGAGGGGGGAA
SYT10 (R) (NM_018803 mus syt10)
GGGGGGTGGTGGTAGGGAGGTGGGATGGAGTAGTAAGGGGGGGGAGTGTGGTGGAATT
GGGGGTTAAGTCTTCCGGTGCACGCGGGTGTGAAATTTGTTGTTGGTATGGGGAAGAAG
ATAGATGTTGAGATAAGGATGAGAAGTTGGTGTGAAATGTTTAGGTGGGAGATGTAAAGC
TTTGATAATTTTAAGAAGTAGGAGTTGATTTTGATAATGATAGTGGAGGGGAAAGTTAAGT
TTGGGAGAGGTGTTGAGGTGGTGTTTTGTGTTGGGGTGGGAGTGAAGGGATTTGTGGTTG
TAGAGTTGTGGTTTTATGCTCCCGATGCTCGTTCTCAAGGGGGAATTGTGGAGATATGGA
TGAGAGTGGGGGGGGGTGGAGGATGGATGTAGAGGGGCGAATTGGGGGTATAGTGAGT
SYT11 (NM_018804 mus syt11 )
GGGGGGTGGTGGGAGGTGGGATGGAGTAGTAAGGGGGGGGAGTGTGGTGGAATTGGGG
GTTGACAAGCGGCATCGAGTGAAGAGGGGAGTGGTTGGGAAGAGGGTGGAGGGGGTGT
TGGATGAGAGGTTGAGGTTGTAGGGGATGGGGTAGAGGGAGGTGGAGGAGGTGGTGCTG
GATTTGGTGGTGGTCAGGTTTGATGGATTGTGTGGGGATGAGGTGATGGGAGAGGTGAT
GGTGGGATTGGGTGGAGTGGAGGGGAGGAGAGGGAAGGTTGAGGTGAGGAGGGAGATG
ATGAAGAGGAAGATTGAGAAGTGGATTAGGAGAGGGGAAGTGGAGGTATGTGTGTGATA
CCAGCCCGTCGCACAAAGGGGGAATTGTGGAGATATGGATGAGAGTGGGGGGGGGTCG
AGGATGGATGTAGAGGGGGGAATTGGGGGTATAGTGAGTGGTATTAGAATTGAGTGGGG
SYT12 (NM_134164mussyt12)
GGGGGTTTGGAAAGGAAGGTGGGATGGAGTAGTAAGGGGGGGGAAGTGTGGTGGAATT
GGGGGTTTGACCAGCGGACCACTACTGGGGGAGGAGGGAGGGGGAAAGGGAGGGTTA
GTATAGAAGACAGGTTTGAGAGGATGAGTGAGGTGGGAGGGGTGGAGGTGATGGGGGG
GGAAGTGGAGTTAGGGGGGTATGGTAGTGTGGGAAAGTGAGAGTGGGGTGAGTGTGTGA
ATTGGATGTGGTGTGTGAGGAAGAGGTTTGGGGAGGATTTGAGGGTGGGGGAGGTGGAG
GTGAGCATGGAGTATGATGGAGGGTGGGAGAGGGTGGAGGTGGGAGTAGTAGAAGGGA
AAGAGCTGGTGGAGGGGGAGGAGGGGAGGTTGGAGTGGTGGTTGATGGGTGTGAGAGT
GGTGCCAGACGAAGAGATCGTGAAGGGGGAATTGTGGAGATATGGATGAGAGTGGGGG
GGGGTGGAGGATGGATGTAGAGGGGGGAATTGGGGGTATAGTGAGTGGTATTAGAATTG
SYT13 (NM„030725 mus syt13)
ATAGAGGGGAAGGGTAGGAGGTGGGATGGAGTAGTAAGGGGGGGGAGTGTGGTGGAAT
TGGGGGTTCGACACATGCACCCCAAGAAGGGGTTGGTGGGGGGGGAGGGTGAGGGGG
AGGGGGAGAAGGGAAGGGGGGGTGTGGTTGAGGGGGGCCAAGAGTTGAAGATTAAAAA
GTGGAGGGAGGGTGTGGAGGGGGGAGGTGTGGTTAAGTTGGGGGAGATGTATGGTGGGG
GGGGAGGGGTGAGGGGGGGAGAAGTGATGAAGTAGGGAGAGTAGAGGTTGGAGAGGAG
AGAGGAGTGTGGTGGAGGTGGGAGGGGGGAGGGGCAGAGTGACAGTCGCCGAAGGGG
GAATTGTGGAGATATGGATGAGAGTGGGGGGGGGTGGAGGATGGATGTAGAGGGGGGAA
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SYT14 (R) (NM_181546 mus syt14)
GCGAACCTTGGGTACGGAGCTCGGATCCACTAGTAACGGCCGCCAGTGTGCTGGAATT
CGCCGTTCCAGTATCACCGGTAACGACATTTTCCCTTGAAGATTCAACTTTGTTAAATAA
AAAATGTTTTGGGGGAGAATGTTTTGTTTGTTGATGGGATGGAGAGGATATAGTGTAAAGG
TAAGTGGATAGTTTGGAATGATGTGGGATTGAAGGTGGTTAAATTTGAATGTTTGTGTGAA
GAGAGGGGATGGTGGTGTGTGGATGCTGGTTTTGGGTGTGTGTTTTTTTATAGGTAGAAG
AAGAAGGTGTAGGTGGCACGAGTTGGGAGGTGTGGTGTTATATGTTGGAATGTGTGTGA
GAGGTGTCACCGTTACCAGGAGCTAAGGGGGAATTCTGGAGATATGGATGAGAGTGGG
GGGGGGTGGAGGATGGATGTAGAGGGGGGAATTGGGGGTATAGTGAGTGGTATTAGAAT
263
A1.2.4 Murine SYT RTPCR Product Sequencing Chromatograms
Pictured below are the sequencing chromatograms corresponding to the sequences 
given in A1.2.3 above. Chromatograms shown begin with the first residue of each 
corresponding RTPCR primer.
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SYT2
7 0  80  90 1 0 0  1 1 0
■ C A G  G C C A A C C à  G C T C A C C  G T  G G G T G T C C T  G C A G G C  T  G G G G A A C T  C C C A G C C
1 5 01 3 0120
2102001 8 01 7 0
2 5 02 4 0220
3X 02 7 0
3 4 0
4 4 0
SYT4
7 n  SO 9 0  1 0 0  1 1 0  ^  ^  ‘
T G  G C C T C G  T C T T C A C  T G  T  C T C T C  T C T  T T G C C  T G G A T  C T  G C  T G  T C A G  A G  A A
1 6 015 01 4 0130
1 9 01 8 01 7 0
l A G C C A A C C C  C A A A G C T G G C A G C  T C T T C  T G A T C T G G A A A A T G T C A C  C C C A A
SYT5
14 0  1 5 0  1 6 0  1 7 0  1 8 0
C r C T C A G  A T C C C  T 7 ,  T G  T G  A A G G T G C i C C  T G C  T C C A G  G G  A G  G T A A A A A G G T
I 1 9 0  2 0 0  2 1 0  2 2 0  23 0
t t c g c a a g a a g a a a a c c i .  c c a t t a a g a a g a a c a c c c t g a a c c c c t a t t a c a
0 2 4 0  25 0  2 6 0  2 7 0  2 8 0
A A C G A G G C C T T C A G C T T T G A G G T G C C C T G T G A C C A G G T G C A G A A A G T C C A C
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3 0 0  3 9 0  4 0 0  4 1 0  4 2 0
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1 2 0  1 3 0  1 4 0  1 5 0  1 6 0
T C T C C C T C T G C T A C C T G C C C A C A G  C A G G C A G G C T C A C C C T C A C A G  T G  a t c a
17 0  I SO 1 9 0  2 0 0  2 1 0
a a g t g t c g a a a t c t c a a a g c a a t g g a c a t c a c a g g c t a c t c a g a t c c c t a
2 7 0  2 8 0  2 9 0  3 0 0  3 1 0
A C G A C C A T A A A A A A G A A C A C C C  T A A A C C C C 6  T C Ï A C A A C G A G G C C A T C A T C
1Û
3 2 0  3 3 0  3 4 0  3 5 0  3 6 0
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T C T G G C C G G G C A C T G G G G C T G T A T T C A C A G C C T T C C C T C C T G C A G G C A A C T
2 7 0  2 0 0  2 9 0  3 0 0  3 1 0
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3 7 0  3 8 0  3 9 0  40 0  410
T G G C A C A A A G G G C G A â T T C T G C A G A T A T C C A T C â C A C T G G C G G C C G C  T C G A
SYT8
SYT9 110100
I SO120
21019 0
2 6 025 0
31 02 9 028 02 7 0
34 03 3 0
4 1 03 9 0
SYT10
7 0  8 0  9 0  1 0 0  110
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1601 4 0120
210190170
3103002902002 7 0
3603 4 032 0
A1.3 Taqman Realtime PCR Primer and Probe Sequences
A1.3.1 Taqman Realtime PCR Primer Sequences
PActin Forward 5’- TGCTCTGGCTCCTAGCACCAT -3’
Reverse 5’ - AC ATCTG GTG GAAG GTG G AC AGT- 3 ’
GLUT4 Forward 5’- ACCGGATTCCATCCCACAA -3’
Reverse 5’-CCCTTTTCCTTCCCAACCATT-3’
Syt 3 Forward 5’-GCAGATCTCGGAGAGCTCAACT-3’
Reverse 5’-CTTTGAGGTTCGCGGCTTTGATGAT-3’
Syt 6 Forward 5’-GGACATCCAGTACGCTAC-3’
Reverse 5’-CTATGATCTCGTTGTGGC-3’
Syt 7 Forward 5’-TGTGCCACTGGTGTCAGC-3’
Reverse 5’-TCGGCCCAGGTTCTCTCG-3’
Syt 8 Forward 5’-AGAAATGGAAGAAGAGCAAAACATC-3’
Reverse 5’-CCACACTCTGGAGCTGGCTAAC-3’
Syt 9 Forward 5’-CCTTATGTCAAGATCTACTTGCTTCCT-3’
Reverse 5’-TTCCGAGCTTCAAGGTCATTGTA-3’
Syt 10 Forward 5-AGAACGAGCATCGGGAGGATA-3'
Reverse 5’-TCATACTGGAGCGCAAAGTTAAGT-3’
Syt 11 Forward 5’-ACAAGCGGCATCGAGTGAA-3'
Reverse 5’-AAGGTGAAGGTCTCATCGAACAC-3’
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Syt 12 Forward 5'-CAAAGGCAGCCTTAGTATACGAAGACA-3’
Reverse 5’-CCGACTGTGACTTTCGGAGAGTAC-3’
Syt 13 Forward 5’-TCAGGCGGCCCAACAGT-3’
Reverse 5’-CCAAGGTGTAGTCTGCGTAGTTGAT-3’
A1.3.2 Taqman Probe Sequences
PActin 5’- TCAAGATCATTGCTCCTCCTGAGCGC-3’
GLUT4 5'-CCCTCACTACGCTCTGGGCTCTCTCC-3’
Syt 3 5’-CTGGGCGCCTCACCGTGACC-3’
Syt 7 5’-TCATGCTGTCCCCAGGTTCTGAGGA-3’
Syt 8 5’-CAAGAAAGGGAGGAGTAGGGGGTAGTTGA-3’
Syt 9 5’-GAGAGTAAAGTTGAGAGGAAGAGGGTGAAGGG-3’
Syt 10 5’-GGAGAAGTGTAGAAGGAGAAATGGGTTGAGTG-3’
Syt 11 5’-AGGGGAGTGGTTGGGAAGAGGG-3’
Syt 12 5’-GGGGGAAGTGGAGTTAGGGGGGTAT-3’
Syt 13 5’-AAGTGGAGGGAGGGTGTGGAGGG-3’
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A1.4 SYT7 and SYT11 Immunogenic Peptides
Table A4
Peptide Name Amino Acid Sequence Residue Number
SYT7-1 YRDPEAASPGAPTRD 2-16
SYT7-2 GTPDSGRGRGEKKAIK 57-72
SYT11-1 KVRRDKDGPRRESGR 77- 91
SYT11-2 LLSHDKDPRGPSPAS 102-116
Table A4 Peptides used to generate SYT7 and SYT11 antisera.
A1.5 SYT11 sIRNA Sequence
5’-GCAGAGAAGAAGCACAAGA-3’
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